Spray-dried dispersions and formulations of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide

Improved formulations of BTK inhibitors with specific excipients and spray-dried dispersions address solubility and concentration issues, enhancing therapeutic efficacy for BTK-related cancers.

JP7596441B2Active Publication Date: 2024-12-09LOXO ONCOLOGY INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023085024
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-11-19
Filing Date
2023-05-24
Publication Date
2024-12-09
Estimated Expiration
2039-07-29

AI Technical Summary

Technical Problem

Existing BTK inhibitors face challenges with low solubility and inconsistent plasma concentrations, necessitating improved formulations to enhance their therapeutic efficacy.

Method used

Formulations comprising compounds of Formula I in specific ratios with HPMCAS polymer, microcrystalline cellulose, mannitol or lactose monohydrate, sodium starch glycolate, croscarmellose sodium, magnesium stearate, and silicon dioxide, spray-dried to create stable dispersions for improved bioavailability.

Benefits of technology

The formulations provide consistent plasma concentrations and enhanced therapeutic effects for treating BTK-related cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007596441000044
    Figure 0007596441000044
  • Figure 0007596441000045
    Figure 0007596441000045
  • Figure 0007596441000046
    Figure 0007596441000046
Patent Text Reader

Abstract

To provide improved formulations for BTK inhibitors, particularly for BTK inhibitors that exhibit low solubility.SOLUTION: The present invention provides a crystalline form which is (S)-5-amino-3-(4-((5-fluoro-2- methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamid, having an X-ray powder diffraction pattern comprising peaks at 2θ values of 15.8±0.2, 16.2±0.2, and 11.9±0.2°.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present disclosure relates to a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof. More specifically, the present invention relates to a pharmaceutical composition comprising the compound of formula (I), a spray-dried dispersion (SDD) thereof, or a pharmaceutical composition thereof. Specifically, it is believed that BTK inhibitors can be used to treat a wide range of conditions, including BTK-associated diseases and disorders. The present invention relates to compositions of compounds of formula I that are useful in the treatment and prevention of diseases. [Background technology]

[0002] BTK is a cytoplasmic non-receptor tyrosine kinase that belongs to the Tec family of kinases. (Herman, SEM et al., Blood. 2011, 117(23 The structure of BTK consists of several domains: the N-terminal plexiform domain; It contains a phosphodiesterase (PH) domain, a proline-rich TEC homology domain, and two SRC homology domains. It has a C-terminal kinase domain (SH3 followed by SH2) and a C-terminal kinase domain (BTK-KD) Marcotte,DJet al.,Protein Sci.2010,19( 3):429-439).

[0003] BTK is expressed in hematopoietic cells, excluding T cells and plasma cells, and mediates proliferation, maturation, differentiation, and apoptosis. involved in all aspects of B cell development, including B cell motility and migration (Wu J., et al. l., J Hematol Oncol. 2016;9:80). BTK inhibits monocyte / macrophage It is also expressed on certain myeloid cells, including phages, neutrophils, and mast cells. In cells, BTK is involved in immune complex-mediated activation of FcγR and FcεR, and is involved in the activation of FcγR and FcεR. It may be involved in the pathogenesis of rheumatoid arthritis (Whang 2014). Because BTK is also required for cellular maturation, inhibiting it may prevent bone erosion associated with rheumatoid arthritis. You can do this.

[0004] PIP3 (phosphatidylinositol-3,4,5-triphosphate) generation and BTK P Binding to the H domain and Tyr-551 of BTK by Src family kinases Phosphorylation stimulates membrane localization and activation of BTK. BTK activation is mediated by Ca 2+ Recruitment and activity of NF-κB and MAP (mitogen-activated protein) kinase pathways (Honigberg et al. Proc. Natl. Acad. Sc iUSA2010 Jul 20;107(29):13075-13080) .

[0005] Aberrant BTK expression and / or activity has been demonstrated in various cancers and autoimmune diseases. are.

[0006] Examples of BTK inhibitors are disclosed in WO17 / 103661.

[0007] To provide improved formulations for BTK inhibitors, particularly for BTK inhibitors that exhibit low solubility. Furthermore, to increase and / or consistently increase plasma concentrations of BTK inhibitors, There is a need to provide formulations that provide plasma concentrations of riboflavin. The present invention addresses one of these needs. Various formulations are provided to address one or more of these issues. Summary of the Invention

[0008] In one aspect, the present invention provides a composition comprising a compound of Formula I present in an amount of about 5% w / w to about 30% w / w. , [ka] HPMCAS polymer present in an amount of about 5% w / w to about 30% w / w, and about 30% w / w Microcrystalline cellulose present in an amount of about 10% w / w to about 60% w / w Mannitol or lactose monohydrate, or a combination thereof, present in a total amount of w and sodium starch glycolate present in a total amount of about 0.5% w / w to about 5% w / w. 0.05% croscarmellose or croscarmellose sodium, or a combination thereof Magnesium stearate present in an amount of from about 2% w / w to about 2% w / w, and optionally and silicon dioxide in an amount of about 0.3% w / w to about 0.6% w / w, where the total is 10 The present invention provides a pharmaceutical composition having a soluble fiber content of 0% or less.

[0009] In one aspect, the present invention provides a composition comprising a compound of Formula I present in an amount of about 5% w / w to about 30% w / w. , HPMCAS polymer present in an amount of about 5% w / w to about 30% w / w, and about 30% w / microcrystalline cellulose present in an amount of from about 10% w / w to about 60% w / w; Mannitol or lactose monohydrate, or a combination thereof, present in a total amount of / w Combined with sodium starch glycolate present in a total amount of about 0.5% w / w to about 5% w / w 0.05g croscarmellose sodium or croscarmellose sodium, or a combination thereof % w / w to about 2% w / w of magnesium stearate, and optionally, and silicon dioxide in an amount of about 0.3% w / w to about 0.6% w / w, the total being 1 The present invention provides a pharmaceutical composition having a solubility of 0.00% or less.

[0010] In one aspect, the present invention provides a composition comprising a compound of Formula I present in an amount of about 5% w / w to about 30% w / w. , HPMCAS polymer present in an amount of about 5% w / w to about 30% w / w, and about 30% w / microcrystalline cellulose present in an amount of from about 10% w / w to about 60% w / w; lactose monohydrate, present in a total amount of about 0.5% w / w to about 5% w / w; Croscarmellose sodium, present in an amount of about 0.05% w / w to about 2% w / w and magnesium stearate, when present, from about 0.3% w / w to about 0.6% w / w and silicon dioxide in an amount of 0.1 to 1.0 wt %, wherein the total is 100% or less.

[0011] In one embodiment, the ratio of the compound of formula I to the HPMCAS polymer is from about 1:4 to about 4:1 In another embodiment, the ratio of the compound of formula I to the HPMCAS polymer is about 1:1. do.

[0012] In another aspect, the present invention provides a compound of formula I present in an amount of about 21% w / w to about 23% w / w. and an HPMCAS polymer present in an amount of about 21% w / w to about 23% w / w. % w / w to about 39% w / w of microcrystalline cellulose, and about 12% w / w to about 1 Mannitol, present in an amount of 3% w / w, and mannitol, present in an amount of about 4% w / w to about 6% w / w. sodium starch glycolate, present in an amount of about 0.4% w / w to about 0.6% w / w and magnesium stearate, wherein the total amount is 100% or less. do.

[0013] In another aspect, the present invention provides a compound of formula I present in an amount of about 21% w / w to about 23% w / w. and an HPMCAS polymer present in an amount of about 21% w / w to about 23% w / w. % w / w to about 34% w / w of microcrystalline cellulose, and about 16% w / w to about 1 Lactose monohydrate, present in an amount of about 7% w / w, and lactose monohydrate, present in an amount of about 2% w / w to about 6% w / w. croscarmellose sodium, present in an amount of about 0.4% w / w to about 0.6% w / w. magnesium stearate present in an amount of about 0.4% w / w to about 0.6% w / w and silicon dioxide, the total of which is 100% or less.

[0014] In another aspect, the present invention provides a compound of formula I present in an amount of about 21% w / w to about 23% w / w. and an HPMCAS polymer present in an amount of about 21% w / w to about 23% w / w. % w / w to about 26% w / w of microcrystalline cellulose, and about 25% w / w to about 2 Mannitol, present in an amount of 6% w / w, and mannitol, present in an amount of about 4% w / w to about 6% w / w. sodium starch glycolate, present in an amount of about 0.4% w / w to about 0.6% w / w and magnesium stearate, wherein the total amount is 100% or less. do.

[0015] In yet another aspect, the present invention provides a composition comprising a compound of formula I present in an amount of about 8% w / w and a composition comprising a compound of formula I present in an amount of about 8% w / w. HPMCAS polymer present in an amount of about 40% w / w and microcrystalline cellulose, mannitol present in an amount of about 40% w / w, and cellulose in an amount of about 3.5% w / w. sodium starch glycolate present in an amount of about 0.3% w / w; and magnesium phosphate.

[0016] In one embodiment, the pharmaceutical composition is formulated as a tablet. The pharmaceutical composition comprises from about 25 mg to about 220 mg of the compound of Formula I. Yet another embodiment In the present invention, the pharmaceutical composition may be selected from one of about 25 mg, about 50 mg, and about 100 mg. The compound of formula I is preferably a compound of formula I.

[0017] In another aspect, the present invention provides a method for treating a BTK-associated cancer in a subject in need of treatment. A method for treating cancer, comprising administering to a subject the pharmaceutical composition described above. In one embodiment, the BTK-associated cancer is mantle cell lymphoma, chronic lymphocytic leukemia, Leukemia, small lymphocytic lymphoma, Waldenstrom's macroglobulinemia, and hepatocellular carcinoma Marginal zone lymphoma.

[0018] In another aspect, the present invention provides a method of treating cancer in a subject in need thereof. The method comprises administering to a subject a compound of Formula I at a dose of about 20 mg to about 120 mg. Cancers include the following: mantle cell lymphoma, chronic lymphocytic leukemia, small bowel disease, and Lymphocytic lymphoma, Waldenstrom's macroglobulinemia, and marginal zone lymphoma In certain embodiments, the dose is selected from about 25 mg, about 50 mg, and about 10 mg. 0 mg.

[0019] In another aspect, the present invention provides a method for administering a compound of formula I in a dose of about 20 mg to 120 mg. , mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom Treatment of BTK-related cancers selected from the group consisting of Rehm's macroglobulinemia and marginal zone lymphoma In certain embodiments, the compound of formula I is administered The dose given is selected from about 25 mg, about 50 mg and about 100 mg.

[0020] In still yet another aspect, the present invention relates to a method for treating mantle cell lymphoma, chronic lymphocytic leukemia, small bowel disease, and the like. Lymphocytic lymphoma, Waldenstrom macroglobulinemia, and marginal zone lymphoma The present invention provides the pharmaceutical composition described above for use in treating a BTK-associated cancer selected from the group consisting of bronchial and bronchial carcinomas. In certain embodiments, the compound of formula I is administered in amounts of about 25 mg, about 50 mg, and about 100 mg. The dose is selected from one of the following:

[0021] In another aspect, the present invention provides a method for treating BTK-associated diseases and disorders with BTK inhibitors. and a spray-dried dispersion or pharmaceutical composition useful for the treatment and prevention of diseases that can be treated with steroids. A compound of formula I is provided: [ka]

[0022] Thus, herein, the compound of formula I and hypromellose acetate succinate ( A spray-dried dispersion is provided comprising a polymer (HPMCAS).

[0023] In some embodiments, the compound of formula I, or a pharmaceutically acceptable salt thereof, is amorphous, Alternatively, the ratio of polymorphic form to HPMCAS polymer is about 1:4 to about 4:1. In some embodiments, the ratio of the compound of Formula I to the HPMCAS polymer is about 1:1. In some embodiments, the HPMCAS polymer is HPMCAS-MG.

[0024] As used herein, the compound of formula I is dissolved in one or more organic solvents before being spray dried. Also provided is a process for preparing a spray-dried dispersion, wherein the dispersion comprises a compound of Formula I. The compound, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof, is spray dried. Before being added, the dichloromethane is preferably mixed with about an 80:20 weight / weight ratio of dichloromethane to methanol. In some embodiments, the compound of Formula I is dissolved in methanol. In yet another embodiment, Form A of the compound of Formula I is one or more It is dissolved in several organic solvents.

[0025] As used herein, a first composition comprising a spray-dried dispersion and one or more pharmaceutical excipients is provided. Also provided is a pharmaceutical composition comprising a spray-dried dispersion of an HPMCAS polymer and a compound of Formula I. or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof.

[0026] In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt thereof, in the spray-dried dispersion The ratio of the salt, amorphous, or polymorphic form to the HPMCAS polymer is about 1:4 to In some embodiments, the ratio of the compound of formula I, or The ratio of a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof to the HPMCAS polymer. is about 1:1. In some embodiments, the HPMCAS polymer is HPMCAS- It's MG.

[0027] In some embodiments, the spray-dried dispersion comprises about 20% to about 75% w / v of the first composition. In some embodiments, the spray-dried dispersion is present in an amount of about 30 wt. In some embodiments, the spray-dried dispersion is present in an amount of from about 60% to about 60% w / w. In some embodiments, the spray-dried The dry dispersion is present in an amount of about 45% w / w of the first composition.

[0028] In some embodiments, the pharmaceutical excipients include fillers, lubricants, and combinations thereof. is selected from the group consisting of:

[0029] In some embodiments, the filler is present in an amount of about 25% to about 80% w / w of the first composition. In some embodiments, the filler is present in an amount of about 45% to about 65% w / w of the first composition. In some embodiments, the filler is present in an amount of about 55% w / w of the first composition. is present in an amount of

[0030] In some embodiments, the filler is a saccharide, gelatin, a synthetic polymer, or the like. In some embodiments, the filler is selected from the group consisting of scrubs, ... Sugar, lactose, microcrystalline cellulose, methylcellulose, ethylcellulose, hydro Hydroxypropyl cellulose, hydroxypropyl methylcellulose, starch, xylitol ethanol, sorbitol, mannitol, polyvinylpyrrolidone, polyethylene glycol, Polyvinyl alcohol, polymethacrylate, poloxamer, magnesium stearate , calcium stearate, sodium stearate, stearic acid, hydrogenated vegetable oil, mineral Oil, sodium lauryl sulfate, magnesium lauryl sulfate, glycerin palmitostearate aryl, sodium benzoate, sodium stearyl fumarate, colloidal silicon dioxide, Sodium benzoate, sodium oleate, sodium acetate, and combinations thereof and the like.

[0031] In some embodiments, the filler is a binder, a disintegrant, or a combination thereof. do.

[0032] In some embodiments, the binder is present in an amount of about 30% to about 80% w / w of the first composition. In some embodiments, the binder is present in an amount of about 40% to about 60% w / v of the first composition. In some embodiments, the binder is present in an amount of about 52% w / w of the first composition. is present in an amount of

[0033] In some embodiments, the binder is selected from the group consisting of microcrystalline cellulose, cellulose ethers, hydrogels, and the like. Hydroxypropyl cellulose, Hydroxypropyl methylcellulose, Sodium carboxylate Dimethylcellulose starch, methylcellulose, ethylcellulose, hydroxypropyl cellulose, mannitol, xylitol, sorbitol, lactose, sucrose, Sorbitol, gelatin, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohols, polymethacrylates, and combinations thereof .

[0034] In some embodiments, the binder is microcrystalline cellulose, mannitol, or the like. It is a combination of the above.

[0035] In some embodiments, the microcrystalline cellulose comprises about 5% to about 55% w / w of the first composition. In some embodiments, the microcrystalline cellulose is present in an amount of 0.1 wt. / wt. In some embodiments, the microcrystalline cellulose is present in an amount of about 10% to about 40% w / w. The sachet is present in an amount of about 20% to about 30% w / w of the first composition. Preferably, the microcrystalline cellulose is present in an amount of about 30% to about 60% w / w of the first composition. In some embodiments, the microcrystalline cellulose is present in an amount of about 26% w / w of the first composition. exist.

[0036] In some embodiments, mannitol comprises about 5% to about 55% w / w of the first composition. In some embodiments, mannitol is present in an amount of about 10% to about 10% of the first composition. In some embodiments, mannitol is present in an amount of 40% w / w. In some embodiments, mannitol is present in an amount of about 20% to about 30% w / w. , present in an amount of about 26% w / w of the first composition.

[0037] In some embodiments, the disintegrant is present in an amount of about 0.5% to about 5% w / w of the first composition. In some embodiments, the disintegrant is present in an amount of from about 1.5% to about 3.5% of the first composition. In some embodiments, the disintegrant is present in an amount of about 2.5% w / w of the first composition. Present in w / w amounts.

[0038] In some embodiments, disintegrants include sodium starch glycolate, alginic acid, Sodium alginate, croscarmellose sodium anion exchange resin, and In some embodiments, the disintegrant is selected from the group consisting of a combination of starch, It is sodium glycolate.

[0039] In some embodiments, the lubricant comprises from about 0.05% to about 2.5% w / w of the first composition. In some embodiments, the lubricant is present in an amount of from about 0.1% to about 1% of the first composition. In some embodiments, the lubricant is present in an amount of about 0.2% w / w of the first composition. Present in an amount of 5% w / w.

[0040] In some embodiments, the lubricant is magnesium stearate, calcium stearate, or Calcium, sodium stearate, stearic acid, hydrogenated vegetable oil, mineral oil, polyethylene glycol Cole, sodium lauryl sulfate, magnesium lauryl sulfate, glycerin palmitostearate Lyceryl, Sodium Benzoate, Sodium Stearyl Fumarate, Colloidal Silicon Dioxide sodium benzoate, sodium oleate, sodium acetate, and combinations thereof In some embodiments, the lubricant is selected from the group consisting of stearic acid malate, methacrylate ... It is magnesium.

[0041] In some embodiments, the spray-dried dispersion comprises about 20% to about 75% w / v of the first composition. the filler is present in an amount of about 25% to about 80% w / w of the first composition, The lubricant is present in an amount of about 0.05% to about 2% w / w of the first composition.

[0042] In some embodiments, the spray-dried dispersion is present in an amount of about 45% w / w of the first composition. the filler is present in an amount of about 55% w / w of the first composition, and the lubricant is present in an amount of about 55% w / w of the first composition. is present in an amount of about 0.25% w / w.

[0043] In some embodiments, the spray-dried dispersion comprises about 40% to about 50% w / v of the first composition. and microcrystalline cellulose is present in an amount of about 20% to about 30% w / w of the first composition. and mannitol is present in an amount of about 20% to about 30% w / w of the first composition, The sodium starch glycolate is present in an amount of about 0.5% to about 5% w / w of the first composition. The magnesium stearate is present in an amount of about 0.05% to about 2% w / w of the first composition. There is.

[0044] In some embodiments, the spray-dried dispersion and pharmaceutical excipients are blended. In some embodiments, the first composition is granulated. is granulated by roller compaction.

[0045] Also provided herein is a pharmaceutical composition comprising the first composition and one or more pharmaceutical excipients. will be done.

[0046] In some embodiments, the first composition is present in an amount of about 15% to about 99% w / w of the total composition. It exists in.

[0047] In some embodiments, the one or more pharmaceutical excipients include fillers, lubricants, and the like. The compound is selected from the group consisting of:

[0048] In some embodiments, the lubricant is present in an amount of about 0.05% to about 2% w / w of the total composition. In some embodiments, the lubricant is present in an amount of from about 0.1% to about 1.0% w / w of the total composition. In other embodiments, the lubricant is present in an amount of about 0.1% to about 0.8% w / v of the total composition. In other embodiments, the lubricant is present in an amount of about 0.4% to about 0.6% w of the total composition. In yet another embodiment, the lubricant is present in an amount of about 0.3% w / w of the total composition. is present in an amount of

[0049] In some embodiments, the lubricant is magnesium stearate, calcium stearate, or Calcium, sodium stearate, stearic acid, hydrogenated vegetable oil, mineral oil, polyethylene glycol Cole, sodium lauryl sulfate, magnesium lauryl sulfate, glycerin palmitostearate Lyceryl, Sodium Benzoate, Sodium Stearyl Fumarate, Colloidal Silicon Dioxide sodium benzoate, sodium oleate, sodium acetate, and combinations thereof In some embodiments, the lubricant is selected from the group consisting of stearic acid malate, methacrylate ... It is magnesium.

[0050] In some embodiments, the filler is present in an amount of about 1% to about 85% w / w of the total composition. do.

[0051] In some embodiments, the filler is sucrose, lactose, microcrystalline cellulose, Methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropyl Pyrmethylcellulose, starch, xylitol, sorbitol, mannitol, polyvinyl alcohol Nylpyrrolidone, polyethylene glycol, polyvinyl alcohol, polymethacrylate , poloxamer, magnesium stearate, calcium stearate, sodium stearate Thorium, Stearic Acid, Hydrogenated Vegetable Oil, Mineral Oil, Sodium Lauryl Sulfate, Lauryl Sulfate Magnesium, glyceryl palmitostearate, sodium benzoate, stearyl fumarate Sodium citrate, colloidal silicon dioxide, sodium benzoate, sodium oleate , sodium acetate, and combinations thereof.

[0052] In some embodiments, the filler is a binder, a disintegrant, or a combination thereof. do.

[0053] In some embodiments, the disintegrant is present in an amount of about 0.5% to about 5% w / w of the total composition. In some embodiments, the disintegrant is present in an amount of about 4% to about 6% w / w of the total composition. In some embodiments, the disintegrant is present in an amount of about 2.5% w / w of the total composition. .

[0054] In some embodiments, disintegrants include sodium starch glycolate, alginic acid, Sodium alginate, croscarmellose sodium anion exchange resin, and In some embodiments, the disintegrant is selected from the group consisting of a combination of starch, It is sodium glycolate.

[0055] In some embodiments, the first composition is present in an amount of about 90% to about 99% w / w of the total composition. In some embodiments, the first composition is present in an amount of about 97% w / w of the total composition. It exists in.

[0056] In some embodiments, the first composition is present in an amount of about 15% to about 60% w / w of the total composition. In some embodiments, the first composition is present in an amount of about 30% to about 40% of the total composition. In some embodiments, the first composition is present in an amount of about 35% w / w of the total composition. Present in w / w amounts.

[0057] In some embodiments, the binder is present in an amount of about 40% to about 85% w / w of the total composition. In some embodiments, the binder is present in an amount of about 55% to about 75% w / w of the total composition. exist.

[0058] In some embodiments, the binder is selected from the group consisting of microcrystalline cellulose, cellulose ethers, hydrogels, and the like. Hydroxypropyl cellulose, Hydroxypropyl methylcellulose, Sodium carboxylate Dimethylcellulose starch, cellulose, methylcellulose, ethylcellulose, hydro Hydroxypropyl cellulose, mannitol, xylitol, sorbitol, lactose, Sucrose, sorbitol, gelatin, polyvinylpyrrolidone, polyethylene glycol , polyvinyl alcohol, polymethacrylate, and combinations thereof. are selected.

[0059] In some embodiments, the binder is microcrystalline cellulose, mannitol, or the like. It is a combination of the above.

[0060] In some embodiments, the microcrystalline cellulose comprises about 25% to about 35% w / w of the total composition. In some embodiments, the microcrystalline cellulose is present in an amount of about 31 wt% of the total composition. Present in an amount of % w / w.

[0061] In some embodiments, mannitol is present in an amount of about 25% to about 35% w / w of the total composition. In some embodiments, mannitol is present in an amount of about 31% w / w of the total composition. It exists in.

[0062] In some embodiments, the first composition is blended with a pharmaceutical excipient. In embodiments, the pharmaceutical compositions are co-milled.

[0063] In some embodiments, the pharmaceutical composition is formulated as a tablet. wherein the compound of formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof, is In some embodiments, the compound of Formula I is present in an amount of about 10 mg to about 50 mg. or its pharmaceutically acceptable salt, amorphous, or polymorphic form, is about 25 mg to about 220 mg More preferably, about 50 mg to about 150 mg, and even more preferably, about 80 mg In an even more preferred embodiment, the amount is about 100 mg. It exists in.

[0064] Also provided herein is a pharmaceutical composition, the pharmaceutical composition comprising: (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl) (phenyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazo 4-carboxamide and HPMCAS polymer, and one or more pharmaceutical excipients.

[0065] In some embodiments, the HPMCAS polymer is HPMCAS-MG.

[0066] In some embodiments, the one or more pharmaceutical excipients include fillers, lubricants, and the like. The compound is selected from the group consisting of:

[0067] In some embodiments, the filler is sucrose, lactose, microcrystalline cellulose, Methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropyl Pyrmethylcellulose, starch, xylitol, sorbitol, mannitol, polyvinyl alcohol Nylpyrrolidone, polyethylene glycol, polyvinyl alcohol, polymethacrylate , magnesium stearate, calcium stearate, sodium stearate, ste Allic acid, hydrogenated vegetable oil, mineral oil, sodium lauryl sulfate, magnesium lauryl sulfate, Glyceryl palmitostearate, sodium benzoate, sodium stearyl fumarate , colloidal silicon dioxide, sodium benzoate, sodium oleate, sodium acetate and combinations thereof.

[0068] In some embodiments, the lubricant is magnesium stearate, calcium stearate, or Calcium, sodium stearate, stearic acid, hydrogenated vegetable oil, mineral oil, polyethylene glycol Cole, sodium lauryl sulfate, magnesium lauryl sulfate, glycerin palmitostearate Lyceryl, Sodium Benzoate, Sodium Stearyl Fumarate, Colloidal Silicon Dioxide sodium benzoate, sodium oleate, sodium acetate, and combinations thereof The compound is selected from the group consisting of:

[0069] In some embodiments, the composition comprises: (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl) (phenyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazo 4-carboxamide and HPMCAS polymer, Microcrystalline cellulose, Mannitol, Sodium starch glycolate, and magnesium stearate.

[0070] In some embodiments, the composition comprises: (S)-5-amino-3-(4-(( 5-Fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trimethylphenyl) (trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide, an HPMCAS polymer present in an amount of about 5% to about 30% w / w of the composition; microcrystalline cellulose present in an amount of about 30% to about 60% w / w of the composition; Mannitol present in an amount of about 30% to about 60% w / w of the composition; Sodium starch glycolate present in an amount of about 0.5% to about 5% w / w of the composition; , and magnesium stearate, present in an amount of about 0.05% to about 2% w / w of the composition. nothing.

[0071] In some embodiments, the composition comprises: (S)-5-amino-3-(4-((5-fluoro- 1-(1,1,1-trifluoro-2-methoxybenzamido)methyl)phenyl propan-2-yl)-1H-pyrazole-4-carboxamide, an HPMCAS polymer present in an amount of about 8% w / w of the composition; microcrystalline cellulose present in an amount of about 40% w / w of the composition; Mannitol present in an amount of about 40% w / w of the composition; sodium starch glycolate present in an amount of about 3.5% w / w of the composition; and magnesium stearate present in an amount of about 0.3% w / w of the composition.

[0072] In some embodiments, the composition comprises: (S)-5-amino-3-(4-( (5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1- (trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide, an HPMCAS polymer present in an amount of about 10% to about 30% w / w of the composition; microcrystalline cellulose present in an amount of about 20% to about 30% w / w of the composition; Mannitol present in an amount of about 20% to about 30% w / w of the composition; sodium starch glycolate present in an amount of about 2% to about 8% w / w of the composition; and magnesium stearate, present in an amount of about 0.05% to about 2% w / w of the composition. nothing.

[0073] In some embodiments, the composition comprises: (S)-5-amino-3-(4-((5-fluoro- (2-Methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro (1H-propan-2-yl)-1H-pyrazole-4-carboxamide, an HPMCAS polymer present in an amount of about 22% w / w of the composition; microcrystalline cellulose present in an amount of about 25% w / w of the composition; Mannitol present in an amount of about 25% w / w of the composition; sodium starch glycolate present in an amount of about 5% w / w of the composition; and magnesium stearate present in an amount of about 0.5% w / w of the composition.

[0074] In some embodiments, the HPMCAS polymer is HPMCAS-MG.

[0075] In some embodiments, the pharmaceutical composition is formulated as a tablet. In this case, the tablets are coated.

[0076] Also provided herein is a method for preparing a pharmaceutical composition, the method comprising: (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl) (phenyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazo The mixture was mixed with hydroxyl-4-carboxamide, HPMCAS polymer, and organic solvent. Forming and spray drying the mixture to form a spray-dried dispersion; and granulating the spray-dried dispersion to form a first composition.

[0077] In some embodiments, the organic solvent is a mixture of dichloromethane and methanol. In some embodiments, the organic solvent is 80:20 dichloromethane:methanol In some embodiments, the spray-dried dispersion may be granulated with one or more pharmaceutical agents. In some embodiments, the spray-dried dispersion is blended with excipients before being granulated. In some embodiments, the spray-dried dispersion is dried in an oven before being granulated. In some embodiments, the spray-dried composition is blended with one or more pharmaceutical excipients. The dispersion is granulated by roller compaction. In some embodiments, the first composition comprises: In some embodiments, the first composition is blended with one or more pharmaceutical excipients. In some embodiments, the first composition is compressed into a tablet. In some embodiments, the tablets are coated. The coating may include a polymer, a plasticizer, a pigment, or a combination thereof.

[0078] In some embodiments, the (S)-5-amino-3-(4-(( 5-Fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trimethylphenyl) (trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide and HPMCA In some embodiments, the ratio of the spray-dried polymer to the S polymer is about 1:4 to about 4:1. (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamide) in a dispersion (1,1,1-trifluoropropan-2-yl)-1H-methylphenyl The ratio of 4-pyrazole-4-carboxamide to HPMCAS polymer is approximately 1:1. In some embodiments, the HPMCAS polymer is HPMCAS-MG.

[0079] Also provided herein is a crystalline form of the compound of Formula I, having the formula: [ka]

[0080] Herein, 15.8±0.2, 16.2±0.2, and 11.9±0.2 °2 Formula I, characterized in that it has an X-ray powder diffraction (XRPD) pattern containing a peak at a θ value Also provided is Form A of the compound:

[0081] Herein, 15.8±0.2, 16.2±0.2, 11.9±0.2, 19.0± X-ray powder diffraction (XRPD) patterns included peaks at °2θ values ​​of 0.2, 18.3 ± 0.2, and 18.3 ± 0.2. Also provided is Form A of the compound of Formula I, characterized as having a turn.

[0082] Herein, 15.8±0.2, 16.2±0.2, 11.9±0.2, 19.0± Pi values ​​of 0.2, 18.3±0.2, 23.8±0.2, and 20.5±0.2°2θ A compound of formula I characterized by having an X-ray powder diffraction (XRPD) pattern containing Form A is also provided.

[0083] Herein, 15.8±0.2, 16.2±0.2, 11.9±0.2, 19.0± 0.2, 18.3±0.2, 23.8±0.2, 20.5±0.2, 25.7±0.2, X-ray powder diffraction (XR) with peaks at °2θ values ​​of 20.1±0.2 and 9.5±0.2 Also provided is Form A of the compound of Formula I, characterized by having a PD) pattern.

[0084] Herein, 15.8±0.2, 16.2±0.2, 11.9±0.2, 19.0± 0.2, 18.3±0.2, 23.8±0.2, 20.5±0.2, 25.7±0.2, 20.1±0.2, 9.5±0.2, 25.0±0.2, and 11.1±0.2°2 having an X-ray powder diffraction (XRPD) pattern containing a peak at a value of θ of Formula I Form A of the compound is also provided.

[0085] Provided herein is a compound of formula I having an XRPD pattern substantially as shown in Figure 4A. Product Form A is also provided.

[0086] As used herein, a differential scanning calorimetry (DSC) curve containing an endotherm with an onset of about 185°C is defined as Also provided is Form A of the compound of Formula I having the formula:

[0087] Provided herein are compounds of Formula I having a DSC thermogram substantially as shown in Figure 4C. Form A of the compound is also provided.

[0088] Also referred to herein are solid oral pharmaceutical compositions comprising a pharmaceutical excipient and a crystalline form of the compound of Formula I. Provided.

[0089] As used herein, crystalline forms of the compound of Formula I prepared by mixing with pharmaceutical excipients are Also provided are solid oral pharmaceutical compositions comprising:

[0090] As used herein, a solid pharmaceutical formulation comprising mixing a crystalline form of the compound of Formula I with pharmaceutical excipients is provided. A process for making the oral pharmaceutical composition is also provided.

[0091] Also provided herein are methods for treating cancer in a subject in need thereof. The method comprises administering a therapeutically effective amount of a compound of Formula I to a spray-dried dispersion, pharmaceutical composition, or In some embodiments, the cancer is a BTK-associated cancer.

[0092] Also provided herein are methods of treating cancer in a subject in need thereof, comprising: This method is (a) the BTK gene, the BTK kinase, or the expression or activity of either thereof; or detecting dysregulation of levels of (b) a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof; administering the spray-dried dispersion, or a pharmaceutical composition thereof, to a subject.

[0093] Also provided herein is a method of treating a BTK-associated cancer in a subject, the method comprising: Compounds of formula I, or pharmaceutically acceptable salts thereof, amorphous or polymorphic forms thereof The spray-dried dispersion, or a pharmaceutical composition thereof, is used to identify or diagnose a patient with a BTK-associated cancer. This includes administering the compound to a subject who has been diagnosed with the condition.

[0094] Also provided herein is a method of treating a BTK-associated cancer in a subject, the method comprising: BTK gene, BTK kinase, or the expression or activity of either Detecting dysregulation of the level of Compounds of formula I, or pharmaceutically acceptable salts thereof, amorphous or polymorphic forms thereof, or a pharmaceutical composition thereof, and administering to the subject.

[0095] Also provided herein are methods of treating a subject, the methods comprising administering a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form of, or a spray-dried dispersion thereof; or These pharmaceutical compositions are administered to a subject who has a BTK gene, a BTK kinase, or any of the foregoing. a subject with clinical documentation indicating that the subject has dysregulated expression or activity or level of This includes administering to

[0096] Provided herein are methods for inhibiting cancer metastasis in a subject in need thereof. Also provided is a method of treating a compound of Formula I, or a pharmaceutically acceptable salt thereof, with an amorphous and administering to a subject a polymorphic or polymorphic form thereof, a spray-dried dispersion thereof, or a pharmaceutical composition thereof. This includes giving.

[0097] In some embodiments, the cancer is a BTK-associated cancer.

[0098] In some embodiments, the compound of formula I, or a pharmaceutically acceptable salt thereof, is amorphous, or polymorphic forms, spray-dried dispersions thereof, or pharmaceutical compositions thereof, may be administered in combination with another chemical Used in combination with forensic drugs.

[0099] Also provided herein are methods for selecting a treatment for a subject, the methods comprising: administering to a subject identified or diagnosed with cancer a compound of Formula I, or a pharmaceutically acceptable salt thereof; Acceptable salts, amorphous or polymorphic forms thereof, spray-dried dispersions thereof, or pharmaceutical compositions thereof Selecting a treatment that includes administering a pharmaceutical composition.

[0100] Also provided herein is a method of selecting a treatment for a subject with cancer, the method comprising: , The expression or expression of the BTK gene, the BTK kinase, or any of them in a subject detecting dysregulation of activity or level; administering to a subject a compound of Formula I, or a pharmaceutically acceptable salt thereof, amorphous or polymorphic and selecting a treatment that involves administration of the compound, a spray-dried dispersion thereof, or a pharmaceutical composition thereof. This includes:

[0101] As used herein, a compound of Formula I, or a pharmaceutically acceptable salt thereof, amorphous or polycrystalline for treatments involving administration of the medicament, a spray-dried dispersion thereof, or a pharmaceutical composition thereof A method of selecting a target is also provided, the method comprising: identifying a subject with a BTK-associated cancer; Compounds of formula I, or pharmaceutically acceptable salts thereof, amorphous or polymorphic forms thereof, and selecting a subject for treatment comprising administering a spray-dried dispersion of the compound of formula (I), or a pharmaceutical composition thereof. This includes: As used herein, a compound of Formula I, or a pharmaceutically acceptable salt thereof, amorphous or polycrystalline for treatments involving administration of the medicament, a spray-dried dispersion thereof, or a pharmaceutical composition thereof Also provided is a method for selecting a subject with cancer, the method comprising: The expression or expression of the BTK gene, the BTK kinase, or any of them in a subject detecting dysregulation of activity or level; Compounds of formula I, or pharmaceutically acceptable salts thereof, amorphous or polymorphic forms thereof, and selecting a subject for treatment comprising administering a spray-dried dispersion of the compound of formula (I), or a pharmaceutical composition thereof. This includes:

[0102] In some embodiments, determining whether a cancer in a subject is a BTK-associated cancer The step of detecting the BTK gene, the BTK kinase protein, or or any of them. In some embodiments, the method includes performing an assay for the detection of a specific gene in a sample from a subject. In some embodiments, the sample is a biopsy sample. In embodiments, the assay is performed by sequencing, immunohistochemistry, immunoblotting, enzyme-linked immunosorbent assay, or the like. and fluorescence in situ hybridization (FISH). In some embodiments, the FISH is a break-apart FISH analysis. In some embodiments, the sequencing is performed by pyrosequencing or next generation sequencing. It is gu.

[0103] In some embodiments, the BTK gene, the BTK kinase protein, or their Dysregulation in the expression, activity, or level of any one of these factors can lead to impaired BCR signaling. Pathway genes, BCR (breakpoint cluster protein) signaling pathway proteins proteins, or dysregulation in the expression or activity or levels of any of them This is the result.

[0104] In some embodiments, a BCR signaling pathway gene or a BCR signaling pathway gene Tract proteins include cyclin-D1, CARD11, CD79B, CD79A, and MYD8 8, and combinations thereof.

[0105] In some embodiments, BCR signaling pathway genes, BCR signaling pathway genes, or a modulation in the expression or activity or level of any one of them. The deficiency is the result of one or more genetic alterations.

[0106] In some embodiments, the one or more genetic alterations are a chromosomal translocation t(11;14 )(q13;q32), deletion of chromosomal region 17p13, deletion of chromosomal region 11q23, deletion of chromosome region 13q14, and trisomy of chromosome 12. .

[0107] In some embodiments, the one or more genetic alterations are in the BCR signaling pathway. It is one or more point mutations in the gene encoding the protein.

[0108] In some embodiments, in a gene encoding a BCR signaling pathway protein One or more point mutations in the BCR signaling vector with one or more amino acid substitutions leading to the translation of transduction pathway proteins, where the BCR signaling pathway proteins CARD11, CD79B, CD79A, MYD88, and their combinations In some embodiments, the BCR signaling pathway protein is selected from the group consisting of: One or more point mutations in the gene that encodes MYD88 L265 Amino acid position of BCR signaling pathways having one or more amino acid substitutions in one or more of In some embodiments, the amino acid substitution results in the translation of a tract protein. L265P is.

[0109] In some embodiments, the BTK gene, the BTK kinase, or any of them The dysregulation of expression or activity or level of the BTK gene is due to one or more In some embodiments, one or more point mutations in the BTK gene is one or more amino acid substitutions at one or more of the following amino acid positions: Leading to translation of BTK protein with: 117, 316, 474, 481, 528 , 560, 562, and 601. In some embodiments, one in the BTK gene or multiple point mutations, including the following amino acid substitutions: T117P, T316A, T474I, T 474M, T474S, C481S, C481F, C481T, C481G, C481R , L528W, P560L, R562W, R562G, and F601L This results in the translation of a BTK protein having one or more of the following:

[0110] Also provided herein are methods of treating cancer in a subject in need thereof, comprising: This method is (a) a BCR signaling pathway gene, a BCR signaling pathway protein, or detecting dysregulation of the expression or activity or level of any of these; (b) a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof; administering the spray-dried dispersion, or a pharmaceutical composition thereof, to a subject.

[0111] Also provided herein are methods of treating a subject, the methods comprising administering a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form of, or a spray-dried dispersion thereof; or These pharmaceutical compositions are administered to subjects who have a BCR signaling pathway gene, a BCR signaling pathway gene, or or dysregulation of the expression or activity or levels of any of them. This includes administering to a subject with clinical documentation indicating that

[0112] In some embodiments, the BTK-associated cancer is Hodgkin's lymphoma, diffuse large cell type B DLBCL (e.g., activated B-cell-like DLBCL (ABC-DLBCL) )), follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone lymphoma) B-cell lymphoma, splenic marginal zone lymphoma), Burkitt lymphoma, Waldenstrom's lymphoma Lymphoplasmacytic lymphoma (LPL), primary central nervous system lymphoma lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (AL) L), B-cell prolymphocytic leukemia, precursor B-lymphoblastic leukemia, hairy cell leukemia, acute bone marrow leukemia Myeloid leukemia (AML), chronic myelogenous leukemia, multiple myeloma, plasma cell myeloma, plasmacytoma , bone cancer, bone metastasis, breast cancer, gastroesophageal cancer, pancreatic cancer, ovarian cancer, prostate cancer, lung cancer, Selected from the group consisting of intestinal cancer, uterine cancer, hepatocellular carcinoma, head and neck cancer, or glioma .

[0113] In some embodiments, the BTK-associated cancer is a hematological cancer. Blood cancers include leukemia, lymphoma (non-Hodgkin's lymphoma), Hodgkin's disease, and myeloma. is selected from the group consisting of:

[0114] In some embodiments, the hematological cancer is acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), or acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic Myeloid leukemia (CML), chronic myelogenous monocytic leukemia (CMML), chronic neutrophilic leukemia ( CNL), acute undifferentiated leukemia (AUL), anaplastic large cell lymphoma (ALCL), prolymphocyte Paracytic leukemia (PML), juvenile myelomonocytic leukemia (JMML), adult T-cell ALL, AML with lineage myelodysplasia (AML / TMDS), mixed lineage leukemia (MLL), bone marrow Dysplastic syndromes (MDS), myeloproliferative disorders (MPD), diffuse large B-cell lymphoma (DLBCL) (e.g., activated B-cell-like DLBCL (ABC-DLBCL)), follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B-cell lymphoma) lymphoma, splenic marginal zone lymphoma), Burkitt's lymphoma, Waldenstrom's macroglobulinemia Lymphoplasmacytic lymphoma (LPL), primary central nervous system lymphoma, small lymphoma Myeloid lymphoma, precursor B lymphoblastic leukemia, hairy cell leukemia, chronic myeloid leukemia, undifferentiated Acute large cell lymphoma, MALT lymphoma, plasma cell myeloma, plasmacytoma, and multiple myeloma and MM.

[0115] In some embodiments, the BTK-associated cancer is a B-cell malignancy. Morphologically, B-cell malignancies include Hodgkin's lymphoma, diffuse large B-cell lymphoma (DCL), and LBCL) (e.g., activated B-cell-like DLBCL (ABC-DLBCL)), follicular lymphoma lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B-cell lymphoma, Splenic marginal zone lymphoma, Burkitt's lymphoma, Waldenstrom's macroglobulinemia lymphoplasmacytic lymphoma (LPL), primary central nervous system lymphoma, small lymphocytic Lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia (ALL), B-cell prolymphocytes leukemia, precursor B lymphoblastic leukemia, or hairy cell leukemia .

[0116] In some embodiments, the BTK-associated cancer is mantle cell lymphoma, chronic lymphocytic leukemia, or Hemophilia, small lymphocytic lymphoma, Waldenstrom's macroglobulinemia, and marginal lymphoma lymphoma, uterine plexus lymphoma, thyroid cancer ...

[0117] In some embodiments, the BTK-associated cancer is not transformed. Non-limiting examples of transformations in cancer include Richter's transformation, prolymphocytic transformation (e.g., For example, prolymphocytic transformation of CLL, transformed non-Hodgkin's lymphoma, and blastoid lymphoma. Included are cytoid lymphomas (e.g., blastoid variant mantle cell lymphoma).

[0118] In some embodiments, the BTK-associated cancer is a cancer known to involve the central nervous system by lymphoma. It is not a cancer that is being treated.

[0119] In some embodiments, the BTK-associated cancer is a solid tumor.

[0120] In some embodiments, the solid tumor is bone cancer, bone metastasis, breast cancer, gastroesophageal cancer, pancreatic cancer, ovarian cancer, prostate cancer, lung cancer, colon cancer, uterine cancer, hepatocellular carcinoma, head and neck cancer, and glioma.

[0121] In some embodiments, the compound of formula I, or a pharmaceutically acceptable salt thereof, is amorphous, or polymorphic forms thereof, spray-dried dispersions thereof, or pharmaceutical compositions thereof, can be.

[0122] In some embodiments, the method further comprises administering an additional therapy or therapeutic agent (e.g., The method further comprises administering to the subject a therapeutic agent.

[0123] In some embodiments, an additional therapy or therapeutic agent nt) are used in combination with radiation therapy, cytotoxic chemotherapy agents, and kinase-targeted therapy (therapeutic agents). ics), apoptosis regulators, signal transduction inhibitors, immune targeting therapy, transcriptional regulator inhibitors, and angiogenesis targeted therapy. In some embodiments, the additional therapy is selected from the group consisting of: In some embodiments, the therapeutic agent is selected from one or more kinase-targeted therapeutic agents. The kinase targeted therapy agent is selected from JAK, Src, IRAK, and combinations thereof. The target kinase is a kinase from a selected kinase family.

[0124] In some embodiments, the additional therapeutic agent is selected from one or more protein inhibitors. In some embodiments, the one or more protein inhibitors are selected from anti-apoptotic cis proteins, heat shock proteins, nuclear export proteins, kinases, histone deacetylases Acetylase, E3 ubiquitin ligase, histone-lysine N-methyltransferase and combinations thereof. In embodiments, the one or more protein inhibitors are selected from the group consisting of PI3K, JAK-2, IRA K1, IRAK4, BMX, TAK1, Src family, HDAC6, MDM2, BC L-2, EZH2, EHMT2, PIM, JAK3, mTOR, ROR-1, Syk, P KC, Hsp90, XPO1, and combinations thereof. In some embodiments, two additional therapeutic agents are administered (e.g., , inhibitors of mTOR and inhibitors of BCL-2).

[0125] In some embodiments, the additional therapeutic agent is an anti-apoptotic protein, a heat shock protein, or a Proteins, nuclear export proteins, kinases, histone deacetylases, E3 ubiquitin Gauze, histone-lysine N-methyltransferase, and their combinations The present invention inhibits a protein selected from the group consisting of:

[0126] In some embodiments, the additional therapeutic agent is a PI3K, JAK-2, IRAK1, IR AK4, BMX, TAK1, Src family, HDAC6, MDM2, BCL-2, E ZH2, EHMT2, PIM, JAK3, mTOR, ROR-1, Syk, PKC, Hs p90, XPO1, and combinations thereof. To harm.

[0127] In some embodiments, the compound of formula I, or a pharmaceutically acceptable salt thereof, is amorphous, or polymorphic forms thereof, spray-dried dispersions thereof, or pharmaceutical compositions thereof, and an additional treatment. The drugs are administered simultaneously in separate doses.

[0128] In some embodiments, the compound of formula I, or a pharmaceutically acceptable salt thereof, is amorphous, or polymorphic forms thereof, spray-dried dispersions thereof, or pharmaceutical compositions thereof, and an additional treatment. The drugs are administered sequentially in separate doses in any order.

[0129] Also provided herein are methods of treating a subject with cancer, the methods comprising: (a) administering one or more doses of a first BTK inhibitor to a subject over a period of time. , (b) After (a), cancer cells in a sample obtained from the subject are subjected to the first B At least one compound that confers increased resistance to treatment with TK inhibitors on cancer cells or tumors determining whether the patient has one BTK inhibitor resistance mutation; and (c) determining whether the subject has increased resistance to treatment with the first BTK inhibitor in step (a). Cancer cells or tumors with at least one BTK inhibitor resistance mutation When a spray-dried dispersion or pharmaceutical composition of a compound of formula I is administered as a monotherapy or or administering to a subject in combination with another anti-cancer agent; or (d) determining whether the subject has increased resistance to treatment with the first BTK inhibitor in step (a). If the cancer cells or tumors do not have BTK inhibitor resistance mutations, administering an additional dose of the first BTK inhibitor of step (a) to the subject.

[0130] In some embodiments, the anticancer agent in step (c) is a second BTK inhibitor, immunotherapy, or a combination thereof.

[0131] In some embodiments, the anti-cancer agent in step (c) is administered in step (a). It is the first BTK inhibitor to be developed.

[0132] In some embodiments, the anticancer agent in step (c) is one or more quinones. In some embodiments, the kinase targeted therapy is selected from JA Kinase families selected from K, Src, IRAK, and combinations thereof These kinases are targeted.

[0133] In some embodiments, the anti-cancer agent in step (c) is an anti-apoptotic protein. Proteins, heat shock proteins, nuclear export proteins, kinases, histone deacetylases , E3 ubiquitin ligase, histone-lysine N-methyltransferase, and and a protein inhibitor that inhibits a protein selected from the group consisting of the above combinations. do.

[0134] In some embodiments, the anti-cancer agent in step (c) is an anti-apoptotic protein. Proteins, heat shock proteins, nuclear export proteins, kinases, histone deacetylases , E3 ubiquitin ligase, histone-lysine N-methyltransferase, and and one or more proteins that inhibit a protein selected from the group consisting of these combinations. Protein inhibitors are selected from:

[0135] In some embodiments, the protein inhibitor is a PI3K, JAK-2, IRAK1, IRAK4, BMX, TAK1, Src family, HDAC6, MDM2, BCL-2 , EZH2, EHMT2, PIM, JAK3, mTOR, ROR-1, Syk, PKC, A protein selected from the group consisting of Hsp90, XPO1, and combinations thereof inhibits.

[0136] In some embodiments, the subject is administered an additional dose of the first BTK inhibitor of step (a). and the method further comprises (e) administering to the subject another anti-cancer agent.

[0137] In some embodiments, the anti-cancer agent in step (e) is a second BTK inhibitor, an immunotherapy law, or a combination thereof.

[0138] In some embodiments, the anticancer agent in step (e) is a compound of Formula I, or a physiologically acceptable salt, amorphous, or polymorphic form thereof, a spray-dried dispersion thereof, or and a pharmaceutical composition thereof.

[0139] Also provided herein are methods of treating a subject with cancer, the methods comprising: (a) administering one or more doses of a first BTK inhibitor to a subject over a period of time. , (b) After (a), cancer cells in a sample obtained from the subject are subjected to the first B At least one compound that confers increased resistance to treatment with TK inhibitors on cancer cells or tumors determining whether the patient has one BTK inhibitor resistance mutation; (c) determining whether the subject has increased resistance to treatment with the first BTK inhibitor in step (a). Cancer cells or tumors with at least one BTK inhibitor resistance mutation If the patient has a BTK inhibitor, a second BTK inhibitor may be administered as monotherapy or in combination with another anti-cancer drug. and administering to a subject; or (d) determining whether the subject has increased resistance to treatment with the first BTK inhibitor in step (a). If the cancer cells or tumors do not have BTK inhibitor resistance mutations, administering to the subject an additional dose of the first BTK inhibitor of step (a), wherein the mutation is , a substitution at amino acid position 481, e.g., C481S, C481F, C481T, C 481G, and C481R.

[0140] In some embodiments, the anti-cancer agent of step (c) is administered in step (a). It is the first BTK inhibitor.

[0141] In some embodiments, the subject is administered an additional dose of the first BTK inhibitor of step (a). and the method further comprises (e) administering another anti-cancer agent.

[0142] In some embodiments, the anti-cancer agent in step (e) is a second BTK inhibitor, an immunotherapy law, or a combination thereof.

[0143] In some embodiments, the anticancer agent in step (e) is a compound of Formula I, or and pharmaceutical compositions of physiologically acceptable salts.

[0144] Also provided herein are methods of treating a subject with cancer, the methods comprising: (a) administering one or more doses of a first BTK inhibitor to a subject over a period of time. , (b) After (a), cancer cells in a sample obtained from the subject are subjected to the first B At least one compound that confers increased resistance to treatment with TK inhibitors on cancer cells or tumors determining whether the patient has one BTK inhibitor resistance mutation; (c) determining whether the subject has increased resistance to treatment with the first BTK inhibitor in step (a). Cancer cells or tumors with at least one BTK inhibitor resistance mutation and a spray-dried dispersion of a compound of formula I or a pharmaceutically acceptable salt thereof, administering the pharmaceutical composition to a subject as a monotherapy or in combination with another anti-cancer agent That, or, (d) determining whether the subject has increased resistance to treatment with the first BTK inhibitor in step (a). If the cancer cells or tumors do not have BTK inhibitor resistance mutations, administering to the subject an additional dose of the first BTK inhibitor of step (a), wherein the mutation is , PLCγ2 amino acid positions, 244, 257, 334, 495, 664, 665, 70 One of 7, 708, 742, 845, 848, 993, 1140, or 1141 It is a substitution in the plural.

[0145] Also provided herein are methods of treating a subject with cancer, the methods comprising: (a) have cancer and have previously received one or more doses of a first BTK inhibitor The cancer cells in the sample obtained from the administered subject are treated with a first BTK inhibitor previously administered to the subject. one or more B-cells that confer increased resistance to treatment with the agent to cancer cells or tumors determining whether the patient has a TK inhibitor resistance mutation; and (b) the subject experiences an increased resistance to treatment with a first BTK inhibitor previously administered to the subject; Cancers with at least one BTK inhibitor resistance mutation that confers additional resistance to cancer cells or tumors If the cells are present, a spray-dried dispersion of a compound of formula I or a pharmaceutically acceptable salt thereof may be used. administering the pharmaceutical composition to a subject as a monotherapy or in combination with another anti-cancer agent That, or, (c) the subject experiences an increased resistance to treatment with a first BTK inhibitor previously administered to the subject; Addition to cancer cells or tumors that do not have BTK inhibitor resistance mutations administering an additional dose of the first BTK inhibitor to the subject.

[0146] Also provided herein are methods of treating a subject with cancer, the methods comprising: (a) have cancer and have previously received one or more doses of a first BTK inhibitor The cancer cells in the sample obtained from the administered subject are treated with a first BTK inhibitor previously administered to the subject. one or more B-cells that confer increased resistance to treatment with the agent to cancer cells or tumors determining whether the patient has a TK inhibitor resistance mutation; and (b) the subject experiences an increased resistance to treatment with a first BTK inhibitor previously administered to the subject; Cancers with at least one BTK inhibitor resistance mutation that confers additional resistance to cancer cells or tumors If the subject has a BTK inhibitor, a second BTK inhibitor may be administered to the subject as monotherapy or in combination with another antibody. administering to a subject in combination with a cancer drug; or (c) the subject experiences an increased resistance to treatment with a first BTK inhibitor previously administered to the subject; Addition to cancer cells or tumors that do not have BTK inhibitor resistance mutations administering to the subject an additional dose of the first BTK inhibitor that was previously administered to the subject.

[0147] Also provided herein are methods of treating a subject with cancer, the methods comprising: (a) administering one or more doses of a compound of formula I, or a pharmaceutically acceptable salt thereof, to a patient in need thereof; administering the spray-dried dispersion or pharmaceutical composition for a period of time; (b) after (a), detecting cancer cells in a sample obtained from the subject with the compound of Formula I of step (a); and a spray-dried dispersion or pharmaceutical composition of the compound or a pharmaceutically acceptable salt thereof. One or more BTK inhibitor resistance mutations that confer increased resistance to the cancer cell or tumor and determining whether the (c) The object is a spray-dried dispersion or a spray-dried dispersion according to any one of claims 1 to 3 in step (a). or an increase in resistance to treatment with a pharmaceutical composition according to any one of claims 7 to 93, Cancer cells that have one or more BTK inhibitor resistance mutations that confer resistance to cancer cells or tumors If the patient has a BTK inhibitor, a second BTK inhibitor may be administered as monotherapy or in combination with another anti-cancer drug. and administering to a subject; or (d) spray-dried dispersion of the compound of formula I or a pharmaceutically acceptable salt thereof of step (a) BT that confers increased resistance to treatment with a cancer cell or tumor by a drug or pharmaceutical composition. A subject having cancer cells that do not have a K inhibitor resistance mutation is administered an additional dose of the compound of formula I of step (a). or a pharmaceutically acceptable salt thereof. thing.

[0148] Also provided herein are methods of treating a subject with cancer, the methods comprising: (a) a patient with cancer and receiving one or more doses of a compound of Formula I, or and a subject previously administered a spray-dried dispersion or pharmaceutical composition of a physiologically acceptable salt. The cancer cells in the sample are treated with a compound of Formula I or a pharmaceutically acceptable salt thereof that was previously administered to the subject. and increasing resistance of cancer cells or tumors to treatment with spray-dried dispersions or pharmaceutical compositions of the salts. To determine whether a tumor has one or more BTK inhibitor resistance mutations, and, (b) the subject is a spray-dried dispersion of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or or one or more compounds that confer increased resistance to treatment with the pharmaceutical composition on cancer cells or tumors. If the patient has cancer cells with multiple BTK inhibitor resistance mutations, a second BTK inhibitor may be administered. administering to a subject as monotherapy or in combination with another anti-cancer agent; or (c) spray-drying a compound of formula I or a pharmaceutically acceptable salt thereof that has been previously administered to a subject; Confers increased resistance to treatment with the dispersion or pharmaceutical composition on cancer cells or tumors Subjects with cancer cells that do not have BTK inhibitor-resistant mutations were given an additional dose of a previously administered formula. A spray-dried dispersion or pharmaceutical composition of the compound of formula I or a pharmaceutically acceptable salt thereof is administered. To do so.

[0149] Also provided herein is a method of treating a BTK-associated cancer in a subject, the method comprising: Includes: (a) as monotherapy, one or more doses of a compound of formula I, or a pharmaceutically acceptable salt thereof; The spray-dried dispersion or pharmaceutical composition of the acceptable salt may be administered to a subject identified or suspected of having a BTK-associated cancer. administering to the diagnosed subject; (b) determining the level of circulating tumor DNA in a biological sample obtained from the subject after step (a); To judge, (c) a spray-dried dispersion or pharmaceutical composition of a compound of formula I, or a pharmaceutically acceptable salt thereof; and additional therapeutic agents or therapies were compared to reference levels of circulating tumor DNA. administering to a subject identified as having single or elevated levels of circulating tumor DNA.

[0150] In some embodiments, the additional therapeutic agent is a second BTK kinase inhibitor. In some embodiments, the additional therapeutic agent or treatment is radiation therapy, a chemotherapy agent, checkpoint inhibitors, or a combination of these. a first kinase inhibitor, surgery, and one or more second kinase inhibitors Includes multiple.

[0151] In some embodiments, the reference level of circulating tumor DNA is determined by measuring the level of circulating tumor DNA in the subject prior to step (a). The levels of circulating tumor DNA in biological samples obtained from

[0152] Also provided herein is a method of treating a BTK-associated cancer in a subject, the method comprising: A spray-dried dispersion or pharmaceutical composition of a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof. The pharmaceutical composition and the additional therapeutic agent or treatment are administered to a patient (i) identified as having or having a BTK-associated cancer. (ii) administering to a subject diagnosed with a rheumatoid arthritis or rheumatoid arthritis, one or more doses of a compound of Formula I, or a compound thereof; previously administered a spray-dried dispersion or pharmaceutical composition of a physiologically acceptable salt as monotherapy. and (ii) administering to the subject one or more doses of a compound of Formula I, or a pharmaceutically acceptable salt thereof. Circulating tumor D after administration of a spray-dried dispersion or pharmaceutical composition of an acceptable salt as monotherapy had similar or elevated levels of circulating tumor DNA compared with reference levels of NA. The method includes administering the method to a subject identified as having the disease.

[0153] In some embodiments, the reference level of circulating tumor DNA is determined by one or more doses of Compounds of formula I, or pharmaceutically acceptable salts thereof, amorphous or polymorphic forms thereof obtained from a subject prior to administration of the spray-dried dispersion or a pharmaceutical composition thereof as monotherapy. The level of circulating tumor DNA in a biological sample.

[0154] In some embodiments, the additional therapeutic agent is a second BTK kinase inhibitor. In some embodiments, the additional therapeutic agent or treatment is radiation therapy, a chemotherapy agent, checkpoint inhibitors, or a combination of these. one or more of a protein inhibitor, surgery, and one or more second protein inhibitors includes plural.

[0155] Also provided herein are methods of selecting a treatment for a subject, the methods comprising administering a therapeutically effective amount of a spray-dried dispersion or pharmaceutical composition of a compound of formula I, or a pharmaceutically acceptable salt thereof, (i) for a subject identified or diagnosed with a BTK-associated cancer, (ii) and for subjects who have previously received one or more doses of a second BTK kinase inhibitor. and (ii) after administration of one or more doses of a second BTK kinase inhibitor, have approximately the same or elevated levels of circulating tumor DNA compared to reference levels of tumor DNA The method includes selecting for subjects identified as having the disease.

[0156] Also provided herein are methods of selecting a treatment for a subject, the methods comprising administering a therapeutically effective amount of a spray-dried dispersion or pharmaceutical composition of a compound of formula I, or a pharmaceutically acceptable salt thereof, Additional therapeutic treatments include (i) BTK (ii) one or more times to a subject identified or diagnosed with a relevant cancer; a spray-dried dispersion or pharmaceutical composition of a compound of formula I, or a pharmaceutically acceptable salt thereof, (ii) to subjects who have previously received the composition as monotherapy, and (iii) one or more Spray-dried dispersion or pharmaceutical composition of a compound of formula I, or a pharmaceutically acceptable salt thereof - Patents.com After administration of the drug, the level of circulating tumor DNA was approximately the same or increased compared to the reference level. This includes selecting for subjects identified as having circulating tumor DNA.

[0157] In some embodiments, the reference level of circulating tumor DNA is determined by one or more doses of Compounds of formula I, or pharmaceutically acceptable salts thereof, amorphous or polymorphic forms thereof obtained from a subject prior to administration of the spray-dried dispersion or a pharmaceutical composition thereof as monotherapy. In some embodiments, the level of circulating tumor DNA in a biological sample is determined by the additional therapeutic treatment. In some embodiments, the additional therapeutic treatment is a second BTK kinase inhibitor. radiation therapy, chemotherapy, checkpoint inhibitors, and one or more second The compound may comprise one or more of the following protein inhibitors:

[0158] Also provided herein is a method of determining the efficacy of a treatment in a subject, the method comprising: (a) obtained from a subject identified or diagnosed with a BTK-associated cancer at a first time point; determining a first level of circulating tumor DNA in the biological sample; (b) administering one or more doses of a compound of Formula I after the first time point and before the second time point; and a spray-dried dispersion or pharmaceutical composition of the compound, or a pharmaceutically acceptable salt thereof. administering it to elephants, (c) determining a second level of circulating tumor DNA in a biological sample obtained from the subject at a second time point; and (d) a reduced second level of circulating tumor DNA compared to the first level of circulating tumor DNA; Identifying a subject determined to have NA for which the treatment is effective; or A second level of circulating tumor DNA that is approximately the same or elevated compared to the first level Identifying subjects who have been determined to have tumor DNA for which treatment is ineffective include.

[0159] Also provided herein are methods for determining whether a subject has developed resistance to a treatment, comprising: This method is (a) obtained from a subject identified or diagnosed with a BTK-associated cancer at a first time point; determining a first level of circulating tumor DNA in the biological sample; (b) administering one or more doses of a compound of Formula I after the first time point and before the second time point; and a spray-dried dispersion or pharmaceutical composition of the compound, or a pharmaceutically acceptable salt thereof. administering it to elephants, (c) determining a second level of circulating tumor DNA in a biological sample obtained from the subject at a second time point; and (d) a reduced second level of circulating tumor DNA compared to the first level of circulating tumor DNA; determining that a subject with NA has not developed resistance to the treatment; or A second level of circulating tumor DNA that is approximately the same or elevated compared to the first level determining that a subject with tumor DNA has developed resistance to the treatment. .

[0160] In any of the above embodiments, the subject has an active, uncontrolled autoimmune hematoma. In some embodiments, the subject does not have an autoimmune cytopenia. In some embodiments, the subject has not received any of the treatments described herein for more than 6 months. Clinically significant, uncontrolled heart disease, cardiovascular disease, or myocardial infarction within months In some embodiments, the subject has no history of a diagnosed heart disease or cardiovascular disease. In some embodiments, the subject has not had a myocardial infarction. In embodiments, the subject does not have a clinically significant active malabsorption syndrome. In some embodiments, the subject has not been diagnosed with a malabsorption syndrome. Elephants showed potent cytochrome P450 3A4 expression during any of the treatments described herein. (CYP3A4) inhibitors (e.g., ritonavir, indinavir, nelfinavir, saquinavir) Bil, clarithromycin, telithromycin, chloramphenicol, ketoconazole , itraconazole, posaconazole, voriconazole, nefazodone, and Covicis tat), or inducers (e.g., carbamazepine, dexamethasone, ethosuximide, Glucocorticoids, griseofulvin, phenytoin, primidone, progesterone, Rifampin, nafcillin, nelfinavir, nevirapine, oxcarbazepine, pheno Barbiturates, phenylbutazone, rofecoxib (mild), St. John's wort, rufadimidine, sulfinpyrazone, and troglitazone) In some embodiments, the subject has been in a Within 7 days, have you taken a proton pump inhibitor (e.g., omeprazole, lansoprazole, or dextromethorphan)? Slansoprazole, esomeprazole, pantoprazole, rabeprazole, ilapra In some embodiments, the subject has not been treated with an active second In some embodiments, the subject does not have an active second malignancy that is in remission. The patient has a pulmonary tumor and the life expectancy of the subject is greater than 2 years.

[0161] Also provided herein are methods for inhibiting BTK kinase activity in mammalian cells. The method comprises injecting mammalian cells with a compound of formula I or a pharmaceutically acceptable salt thereof. contacting the spray-dried dispersion, pharmaceutical composition, or polymorphic form with the

[0162] Also provided herein are methods for treating an autoimmune or inflammatory disease in a subject, the methods comprising: The method comprises administering to a subject identified or diagnosed with an autoimmune or inflammatory disease a compound of formula I A spray-dried dispersion or pharmaceutical composition of the compound, or a pharmaceutically acceptable salt thereof, is administered to a subject. This includes giving.

[0163] Unless otherwise defined, all technical and scientific terms used herein are defined by the present invention. The term "compound" has the same meaning as commonly understood by a person skilled in the art. Methods and materials for use are described herein. Suitable methods and materials may also be used. The materials, methods, and examples are for illustrative purposes only. All publications, patents, and other references mentioned herein are for illustrative purposes only and are not intended to be limiting. Patent applications, patents, sequences, database entries, and other references are incorporated herein by reference. In case of conflict, the present specification, including definitions, will control.

[0164] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will become apparent from the description and drawings, as well as from the patents. This will be clear from the claims. [Brief explanation of the drawings]

[0165] [Figure 1] 1 is an X-ray powder diffraction scan of Form A of the compound of formula I (free base). [Figure 2A] 2A is a differential scanning calorimetry (DSC) scan of a mixture of Form A and Form B of the compound of Formula I. FIG. 2A is a differential scanning calorimetry (DSC) scan of a mixture of polymorphic Form A and Form B of the compound of Formula I. [Figure 2B] 2A is a scan of a mixture of Forms A and B of the compound of Formula I. FIG. 2B is a 1H NMR spectrum of a mixture of polymorphic Forms A and B of the compound of Formula I. [Figure 3A] 3A is a scan of Form C of the compound of Formula I. FIG. 3A is a 1H NMR spectrum of Form C of the compound of Formula I. [Figure 3B] Figure 3B is a differential scanning calorimetry scan of Form C of the compound of Formula I. Figure 3B is a differential scanning calorimetry scan of Form C of the compound of Formula I (hemi-1,4-dioxane solvate). [Figure 4A] 4A is an X-ray powder diffraction scan of Form A of the compound of Formula I. FIG. 4A is an X-ray powder diffraction scan of Form A of the compound of Formula I. [Figure 4B] Figure 4A is a scan of Form A of the compound of Formula I. Figure 4B is a 1H NMR spectrum of Form A of the compound of Formula I. [Figure 4C] 4A is a scan of Form A of the compound of Formula I. FIG. 4C is a differential scanning calorimetry scan of Form A of the compound of Formula I. [Figure 5] 1 is a modulated DSC scan of a spray-dried dispersion prototype of the compound of Formula I. [Figure 6]1 is an X-ray powder diffraction scan of a spray-dried dispersion prototype of the compound of Formula I. [Figure 7] 1 is a thermogravimetric analysis (TGA) scan of a spray-dried dispersion prototype of the compound of Formula I. [Figure 8] 1 shows the dissolution of tablets containing a spray-dried dispersion of the compound of Formula I and HPMCAS polymer. [Figure 9] 1 shows the concentration of the compound of Formula I in plasma over time from an in vivo dog bioavailability and pharmacokinetic study. [Figure 10A] Figures 10A and 10B show the dose-response effect of the compound of Formula I and ibrutinib on Y223 autophosphorylation in HEK293 cells stably expressing BTK (tBTK) (referring to total BTK) (Figure 10A) and BTK C481S (Figure 10B). Figures 10C and 10D are dose-response curves generated from the Western blot data of Y223 autophosphorylation in HEK293 cells stably expressing BTK (Figure 10C) and BTK C481S (Figure 10D). The compound of Formula I inhibited BTK Y223 autophosphorylation with IC50 values ​​of 8.6 ± 0.3 nM and 8.8 ± 1.8 nM in both the wild-type and C481S mutant proteins, respectively. Ibrutinib inhibited BTK wild-type with an IC50 of 5.7 ± 0.5 nM, and its activity against the C481S mutant failed to fit an IC50 curve. [Figure 10B] Same as above. [Figure 10C] Same as above. [Figure 10D] Same as above. [Figure 11A] 1 is a Western blot showing the dose response of the compound of Formula I on BTK Y223 and PLCγ2 Y1217 phosphorylation in Ramos RA1 cells. [Figure 11B]Figure 1 is a plot of Western blot data for BTK Y223 in Ramos RA1 cells. The compound of Formula I inhibited BTK Y223 autophosphorylation with an IC50 of 3.2 ± 0.6 nM and PLCγ2 Y1217 phosphorylation with an IC50 of 8.2 nM ± 4.3. [Figure 11C] 1 is a plot of Western blot data for PLCγ2 Y1217 phosphorylation in Ramos RA1 cells. The compound of Formula I inhibited BTK Y223 autophosphorylation with an IC50 of 3.2±0.6 nM and PLCγ2 Y1217 phosphorylation with an IC50 of 8.2 nM±4.3. [Figure 12A] 1 is a plot showing dose-response inhibition of compounds of Formula I on TMD8 proliferation. [Figure 12B] 12B is a plot showing the area under the curve (AUC) (mean ± SD) versus inhibitor concentration from FIG. 12A. Quantitation of the area under the curve (AUC) for each individual curve allowed the determination of an IC50 of 2.33 nM for the compound of Formula I against TMD8 proliferation. [Figure 13A] Figure 13A shows dose-dependent inhibition of tumor growth in an OCI-Ly10 human B cell lymphoma cell line xenograft tumor mouse model. Figure 13B shows tumor growth by tumor volume, expressed as the mean ± SEM, of human B cell lymphoma cell line xenograft tumor mouse models administered with the indicated vehicle or inhibitor. [Figure 13B] Figure 13A shows dose-dependent inhibition of tumor growth in an OCI-Ly10 human B-cell lymphoma cell line xenograft tumor mouse model. Figure 13B shows tumor growth after treatment is stopped in a human B-cell lymphoma cell line xenograft tumor mouse model. [Figure 13C] Figure 13C shows dose-dependent inhibition of tumor growth in an OCI-Ly10 human B-cell lymphoma cell line xenograft tumor mouse model. Figure 13C shows normalized body weight values, expressed as mean ± SEM, of mice over the course of treatment. [Figure 14A]Figure 14A shows dose-dependent inhibition of tumor growth in a TMD8 human B-cell lymphoma cell line xenograft tumor mouse model. Figure 14B shows tumor growth by tumor volume, expressed as mean ± SEM, in a TMD8 human B-cell lymphoma cell line xenograft tumor mouse model administered with the indicated vehicle or inhibitor. [Figure 14B] Figure 14B shows the dose-dependent inhibition of tumor growth in a TMD8 human B-cell lymphoma cell line xenograft tumor mouse model. Figure 14B shows the tumor weight after 14 days of administration of the compound of Formula I in a TMD8 human B-cell lymphoma cell line xenograft tumor mouse model. [Figure 14C] Figure 14C shows dose-dependent inhibition of tumor growth in a TMD8 human B-cell lymphoma cell line xenograft tumor mouse model. Figure 14C shows normalized body weight values, expressed as mean ± SEM, of mice over the course of treatment. [Figure 15A] Figure 15A shows the concentration of the compound of Formula I in the plasma of dogs over a 48 hour period. Figure 15B shows the concentration of the compound of Formula I in the plasma of fed and fasted dogs administered the crystalline compound of Formula I in suspension. [Figure 15B] Figure 15B shows the concentration of the compound of Formula I in dog plasma over a 48 hour period. Figure 15B shows the concentration of the compound of Formula I in the plasma of fed and fasted dogs for dogs administered a 50% SDI of the compound of Formula I.

[0166] Like reference symbols in the various drawings indicate like elements. DETAILED DESCRIPTION OF THE INVENTION

[0167] definition As used herein, the term "polymorph" refers to a polymorph resulting from the ordering of molecules within a crystal lattice. Polymorphism refers to the crystallization of the same compound with different physical properties. are characterized by one or more distinct chemical, physical, mechanical, electrical, thermodynamic, and The differences in physical properties exhibited by polymorphs can be attributed to storage and / or biological properties. Stability, compressibility, density (important in formulation and product manufacturing), dissolution rate (bio- (important factors for determining availability), solubility, melting point, chemical stability, physical stability, It can affect pharmaceutical parameters such as powder flowability, moisture sorption, compaction, and particle morphology. Differences in stability can be attributed to chemical reactivity (e.g., a compound is more likely to be present in one polymorph than in another). When constructed, the dosage form may discolor more rapidly due to different oxidation) or mechanical changes (e.g. For example, during storage when the kinetically favored polymorph converts to the thermodynamically more stable polymorph. crystallographic changes), or both (e.g., one polymorph is more hygroscopic than the other). Some transitions may be effective as a result of differences in solubility / degradation. Furthermore, the physical properties of the crystals can be important in processing, e.g. One polymorph is more likely to form a solvate, or the impurities can be filtered and washed away. It can be difficult to exclude particles from the rest of the sample (i.e., particle shape and size distribution may differ from other (The chemical structure of one polymorph may differ from that of the other polymorph). When used herein, "polymorph" does not include amorphous forms of a compound. "Amorphous" refers to a non-crystalline form of a compound, which may be a solid state form of the compound or a solubilized form of the compound. For example, "amorphous" refers to a material that has no regular repeating arrangement of molecules or external planes. "A compound" refers to a compound that is not in a liquid state (e.g., a solid form of a compound).

[0168] As used herein, the term "anhydrous" refers to a compound of Formula I having 1% or less water by weight. Refers to the crystalline form of a compound. For example, 0.5% by weight or less, 0.25% by weight or less, or 0. It contains less than 1% water by weight.

[0169] As used herein, the term "solvate" refers to a compound in which the crystalline lattice is one or more refers to a crystalline form of a compound of Formula I, including a polymorphic form of the compound, including a solvent of crystallization.

[0170] "Purity" when used in reference to a composition containing a polymorph of the compound of Formula I refers to One particular polymorphic form of the compound of formula I in a composition relative to another polymorphic form or amorphous form. For example, a composition containing polymorph Form 1 with a purity of 90% would be 90 parts by weight of Form 1 and 10 parts by weight of other polymorphic forms and / or amorphous forms of the compound of Formula I and a quantity portion.

[0171] As used herein, a compound or composition does not contain significant amounts of other components. , a compound or composition is "substantially free" of one or more such other components. For example, the composition may contain less than 5%, 4%, 3%, 2%, or 1% by weight of other ingredients. Such components may include starting materials, residual solvents, or the components described herein. Other compounds and compositions that may result from the preparation and / or isolation of the compounds and compositions provided herein. In some embodiments, the polymorphic forms provided herein may contain other impurities. In some embodiments, a particular polymorph of the compound of formula I is When a particular polymorph constitutes at least about 95% by weight of the compound of Formula I in existence, other "Substantially free" of polymorphs. In some embodiments, a particular polymorph of a compound of Formula I is at least about 97%, about 98%, about 99%, or about 100% by weight of a compound of Formula I in which a particular polymorph exists. 99% by weight, or about 99.5% by weight, is "substantially free" of other polymorphs. In certain embodiments, the particular polymorph of the compound of Formula I has an amount of water that is about 2% by weight of the polymorph. , about 1% by weight, or about 0.5% by weight or less.

[0172] As used herein, "substantially pure" refers to a polymorphic form of the compound of Formula I. When used, 91%, 92%, 93%, 94%, based on the weight of the compound, Including 95%, 96%, 97%, 98%, and 99% as well as those equal to approximately 100% "Polymorphic" means a sample of a polymorphic form of a compound having a purity greater than 90%, including greater than 90%. The remaining material may be other form(s) of the compound, and / or reaction impurities and / or For example, polymorphic forms of the compound of Formula I are known in the art and include process impurities arising from its preparation. When measured by means currently known and generally accepted in the field, The polymorphic form of the compound of formula I is greater than 90% pure, with the remaining material being less than 10% of the compound of formula I. and / or reaction impurities and / or processing impurities. It may be considered substantially pure in that it is free from reaction and / or processing impurities. The present invention can be carried out by, for example, chromatography, nuclear magnetic resonance spectroscopy, mass spectroscopy, or infrared spectroscopy. This can be determined by any analytical technique known in the art.

[0173] Values ​​for DSC, TGA, TG (glass transition temperature) or DTA (differential thermal analysis) The term "about" precedes temperatures that are reported as degrees Celsius and have an acceptable variation of ±5°C.

[0174] To provide a more concise description, some of the quantitative expressions herein may be expressed as about a quantity X to about a quantity When a range is listed, the range includes the upper and lower limits of the range. It is not limited to the addition and subtraction of X or Y, but rather the entire range from X to Y, or any range therein. Includes enclosure.

[0175] "Room temperature" or "RT" refers to typical laboratory ambient temperature, typically about 25°C. do.

[0176] "Spray drying" refers to a process for producing a dry powder from a solution or slurry. The slurry is then sprayed or rapidly dried with a hot gas such as air or nitrogen. The dispersion is then dried, which allows the solvent to evaporate quickly and uniformly. It refers to the powder obtained from the drying process.

[0177] The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any Any and all solvents, co-solvents, complexing agents, dispersants, etc. that are not chemically or otherwise undesirable. These may include dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, it is not intended to be used in conjunction with any conventional media or agent. Supplementary active ingredients may also be incorporated into the compositions. In addition, various excipients commonly used in the art may be included. These and other such compounds can be found in the literature, e.g., Merck Inde x, Merck & Company, Rahway, NJ. Discussions about the inclusion of various components in the s.)(2010);Goodman and Gilman's: The Pharm Acological Basis of Therapeutics,12th Ed .,listed at The McGraw-Hill Companies.

[0178] As used herein, the terms "subject," "individual," or "patient" are used interchangeably. Used for mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, and sheep It refers to any animal, including mammals such as horses, primates, and humans. In some embodiments, the subject is a human.

[0179] In some embodiments, the subject is a minor with the disease or disorder to be treated and / or prevented. In some embodiments, the subject is experiencing and / or exhibiting at least one symptom. , the BTK gene, the BTK protein, or the expression or activity of any of them. have been identified or diagnosed as having cancer with dysregulated levels of BTK (BTK-associated cancers) (e.g., determined using a regulatory agency-approved, e.g., FDA-approved, assay or kit) In some embodiments, the subject has a genetic disorder characterized by a BTK gene, BTK protein, or The present study involves the development of tumors that are positive for dysregulation of the expression, activity, or level of any of these. (e.g., as determined using a regulatory agency-approved assay or kit). The TK gene, the BTK protein, or the expression or activity or level of either thereof The subject may have tumor(s) that are positive for dysregulation of bell (e.g., regulatory (identified as positive using an approved, e.g., FDA-approved, assay or kit) Subjects are randomly assigned to receive a BTK gene, BTK protein, or either of these tumors. or a subject having dysregulated activity or levels (e.g., a tumor or Identified as such using an agency-approved, e.g., FDA-approved, kit or assay In some embodiments, the subject is suspected of having a BTK-associated cancer. In some embodiments, the subject has been identified or diagnosed as having a hematological cancer. In embodiments, the subject has been identified or diagnosed as having a B-cell malignancy. In embodiments, the subject is a patient with a genetic disorder characterized by a BTK gene, a BTK protein, or both. Clinical records showing that the patient has a tumor with dysregulated expression or activity or level of and optionally, the clinical record indicates that the subject has received a In some embodiments, the subject is a pediatric patient. is a person.

[0180] As used herein, the term "pediatric patient" refers to a patient under the age of 21 at the time of diagnosis or treatment. The term "child" refers to patients in the following age groups: newborns (from birth to 1 month of age), infants (1 month old), months to 2 years), children (2 to 12 years), and adolescents (12 to 21 years). and various subgroups, including (up to but excluding) their 22nd birthday. Berhman RE, Kliegman R, Arvin AM, Nelson WE's Textbook of Pediatrics, 15t h Ed.Philadelphia:WBSaunders Company,1 996, Rudolph AM et al. Rudolph's Pediatrics, 21s t Ed.New York:McGraw-Hill,2002, and Avery MD, First LR Pediatric Medicine, 2nd Ed.Ba See Eltimore: Williams & Wilkins; 1994. In some embodiments, the pediatric patient is between birth and 28 days of age, between 29 days of age and under 2 years of age, between 29 days of age and under 2 years of age, Between the ages of 12 and under, or between the ages of 12 and 21 (up to their 22nd birthday, but In some embodiments, pediatric patients are treated from birth to 28 days of age. 29 days to under 1 year old, 1 month to under 4 months old, 3 months to under 7 months old, 6 months to under 1 year old, 1 year to under 2 years old, 2 years to under 3 years old, 2 years to under 7 years old, 3 years to under 5 years old Full-age, 5 to under 10 years old, 6 to under 13 years old, 10 to under 15 years old, or 15 to 22 years old is less than.

[0181] As used herein, the terms "treat" or "treatment" refer to therapeutic or Refers to palliative measures. Beneficial or desirable clinical outcomes include detectable or undetectable outcomes. the total or partial alleviation of symptoms associated with a disease or disorder or condition, regardless of whether the disease a decrease in severity, a stable state of disease (i.e., not worsening), a delay in disease progression, or Slowing, improvement or alleviation of a disease state (e.g., one or more symptoms of a disease), and remission This includes, but is not limited to, solutions (whether partial or total). " also means an increase in survival compared with the expected survival without treatment. You can also taste it.

[0182] The term "therapy" refers to one or more doses administered to a subject as part of a treatment regimen. refers to the administration of an active compound or pharmaceutical agent.

[0183] In one embodiment, as used herein, the term "preventing" refers to the onset, recurrence or spread of any disease or condition described herein, or its symptoms, in whole or in part; This means prevention of

[0184] The term "progression" is defined by the National Cancer Institute (NCI) Cancer Glossary. For example, progression refers to the progression of cancer cells in a subject. an increase in the number of tumors, an increase in the size of one or more tumors in a subject, an increase in tumor burden, metastasis an increase in the rate or severity of the disease, a worsening of symptoms related in whole or in part to the cancer, or the extent of the disease "Progression" can also include an increase in the risk of developing a disease without treatment, and / or an accelerated progression of the disease. It can also mean shortened survival compared to the survival expected in the same patient. In some embodiments, progression is characterized by an increase in the percentage of blasts, an increase in the myeloid to erythroblast ratio, atypical myeloid erythroid leukemia, or atypical myeloid leukemia. Increased bone marrow plasma cell percentage and bone marrow leukocyte dysplasia (e.g., leukodysplasia) The method may include detecting one or more of an increase in the percentage of marrow lymphocytes ( See, for example, Sever, et al., A. rch Pathol Lab Med.2016 Sep;140(9):932-4 9). In some embodiments, progression is measured by measuring the number of white blood cells (e.g., polymorphonuclear leukocytes). ) percentage, decreased platelet count, and decreased hemoglobin in peripheral blood. In some embodiments, the tumor burden may include detecting one or more of R Evaluate using RECIST (e.g., RECIST version 1 or version 1.1) See, for example, Eisenhower, "Principles of the Invention," which is incorporated herein by reference in its entirety. nhauer et al.,Eur.J.Cancer.2009,45(2):22 See 8-47. In some embodiments, tumor burden is assessed using PERCIST. For example, Watson et al., "Study on the Quantitative Analysis of Electron Microscopy," which is incorporated herein by reference in its entirety. See hl,et al.J.nucl.med.2009,50:122S-150S I want to be done that.

[0185] The term "recurrence" is defined by the National Cancer Institute (NCI) Cancer Glossary: refers to the return of signs and symptoms of a disease or disease after a period of improvement, as in For example, relapse can be an increase in the number of cancer cells in a subject after a period of improvement, or a single tumor in a subject. or an increase in the size of multiple tumors, an increase in tumor burden, an increase in the rate or extent of metastasis, or an overall or worsening of symptoms, increased extent of disease, and / or progression of disease that are partly related to cancer In some embodiments, relapse may include detecting an acceleration of progression after a period of improvement. In some embodiments, the period of improvement may include progression of cancer. a reduction in the size of one or more tumors in a subject, a reduction in tumor burden, a reduction in the rate of metastasis or a decrease in the extent, improvement in symptoms related in whole or in part to cancer, or a decrease in the extent of disease and / or detecting a slowing of disease progression. Relapse is characterized by an increase in the percentage of blasts, an increase in the myeloid-to-erythroid ratio, and atypia after a period of improvement. Increased proliferation (e.g., leukodysplasia), increased percentage of bone marrow plasma cells, and bone marrow The method may include detecting one or more of an increase in the percentage of lymphocytes. In some embodiments, the period of improvement includes a decrease in the percentage of blasts, a decrease in the myeloid-to-erythroid ratio, or reduction in dysplasia (e.g., leukodysplasia), reduction in the percentage of bone marrow plasma cells, and and a decrease in the percentage of bone marrow. In some embodiments, relapse is characterized by a decrease in white blood cell (e.g., polymorphonuclear leukocyte) percentage after a period of improvement. one of the following: increased blood count, decreased platelet count, and decreased hemoglobin in peripheral blood In some embodiments, the duration of improvement may include detecting a decrease in white blood cells ( For example, a decrease in the percentage of polymorphonuclear leukocytes (PMNs), an increase in platelet count, and a decrease in hemoglobin levels in the peripheral blood. The method may include detecting one or more of an increase in IgG4-associated leukemia (LEK) or an increase in IgG4-associated leukemia (LEK).

[0186] "Relapse" is also defined by the National Cancer Institute as a period when cancer usually goes undetected. may include "recurrence," defined as cancer that has returned after a period of time Cancer may come back in the same place in the body as the original (primary) tumor or in another place in the body. (NCI Cancer Dictionary). In some embodiments, not detecting cancer is No cancer cells are detected in the subjects, no tumors are detected in the subjects, and / or or may include the total or partial absence of symptoms related to cancer.

[0187] As used herein, the terms "intolerance" and "intolerant" refer to a condition that occurs during therapy. unplanned hospitalization, discontinuation of therapy and / or reduction in therapy dose, and therapy-related functional decline severe, disabling, and / or resulting in a decrease in performance status; In some embodiments, performance may refer to the occurrence of a life-threatening adverse event. A decline in performance status is defined as a decrease in the Eastern Cooperative Oncology Group (ECOG) performance status can be evaluated using a method (e.g., the method described herein, which is incorporated by reference in its entirety). Oken et al. Am. J. Clin. Oncol. 5:649-655 (1982), which is incorporated by referenc. (See e in its entirety herein.) In terms of morphology, the decline in performance status is due to the Karnofsky performance status. The assay can be evaluated using a method such as Peus et al., BMC Med.Inform.Decis.Mak. 13:72 (2013). In some embodiments, the subject is a pediatric patient. Performance status is assessed by the Lansky Performance Score. (See, e.g., Lansky et al., herein incorporated by reference in its entirety. ., Cancer. 60(7):1651-6 (1987).

[0188] As used herein, the term "prevent" refers to preventing or preventing a disease or condition as described herein. means preventing the onset, recurrence or spread of a condition, or its symptoms, in whole or in part.

[0189] The terms "administration" or "administering" refer to the administration of a substance to a mammal, bird, fish, or amphibian, including a spinal cord. It refers to a method of administering a dose of a compound or pharmaceutical composition to a vertebrate or invertebrate. The preferred method of administration will depend on various factors, such as the components of the pharmaceutical composition, the site of the disease, and the severity of the disease. May vary depending on severity.

[0190] As provided herein, a "therapeutically effective amount" or "pharmaceutically effective amount" of a compound refers to a the amount of the compound in an amount sufficient to achieve the desired effect, taking into account the nature and severity of the disease state and the A therapeutic effect may vary according to the efficacy of the drug. The sum of the above and the above may include curing a disease. "Cure" means that the symptoms of an active disease are eliminated. However, even after a cure is achieved, certain long-term or permanent symptoms of the disease may persist. There may be consequences (e.g., widespread tissue damage, etc.).

[0191] "The expression or activity or level of a gene, protein, or any of them The term "dysregulated" refers to genetic mutations (e.g., kinase domain and fusion partner mutations). chromosomal translocation, resulting in expression of a fusion protein containing Mutations in genes that result in the expression of proteins containing a single amino acid deletion, A genetic disorder that results in the expression of a protein that contains one or more point mutations compared to the normal protein. Mutations in the offspring, including at least one inserted amino acid compared to the wild-type protein Mutations in genes that result in the expression of proteins containing α-glucan, or in the level of proteins in cells in regulatory sequences (e.g., promoters and / or enhancers) that result in an increase mutation), a deletion of at least one amino acid in the protein compared to the wild-type protein alternatively spliced ​​versions of mRNA that result in proteins with deletions), or aberrant cell signaling and / or is a neurotransmitter in mammalian cells caused by dysregulated autocrine / paracrine signaling. It refers to increased expression (e.g., increased levels) of a native protein. Dysregulation of expression or activity or levels of a gene, protein, or any of them is a protein encoded by a gene that is constitutively active or does not contain a mutation The mutation may be in a gene encoding a protein with increased activity compared to the original protein. For example, a gene, a protein, or the expression or activity of any of them. Dysregulation of levels occurs in the first part of the protein, which contains a functional kinase domain, and in the second part, which contains a a fusion protein comprising a second portion of a parent protein (i.e., not the primary protein) It can be the result of a genetic or chromosomal translocation that results in the expression of a protein. Modulation of the expression or activity or levels of a gene, protein, or any of them The deficiency may be the result of a genetic translocation of one gene with another.

[0192] "The BTK gene, the BTK kinase, or the expression or activity of either thereof The phrase "dysregulated levels" refers to increased expression of BTK kinase, transcription of the BTK gene, and This refers to an increase in the activity of BTK kinase or an increase in its phosphorylation. gene, BTK kinase, or the expression or activity or level of any of them Dysregulation can be caused by genetic mutations (e.g., BTK gene translocations resulting in expression of fusion proteins, A BTK protein containing at least one amino acid deletion compared to the wild-type BTK protein. A deletion or one or more point mutations in the BTK gene resulting in expression of the protein mutations in the BTK gene that result in the expression of the BTK protein, or B Pathological increase in the activity of the kinase domain of the TK protein (e.g., BTK protein) Overexpression of the BTK gene in cells results in a constitutively active kinase domain ( BTK gene expression, resulting in overexpression or autocrine activity of the BTK protein In another example, the BTK gene, the BTK protein, or their Dysregulation of the expression, activity, or level of either BTK mRNA is a selective Spliced ​​versions, or alternative promoters, compared to wild-type BTK mRNA In some embodiments, the BTK mRNA is transcribed starting at . Alternatively spliced ​​versions of the mRNA were compared with wild-type BTK protein. to result in a BTK with a deletion of at least one amino acid in the BTK protein. In some embodiments, the BTK kinase is transcribed from an alternative promoter compared to the wild-type BTK kinase. The BTK mRNA expressed in the N-terminus of the BTK kinase was significantly higher than that of the wild-type BTK kinase. In another example, the BTK kinase is K gene, BTK protein, or the expression, activity, or level of either thereof Dysregulation of BTK is controlled by constitutively active or mutation-free BTK genes. B encodes a BTK protein with increased activity compared to the protein it is designed to encode. The mutation may be in the BTK gene. Further examples of dysregulation of either expression or activity or level include BTK inhibitor resistance. Non-limiting examples of BTK inhibitor-resistant mutations are listed in Table 2.

[0193] In some embodiments, the BTK gene, the BTK kinase, or any of them Dysregulation of expression or activity or levels of BCR signaling pathway genes, BCR Signal transduction pathway proteins, or the expression or activity or levels of any of them In some embodiments, the BCR signaling pathway genes, BCR Signal transduction pathway proteins, or the expression or activity or levels of any of them Dysregulation of the IL-1 pathway leads to activation of one or more of the BCR complex or downstream signaling components. mutations, continuous BCR stimulation by microbial or autoantigens present in the tissue microenvironment, or ligand-independent, resulting in a pathogenic increase in BTK protein expression or activation. In some embodiments, the BCR signaling pathway is a sustained BCR signaling pathway. tract genes, BCR signaling pathway proteins, or the expression or Dysregulation of activity or levels of one or more BCR signaling pathway proteins For example, overexpression or overactivation of the BTK gene, BTK protein, or Dysregulation of the expression, activity, or levels of any of them disrupts BCR signaling. Genetic mutations in pathway proteins (e.g., BCR pathway mutations leading to expression of fusion proteins) signaling pathway gene translocations, and fewer BCR signaling pathway proteins compared to wild-type B, which results in the expression of BCR signaling pathway proteins containing a single amino acid deletion BCR signaling pathway gene deletion or BCR signaling pathway gene deletion with one or more point mutations mutations in BCR signaling pathway genes that result in expression of null transduction pathway proteins; BCR signaling pathway proteins compared to wild-type BCR signaling pathway proteins BCR signaling pathway proteins that result in the deletion of at least one amino acid in the alternatively spliced ​​versions of BCR signaling pathway protein mRNAs Non-limiting examples of BCR signaling pathway mutations are listed in Table 4. The BTK gene, the BTK protein, or the expression or activity of either of them A further example of dysregulated BCR levels is BTK inhibitor resistance mutations. Non-limiting examples of BTK inhibitor resistance mutations in pathway proteins are listed in Table 3. .

[0194] As used herein, the term "BTK-associated disease or disorder" refers to a disorder or disorder that results from a genetic disorder related to BTK. BTK kinase (referred to herein as BTK kinase protein or BTK kinase (also referred to as "genes"), or the expression or activity of any (e.g., one or more) thereof or dysregulated levels (e.g., any type of BTK gene described herein, BTK kinase, BTK kinase domain, or the expression or activity of any of them refers to a disease or disorder associated with or involving dysregulation of BTK levels. Non-limiting examples of related diseases or disorders include, for example, cancer and autoimmune diseases such as arthritis and lupus. Includes epidemics.

[0195] As used herein, the term "BTK-associated cancer" refers to a cancer that is caused by a mutation in the BTK gene, BTK Kinase (also referred to herein as BTK kinase protein or BTK kinase) or associated with dysregulation of the expression or activity or levels of any of them Non-limiting examples of BTK-associated cancers are described herein. It has been done.

[0196] The term "activating mutation" refers to a mutation that, when assayed under identical conditions, e.g., wild-type Mutations in genes that result in the expression of proteins with increased activity compared to the protein For example, activating mutations can be expressed in fusion proteins comprising a kinase domain and a fusion partner. In another example, an activating mutation can result in expression of a protein, e.g., one or more proteins that, when synthesized, result in increased protein activity, e.g., compared to the wild-type protein. A number (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10) of amino acid substitutions (e.g., amino acid substitutions described herein). In another example, an activating mutation can be a mutation in a gene that results in expression of a protein. For example, when assayed under identical conditions, one or more Multiple (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid deletions In another example, an activating mutation can be a mutation in a gene that results in the expression of a protein that activates the The difference may be, for example, a small difference when compared to the wild-type protein when assayed under identical conditions. At least one (e.g., at least two, at least three, at least four, at least five, at least 6, at least 7, at least 8, at least 9, at least 10, at least 1 2, at least 14, at least 16, at least 18, or at least 20 The mutation may be in a gene that results in the expression of a protein with the inserted amino acid.

[0197] In some embodiments, an "activating mutation" is, for example, , e.g., expression of a BTK kinase with increased kinase activity compared to wild-type BTK kinase. For example, an activating mutation refers to a mutation in the BTK kinase gene that results in This can result in the expression of a fusion protein comprising the enzyme domain and the fusion partner. In an example, an activating mutation may be present in a protein that is more potent than, for example, a wild-type BTK kinase when assayed under identical conditions. one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 6 6, 7, 8, 9, or 10) amino acid substitutions (e.g., amino acids described herein) B, resulting in expression of BTK kinase having any of the substitutions (any combination of the substitutions) In another example, the activating mutation can be a mutation in the TK kinase gene, e.g., When assayed under these conditions, the BTK kinase exhibits one or more ( B having an amino acid deletion (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10) Another example may be a mutation in the BTK kinase gene that results in expression of the TK kinase. For example, an activating mutation may be a mutation that, when assayed under the same conditions, e.g., as described herein, When compared to wild-type BTK kinase, such as a typical wild-type BTK kinase, at least 1 (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, a few at least 14, at least 16, at least 18, or at least 20 inserted Mutations in the BTK kinase gene resulting in expression of BTK kinase with an incorrect amino acid Further examples of activating mutations are known in the art.

[0198] In some embodiments, an "activating mutation" is, for example, For example, a BCR signaling pathway protein that has increased activity compared to a wild-type BCR signaling pathway protein. In BCR signaling pathway protein genes, which leads to the expression of neutrophil signaling pathway proteins For example, activating mutations refer to mutations in BCR signaling pathway protein domains and In another example, an activating mutation can result in the expression of a fusion protein comprising the activating mutation and a fusion partner. The difference may be, for example, a difference between wild-type BCR signaling pathway proteins when assayed under identical conditions. one or more (e.g., 2, 3, 4, 5, 6, 7) proteins that have increased activity compared to the , 8, 9, or 10) amino acid substitutions (e.g., amino acid substitutions described herein). BCR signaling pathways leading to expression of BTK kinase (any combination of any of the above). In another example, the activating mutation may be a mutation in a signal transduction pathway protein gene. For example, when assayed under identical conditions, e.g., wild-type BCR signaling pathway proteins Compared to quality, one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 1 BC resulting in the expression of BCR signaling pathway proteins with a 0 amino acid deletion In another example, an activating mutation can be in a gene encoding a protein in the R signaling pathway. is a wild-type BCR signaling pathway protein when assayed under identical conditions, e.g. When comparing with at least 1 (e.g., at least 2, at least 3, at least 4) , at least 5, at least 6, at least 7, at least 8, at least 9, at least At least 10, at least 12, at least 14, at least 16, at least 18, or Expression of BCR signaling pathway proteins with inserted amino acids (at least 20) The mutations may be in BCR signaling pathway protein genes that result in activation. Further examples of mutations are known in the art.

[0199] The term "wildtype" or "wild-type" does not have a BTK-associated disease, e.g., a BTK-associated cancer (and optionally, Not at increased risk of developing the disease and / or not suspected of having a BTK-related disease ) or do not have a BTK-associated disease, e.g., a BTK-associated cancer. and optionally, without an increased risk of developing a BTK-related disease and / or Nucleic acids (e.g., B12) found in cells or tissues from subjects (not suspected of having a B12-associated disease) BTK gene or BTK mRNA) or protein (e.g., BTK protein) Represents.

[0200] The term "regulatory authority" refers to the national authority that approves the medical use of medicines in each country. For example, one non-limiting example of a regulatory authority is the United States Food and Drug Administration (FDA).

[0201] As defined herein, a "BTK kinase inhibitor" includes any compound that exhibits BTK inhibitory activity. In some embodiments, the BTK kinase inhibitor is a BTK kinase inhibitor. Exemplary BTK kinase inhibitors are selective for the enzymes described herein. When measured by HPLC, the concentration is less than about 1000 nM, less than about 500 nM, less than about 200 nM, and less than about 10 less than 0 nM, less than about 50 nM, less than about 25 nM, less than about 10 nM, or less than about 1 nM , inhibitory activity against BTK kinase (IC 50 In some embodiments, BTK kinase inhibitors have a potency of less than about 25 nM as measured in the assays provided herein. less than about 10 nM, less than about 5 nM, or less than about 1 nM of inhibitory activity against BTK kinase Harmful activity (IC 50 ) can be shown.

[0202] As used herein, a "first BTK kinase inhibitor" or "first BTK inhibitor" refers to a compound that inhibits BTK kinase activity. An "inhibitor" is a BTK kinase inhibitor as defined herein, but is not limited to a BTK kinase inhibitor as defined herein. Compound of formula I, or a pharmaceutically acceptable salt thereof, amorphous, polymorphic form, or spray-dried form thereof As used herein, "second B" does not include a dispersion, or a pharmaceutical composition thereof. A "BTK kinase inhibitor" or "second BTK inhibitor" refers to a BTK kinase inhibitor, as defined herein. and a compound of formula I as defined herein, or a pharmaceutically acceptable salt thereof. The present invention does not include salts, amorphous, or polymorphic forms thereof. When both BTK inhibitors are present, the first and second BTK kinase inhibitors are different.

[0203] The term "immunotherapy" refers to agents that modulate the immune system. In some embodiments, Immunotherapy can increase the expression and / or activity of regulators of the immune system. In some embodiments, immunotherapy involves reducing the expression and / or activity of regulators of the immune system. In some embodiments, immunotherapy can mobilize and stimulate the activity of immune cells. and / or augmented.

[0204] As used herein, the term "pharmaceutical combination" refers to a mixture of two or more active ingredients. refers to pharmaceutical therapies resulting from fixed and non-fixed combinations of active ingredients. This includes both.

[0205] The term "fixed combination" refers to a compound of Formula I, or a pharmaceutically acceptable salt thereof. , amorphous, or polymorphic form, a spray-dried dispersion thereof, or a pharmaceutical composition thereof; and at least one additional therapeutic agent (e.g., a chemotherapeutic agent), both in a single composition or It means that the two components are administered to a subject simultaneously in the form of a single dosage.

[0206] The term "non-fixed combination" refers to a compound of Formula I or a pharmaceutically acceptable salt thereof. salts, amorphous or polymorphic forms thereof, spray-dried dispersions thereof, or pharmaceutical compositions thereof; , at least one additional therapeutic agent (e.g., a chemotherapeutic agent), and can be administered simultaneously, concomitantly, or sequentially with various time interval limits to the subject and such administration results in effective levels of two or more compounds in the body of the subject. These are meant to be formulated as separate compositions or dosages such as The invention also applies to teratology, for example the administration of three or more active ingredients.

[0207] The term "metastasis" is an art-recognized term and refers to the loss of a subject or a primary site in a subject. This refers to the formation of additional tumors (e.g., solid tumors) at sites distant from the original tumor, and The tumor contains the same or similar cancer cells as the primary tumor.

[0208] The phrase "risk of developing metastases" refers to the risk that a subject with a primary tumor or a subject or the formation of additional tumors (e.g., solid tumors) at sites distant from the primary tumor in the subject. This means the risk of getting a new tumor, and the new tumor contains the same or similar cancer cells as the primary tumor. The present invention provides a method for reducing the risk of developing metastases in a subject having cancer or in a subject. It's listed in the fine print.

[0209] The phrase "risk of developing further metastases" refers to the risk of developing metastases from the primary tumor and from sites distant from the primary tumor. one or more additional tumors at the site (wherein the one or more additional tumors are the primary tumor a subject or subject with a tumor (including cancer cells the same as or similar to the primary tumor) is The risk of developing one or more additional tumors in the primary tumor. Contains the same or similar cancer cells as the tumor. Reduces the risk of developing further metastases. The methods are described herein.

[0210] As used herein, the term "contacting" refers to an in vitro system or an in vivo system. The term "system" refers to the combination of the indicated moieties in a system. For example, the BTK kinase is provided herein. "Contacting" a subject with a compound refers to contacting a subject with a compound that is present in an individual, such as a human, that has BTK kinase or a mammal that has BTK kinase. Administering a compound provided herein to a subject and administering, e.g., a compound provided herein, introducing the compound into a sample containing cells or a purified preparation containing BTK kinase; include.

[0211] The phrase "effective amount" means that, when administered to a subject in need of such treatment, (i) (ii) to treat a specific disease, condition, or disorder associated with BTK kinase; (iii) attenuate, ameliorate, or eliminate one or more symptoms of the disorder; or Delay the onset of one or more symptoms of a specific disease, condition, or disorder described in the literature , means an amount of a compound of formula I corresponding to such an amount, or its pharmaceutically acceptable salts, amorphous or polymorphic forms, spray-dried dispersions thereof, and The amount of each of these pharmaceutical compositions may vary depending on the particular compound, the disease state and its severity, the type of treatment required, and the dosage. This may vary depending on factors such as the individual's personality (e.g., weight), but This can be routinely determined by one of ordinary skill in the art.

[0212] 1. Pharmaceutical Compositions of Compounds of Formula I The present disclosure provides a method for producing a polymer and a compound of formula I: [ka] or a pharmaceutical composition comprising a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof. More specifically, it is a BTK kinase inhibitor, including BTK-related diseases and disorders. Compounds of formula I and their pharmaceutical compositions are useful in the treatment and prevention of diseases that can be treated. Spray-dried dispersions or oral pharmaceutical compositions of therapeutically acceptable salts, amorphous or polymorphic forms thereof do.

[0213] spray dried dispersion As used herein, the compound of formula I and hypromellose acetate succinate (HPMCAS ) polymer. Non-limiting examples of HPMCAS polymers are: HPMCAS-MG, HPMCAS-LF, HPMCAS-LG, HPMCAS- HPMCAS types include MF, HMPCAS-HF, and HPMCAS-HG. L is a polymer with a high ratio of succinoyl substitution to acetyl substitution (S / A ratio). However, Type H HPMCAS is a polymer with a low S / A ratio, and Type M HPMCA S polymer has a medium S / A ratio. HPMCAS types F and G are fine particles, respectively. In some embodiments, the compound of Formula I and the HPMCAS polymer In some embodiments, the ratio of the compound of Formula I to the polymer is about 1:4 to about 4:1. The ratio of HPMCAS polymer is about 4:1, about 3:1, about 7:3, about 13:7, about 3:2 , about 11:9, about 1:1, about 9:11, about 2:3, about 7:13, about 3:7, about 1:3, In some embodiments, the ratio of the compound of Formula I to the HPMCAS polymer is about 1:4. In some embodiments, the HPMCAS polymer is HPMCA S-LF, HPMCAS-LG, HPMCAS-MF, HMPCAS-HF, HPMCA S-HG, or a combination thereof. The rema is HPMCAS-MG.

[0214] Also provided herein is a method for preparing a spray-dried dispersion of a compound of Formula I. The method comprises adding an HPMCAS polymer to a compound of formula I and spray-drying the mixture to form a spray-coated product. and forming a dry dispersion. In some embodiments, the compound of formula I and the HPM In some embodiments, the ratio of the CAS polymer to the CAS polymer is about 1:4 to about 4:1. The ratio of compound to HPMCAS polymer is about 4:1, about 3:1, about 7:3, about 13:7, Approx. 3:2, Approx. 11:9, Approx. 1:1, Approx. 9:11, Approx. 2:3, Approx. 7:13, Approx. 3:7, Approx. 1 In some embodiments, the ratio of the compound of formula I to the HPMCAS polymer is about 1:3, or about 1:4. In some embodiments, the ratio of the compound of Formula I to HPMCAS is about 1:1. In some embodiments, the HPMCAS polymer is in a ratio of about 1:1. PMCAS-MG.

[0215] In some embodiments, the compound of formula I is spray dried in a solution-forming solution. In some embodiments, the solvent is one or more organic solvents. In some embodiments, the organic solvent is methanol, acetone, dichloromethane, or the like. methane, tetrahydrofuran, and combinations thereof. In some embodiments, the solvent is a mixture of an organic solvent and water. The solvent is a mixture of tetrahydrofuran and water. For example, the organic solvent is a 95:5 mixture of tetrahydrofuran and water. In some embodiments, the organic solvent is dichloromethane. For example, the organic solvent is a mixture of dichloromethane and methanol (80:20 w / w% by volume). In another example, the solvent is 100% methanol. In some embodiments, Form A of the compound of Formula I is dissolved in one or more organic solvents. .

[0216] In some embodiments, the solution of the compound of Formula I is added to the HPMCAS polymer. In some embodiments, the compound of formula I and the HPMCAS polymer are mixed and then polished and filtered. The solution is polish filtered before being spray dried. The polymer is HPMCAS-MG.

[0217] In some embodiments, the HPMCAS polymer is dissolved in an organic solvent. In an embodiment, the HPMCAS polymer is HPMCAS-MG.

[0218] In some embodiments, the HPMCAS polymer is dissolved in one or more solvents. In some embodiments, the solvent is one or more organic solvents. In embodiments, the organic solvent is methanol, acetone, dichloromethane, tetrahydrofuran. and combinations thereof. is a mixture of an organic solvent and water. In some embodiments, the solvent is tetrahydrofuran. and water. For example, the organic solvent is 95:5 tetrahydrofuran:water. In some embodiments, the organic solvent is a mixture of dichloromethane and methanol. For example, the organic solvent can be 80:20 w / w% dichloromethane:methanol. In another example, the solvent is 100% methanol. The compound of Formula I is then added and dissolved. In some embodiments, the HPMCAS polymer is HPMCAS-MG.

[0219] The method further comprises spray drying a solution of the compound of Formula I and the HPMCAS polymer. In some embodiments, the HPMCAS polymer is HPMCAS-MG. .

[0220] In some embodiments, the method further comprises drying the spray-dried dispersion. In some embodiments, the spray-dried dispersion is dried, e.g., to remove residual solvent. In some embodiments, the spray-dried dispersion is dried in an oven. In some embodiments, the spray-dried dispersion is dried at a temperature of about 30° C. to about 50° C. In the present invention, the spray-dried dispersion is dried at a temperature of about 35°C to about 45°C, for example, about 40°C. In some embodiments, the spray-dried dispersion is dried in vacuum under a N purge. In some embodiments, the spray-dried dispersion is dried for about 10 to about 40 hours, about 30 to about 60 hours, or about 50 to 80 hours, 70 to 100 hours, 40 hours, 50 hours, 60 hours, 70 hours In some embodiments, the mixture is dried for about 80 hours, about 90 hours, or about 100 hours. In this case, the spray dried dispersion is spray dried for about 20,000 ppm until less than about 40,000 ppm of solvent remains. until less than about 10,000 ppm of solvent remains, or until less than about 5000 ppm of solvent remains until less than about 2,500 ppm of solvent remains, or until less than about 1,000 ppm of solvent remains. It is dried until less than ppm of solvent remains, or until less than about 600 ppm of solvent remains. In some embodiments, the solvent is a mixture of dichloromethane and methanol, and the solvent is spray-dried. The dry dispersion contains less than about 2000 ppm dichloromethane and less than about 15,000 ppm Less than about 1,500 ppm dichloromethane and about 10,000 ppm methanol remain. until less than ppm of methanol remains, or less than about 600 ppm of dichloromethane and It is dried until less than about 3,000 ppm of methanol remains. In some embodiments using ethanol, the spray-dried dispersion contains less than about 3,000 ppm The mixture is dried until 100% of the methanol remains.

[0221] Pharmaceutical Composition Provided herein are pharmaceutical compositions comprising a spray-dried dispersion of a compound of Formula I and an HPMCAS polymer. In some embodiments, the HPMCAS polymer is HPMCAS-MG is.

[0222] In some embodiments, the pharmaceutical composition comprises a spray-dried dispersion and one or more pharmaceutical agents. The spray-dried dispersion comprises a first composition having an excipient, and the spray-dried dispersion comprises an HPMCAS polymer and the present invention. In some embodiments, the HPMCAS polymer comprises a compound of formula I as described herein. HPMCAS-MG.

[0223] In some embodiments, the spray-dried dispersion comprises about 20% to about 75% w / v of the first composition. In some embodiments, the spray-dried dispersion is present in an amount of about 20 wt. % to about 50% w / w, about 50% to about 75% w / w, or about 30% to about 60% w / w For example, the first composition is present in an amount of about 20% to about 40% w / w, about 30% to about 50% w / w. In some cases, the content is about 40% to about 60% w / w, or about 50% to about 75% w / w. In embodiments, the spray-dried dispersion comprises from about 30% to about 40% w / w of the composition, from about 40% to about 50% w / w of the composition. % w / w, about 50% to about 60% w / w, for example, about 35% of the first composition. w / w, about 40% w / w, about 45% w / w, about 50% w / w, about 55% w / w, or about It is 60% w / w.

[0224] In some embodiments, the pharmaceutical excipients of the first composition include fillers, lubricants, and the like. and combinations thereof.

[0225] In some embodiments, the first composition described herein can include a filler. Agents include binders, diluents, disintegrants, glidants, and surfactants added to pharmaceutical compositions. In some embodiments, the filler may comprise a saccharide (e.g., sugar, starch, and cellulose), gelatin, and synthetic polymers [e.g., polyvinylpyrrolidone, Polyethylene glycol, and poloxamers (e.g., poloxamer 188, polyoxamer Exemplary fillers include: Glucose, sucrose, lactose (e.g., Foremost Fast Flow 316 lactose monohydrate), starch [sodium starch glycolate (e.g., modified starches such as EXPLOTAB®, xylitol, dextrose, Phosphorus, sucrose, sorbitol, mannitol [e.g., PARTECK® ) M200 (mannitol with an average particle size of approximately 50 μm to approximately 500 μm) or PARTEC K® M100 (mannitol with an average particle size of less than 212 μm)] or Mann ogemEZ spray-dried mannitol, cellulose, polyvinylpyrrolidone, polyethylene Glycol, polyvinyl alcohol, polymethacrylate, dibasic calcium phosphate, Magnesium stearate, calcium stearate, sodium stearate, stearic acid Phosphoric acid, hydrogenated vegetable oil, mineral oil, sodium lauryl sulfate, magnesium lauryl sulfate, palm oil Glyceryl lumitostearate, sodium benzoate, sodium stearyl fumarate, Colloidal silicon dioxide (e.g., sodium benzoate, sodium oleate, sodium acetate) Tritium, alginic acid, alginate (e.g., Syloid 244FP) alginic acid Includes, but is not limited to, sodium, calcium silicate, and ion exchange resins. Exemplary cellulose fillers include microcrystalline cellulose [e.g., AVICEL (registered trademark)]. PH-101 (microcrystalline cellulose with an average particle size of approximately 50 μm) or AVICE L® PH200 (microcrystalline cellulose with an average particle size of about 180 μm)], or AVICEL® PH102 Methylcellulose, Ethylcellulose, Croscal Sodium mellose (e.g., AC-Di Sol®), hydroxypropyl cellulose, and hydroxypropyl methylcellulose. The pyrrolidone filler is KOLLIDON (registered trademark) CL (average particle size 90 μm to 1 30 μm crospovidone) or KOLLIDON® CL-SF (average particle size Cross-linked polyvinylpyrrolidone such as crospovidone (having a particle size of 10 μm to 30 μm) is included. Other fillers known to those skilled in the art may also be useful when incorporated into the compositions described herein. It is thought to be useful.

[0226] In some embodiments, the filler is glucose, sucrose, lactose, starch [Modified starch such as sodium starch glycolate (EXPLOTAB®)] Contains gluten, xylitol, dextrin, sucrose, sorbitol, mannitol [For example, PARTECK (registered trademark) M200 (average particle size: about 50 μm to about 500 μm) mannitol) or PARTECK® M100 (average particle size less than 212 μm) full mannitol)], cellulose, polyvinylpyrrolidone, polyethylene glycol, Polyvinyl alcohol, polymethacrylate, dibasic calcium phosphate, stearic acid Magnesium, calcium stearate, sodium stearate, stearic acid, hydrogen Hydrogenated vegetable oil, mineral oil, sodium lauryl sulfate, magnesium lauryl sulfate, palmitostearin Glyceryl phosphate, sodium benzoate, sodium stearyl fumarate, colloidal diglyceride Silicon oxide (e.g., sodium benzoate, sodium oleate, sodium acetate, Ligic acid, alginate (e.g., sodium alginate), calcium silicate, ions exchange resins, or a combination thereof. In one embodiment, the cellulose is microcrystalline cellulose (e.g., AVICEL® ) PH-101 (microcrystalline cellulose with an average particle size of approximately 50 μm) or AVICEL (registered trademark) Registered trademark) PH200 (microcrystalline cellulose with an average particle size of approximately 180 μm), methylcellulose cellulose, ethyl cellulose, croscarmellose sodium, hydroxypropyl cellulose hydroxypropyl methylcellulose, or a combination thereof. In some embodiments, the polyvinylpyrrolidone is selected from the group consisting of KOLLIDON® and KOLLIDON®. Trademark) CL (crospovidone with an average particle size of 90 μm to 130 μm), KOLLIDON ( Registered trademark) CL-SF (crospovidone with an average particle size of 10 μm to 30 μm), or and crosslinked polyvinylpyrrolidone such as a combination of these.

[0227] In some embodiments, the filler is present in an amount of about 25% to about 80% w / w of the first composition. For example, about 25% to about 50% w / w, about 50% to about 80% w / w of the first composition. In some embodiments, the filler is from about 40% to about 70% w / w of the first composition. Approximately 30% to 50% w / w, approximately 45% to 65% w / w, approximately 55% to 75% w / w For example, about 40% w / w, about 45% w / w, about 50% w / w, or about 50% w / w of the first composition. w / w, about 55% w / w, about 60% w / w, about 65% w / w, or about 70% w / w do.

[0228] In some embodiments, the filler is selected from the group consisting of a binder, a disintegrant, or a combination thereof. be selected.

[0229] Binders include agents that hold active pharmaceutical ingredients and inactive ingredients together into a cohesive mixture. Exemplary binders include glucose, sucrose, lactose, starch [starch including modified starches such as sodium glycolate (EXPLOTAB®). , xylitol, dextrin, sucrose, sorbitol, mannitol [e.g., PARTECK (registered trademark) M200 (mannite with an average particle size of approximately 50 μm to approximately 500 μm) PARTECK (registered trademark) M100 (mannitol having an average particle size of less than 212 μm) cellulose, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol These include cellulose, polymethacrylate, and sodium starch glycolate. Exemplary cellulose fillers include, but are not limited to, microcrystalline cellulose [e.g., A VICEL® PH-101 (microcrystalline cellulose with an average particle size of approximately 50 μm) or AVICEL (registered trademark) PH200 (microcrystalline cellulose with an average particle size of approximately 180 μm) cellulose)], or methylcellulose, ethylcellulose, croscarmellose sodium, Includes hydroxypropyl cellulose and hydroxypropyl methylcellulose Exemplary polyvinylpyrrolidone fillers include KOLLIDON® CL (average Crospovidone with particle size of 90 μm to 130 μm) or KOLLIDON® C Cross-linked polyvinylpyrrolidone such as L-SF (crospovidone with an average particle size of 10 μm to 30 μm) Other binders known to those skilled in the art may also be used in the compositions described herein. It is believed to be useful when combined.

[0230] In some embodiments, the binder is present in an amount of about 30% to about 80% w / w of the first composition. For example, about 30% to about 50% w / w, about 50% to about 80% w / w of the first composition. In some embodiments, the filler is from about 40% to about 70% w / w of the first composition. of the substance, about 30% to about 50% w / w, about 35% to about 55% w / w, about 40% to about 60% w / It is present in an amount of about 45% to about 65% w / w, about 55% to about 75% w / w. of the composition of 1, about 40% w / w, about 45% w / w, about 50% w / w, about 52% w / w, about 55% w / w, about 60% w / w, about 65% w / w, or about 70% w / w.

[0231] In some embodiments, the binder is selected from the group consisting of microcrystalline cellulose, cellulose ethers, hydrogels, and the like. Hydroxypropyl cellulose, Hydroxypropyl methylcellulose, Sodium carboxylate Dimethylcellulose starch, methylcellulose, ethylcellulose, hydroxypropyl cellulose, mannitol, xylitol, sorbitol, lactose, sucrose, Sorbitol, gelatin, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohols, polymethacrylates, and combinations thereof .

[0232] In some embodiments, the binder is microcrystalline cellulose, mannitol, or the like. In some embodiments, the microcrystalline cellulose is a combination of the first composition. For example, about 5% to about 40% of the first composition. w / w, about 40% to about 80% w / w, about 20% to about 60% w / w, about 5% to about 30% w / w, about 30% to about 55% w / w, about 10% to about 40% w / w, or about 15% to about 35% In some embodiments, the microcrystalline cellulose is present in an amount of about 1% by weight of the first composition. 0% to about 20% w / w, about 20% to about 30% w / w, about 30% to about 40% w / w, about 40 % to about 50% w / w, about 50% to about 60% w / w, or about 60% to about 70% w / w For example, the first composition may be present in an amount of about 15% w / w, about 20% w / w, about 25% w / w, or about 30% w / w of the first composition. w, about 26%w / w, about 30%w / w, about 35%w / w, about 40%w / w, about 45%w / w, about 50% w / w, or about 60% w / w.

[0233] In some embodiments, mannitol comprises about 5% to about 80% w / w of the first composition. For example, about 5% to about 40% w / w, about 40% to about 80% of the first composition. w / w, about 20% to about 60% w / w, about 5% to about 30% w / w, about 30% to about 55% w / w / w, about 10% to about 40% w / w, or about 15% to about 35% w / w. In embodiments, mannitol comprises about 10% to about 20% w / w of the first composition, about 20% to about 30% w / w of the first composition. Approximately 30% w / w, approximately 30% to approximately 40% w / w, approximately 40% to approximately 50% w / w, approximately 50% to approximately 60% w / w, or about 60% to about 70% w / w. For example, the first composition of about 15%w / w, about 20%w / w, about 25%w / w, about 26%w / w, about 30%w / w, about 35% w / w, about 40% w / w, about 45% w / w, about 50% w / w, or about 60 %w / w.

[0234] In some embodiments, the binder is a combination of microcrystalline cellulose and mannitol. In some embodiments, the microcrystalline cellulose comprises from about 5% to about 40% w / w, about 40% to about 75% w / w, about 20% to about 60% w / w, about 5% to about 30 % w / w, about 30% to about 55% w / w, about 10% to about 40% w / w, or about 15% to about 35% w / w, and mannitol is present in an amount of about 5% to about 40% w / w of the first composition. , about 40% to about 75% w / w, about 20% to about 60% w / w, about 5% to about 30% w / w, about 30% to about 55% w / w, about 10% to about 40% w / w, or about 15% to about 35% w / w In some embodiments, the microcrystalline cellulose is present in an amount of about 10% to about 20% w / w, about 20% to about 30% w / w, about 30% to about 40% w / w, about 4 0% to about 50% w / w, about 50% to about 60% w / w, or about 60% to about 70% w / w and mannitol is present in an amount of about 10% to about 20% w / w, about 20% to about 30% w / w of the first composition. Approximately 30% w / w, approximately 30% to approximately 40% w / w, approximately 40% to approximately 50% w / w, approximately 50% to approximately 60% w / w, or about 60% to about 70% w / w. For example, microcrystalline The sucrose may comprise about 15% w / w, about 20% w / w, about 25% w / w, about 26% w / w, or about 30% w / w of the first composition. %w / w, about 30%w / w, about 35%w / w, about 40%w / w, about 45%w / w, about 50 % w / w, or about 60% w / w, of the first composition, and mannitol is present in an amount of about 1 5%w / w, about 20%w / w, about 25%w / w, about 26%w / w, about 30%w / w, about 35 % w / w, about 40% w / w, about 45% w / w, about 50% w / w of the initial composition, or about Present in an amount of 60% w / w.

[0235] Disintegrants include any agent that promotes the breakdown of a formulation in an aqueous environment. This is to facilitate more rapid release of the drug ingredient. Exemplary disintegrants include starch and Modified starches such as sodium starch glycolate, croscarmellose sodium, Alginic acid, alginates such as sodium alginate, polyvinylpyrrolidone, silicic acid Examples of suitable ion exchange resins include, but are not limited to, calcium, and anion exchange resins. In this embodiment, the disintegrants are sodium starch glycolate and sodium croscarmellose. Other disintegrants known to those skilled in the art may also be used in the compositions described herein. It is thought to be useful when combined with

[0236] In some embodiments, the disintegrant is present in an amount of about 0.5% to about 5% w / w of the first composition. For example, from about 0.5% to about 2.5% w / w of the first composition, from about 2.5% w / w In some embodiments, the concentration is from about 1.5% to about 5% w / w, or from about 1.5% to about 3.5% w / w. The disintegrant may comprise from about 0.5% to about 2% w / w, from about 1% to about 3% w / w, or from about 2% w / w of the first composition. % to about 4% w / w, or about 3% to about 5% w / w. For example, in the first composition of about 1% w / w, about 1.5% w / w, about 2% w / w, about 2.5% w / w, about 3% w / w , about 3.5% w / w, or about 4% w / w.

[0237] In some embodiments, disintegrants include sodium starch glycolate, alginic acid, Sodium alginate, croscarmellose sodium anion exchange resin, and In one embodiment, the disintegrant is selected from the group consisting of starch glycolates and combinations thereof. The preferred hydroxybenzoates are selected from sodium hydroxybenzoates, sodium benzoate, and croscarmellose sodium.

[0238] In some embodiments, the sodium starch glycolate comprises about 0.5% of the first composition. It is present in an amount of 5% to about 5% w / w, for example, about 0.5% to about 2.5% w / w of the first composition. / w, about 2.5% w / w to about 5% w / w, or about 1.5% to about 3.5% w / w In some embodiments, the sodium starch glycolate comprises about 0.05% of the first composition. 0.5% to about 2% w / w, about 1% to about 3% w / w, about 2% to about 4% w / w, or about 3% It is present in an amount of about 5% w / w, e.g., about 1% w / w, about 1.5% w / w of the first composition. w, about 2% w / w, about 2.5% w / w, about 3% w / w, about 3.5% w / w, or about 4% It is w / w.

[0239] In some embodiments, the first composition described herein may include a lubricant. Lubricants are agents added to pharmaceutical formulations to reduce friction during processing. Exemplary lubricants include: Contains magnesium stearate, calcium stearate, sodium stearate, Stearic acid, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium lauryl sulfate, Magnesium lauryl sulfate, glyceryl palmitostearate, sodium benzoate, Sodium tearyl fumarate, colloidal silicon dioxide, sodium benzoate, olein Examples of suitable soluble ... Other lubricants known to those skilled in the art have also been found to be useful when incorporated into the compositions described herein. It is possible.

[0240] In some embodiments, the lubricant comprises from about 0.05% to about 2.5% w / w of the first composition. For example, from about 0.05% w / w to about 1.25% w / w of the first composition, 1.25% to about 2.5% w / w, or about 0.1% to about 1% w / w. In embodiments, the lubricant comprises from about 0.05% to about 0.15% w / w of the first composition, about 0.1 5%~about 0.25%w / w, about 0.25%~about 0.35%w / w, about 0.35%~about 0. In some embodiments, the amount of hydroxybenzoates is about 45% w / w, about 0.45% to about 0.55% w / w. In the first composition, the lubricant is present in an amount of about 0.2% to about 0.3% w / w. In some embodiments, the lubricant comprises about 0.1%, about 0.15%, about 0.2%, or about 0.4% of the first composition. w / w, approximately 0.25% w / w, approximately 0.3% w / w, approximately 0.35% w / w, approximately 0.4% w / w, about 0.45% w / w, about 1% w / w, about 1.5% w / w, or about 2% w / w exist.

[0241] In some embodiments, the lubricant is magnesium stearate and / or dioxide. In some embodiments, the first composition is magnesium stearate, about 100% silicon dioxide ... It is present in an amount of 0.05% to about 2.5% w / w, e.g., about 0.05% w / w of the first composition. / w to about 1.25% w / w, about 1.25% to about 2.5% w / w, or about 0.1% to about 1 % w / w. In some embodiments, magnesium stearate is present in the first composition of about 0.05% to about 0.15% w / w, about 0.15% to about 0.25% w / w, about 0.2 5%~about 0.35%w / w, about 0.35%~about 0.45%w / w, about 0.45%~about 0. In some embodiments, magnesium stearate is present in an amount of 55% w / w. In some embodiments, the first composition is present in an amount of about 0.2% to about 0.3% w / w. , magnesium stearate is about 0.1%, about 0.15%, about 0.2% of the first composition %w / w, approximately 0.25%w / w, approximately 0.3%w / w, approximately 0.35%w / w, approximately 0.4%w / w, about 0.45% w / w, about 1% w / w, about 1.5% w / w, or about 2% w / w It exists in.

[0242] In some embodiments, the spray-dried dispersion and pharmaceutical excipients form a first composition. In some embodiments, the first composition is granulated. In some embodiments, the first composition is granulated by roller compaction.

[0243] A pharmaceutical composition comprising the first composition As used herein, a first composition as described herein and one or more additional pharmaceutical excipients Also provided are pharmaceutical compositions comprising the agent. In some embodiments, the first composition comprises the entire composition. is present in an amount of about 15% to about 99% w / w.

[0244] In some embodiments, the additional pharmaceutical excipients include fillers, lubricants, glidents, and and combinations thereof.

[0245] In some embodiments, the lubricant is present in an amount of about 0.05% to about 2% w / w of the total composition. For example, about 0.05% to about 1% w / w, about 1% to about 2% w / w, or In some embodiments, the lubricant is present in an amount of about 0.5% to about 1.5% w / w of the total composition. about 0.05% to about 0.5% w / w, about 0.1% to about 0.8% w / w, or about 0.5% It is present in an amount of about 0.1% w / w, about 0.2% w / w, or about 1% w / w of the total composition. w, about 0.3% w / w, about 0.4% w / w, or about 0.5% w / w.

[0246] In some embodiments, the lubricant is magnesium stearate, calcium stearate, or Calcium, sodium stearate, stearic acid, hydrogenated vegetable oil, mineral oil, polyethylene glycol Cole, sodium lauryl sulfate, magnesium lauryl sulfate, glycerin palmitostearate Lyceryl, Sodium Benzoate, Sodium Stearyl Fumarate, Colloidal Silicon Dioxide sodium benzoate, sodium oleate, sodium acetate, and combinations thereof The compound is selected from the group consisting of:

[0247] In some embodiments, the lubricant is magnesium stearate and / or dioxide. In some embodiments, magnesium stearate accounts for about 0.05% of the total composition. It is present in an amount of from about 0.05% to about 2% w / w, for example, from about 0.05% to about 1% w / w of the total composition. w / w, about 1% to about 2% w / w, or about 0.5% to about 1.5% w / w. In embodiments, magnesium stearate is present in an amount of about 0.05% to about 0.5% w / w of the total composition. , about 0.1% to about 0.8% w / w, or about 0.5% to about 1% w / w. For example, about 0.1% w / w, about 0.2% w / w, about 0.3% w / w, about 0.4% of the total composition. w / w, or about 0.5% w / w.

[0248] In some embodiments, the filler is present in an amount of about 1% to about 85% w / w of the total composition. In some embodiments, the filler is glucose, sucrose, lactose, starch, or the like. Modified starch such as sodium starch glycolate (EXPLOTAB®) Contains gluten, xylitol, dextrin, sucrose, sorbitol, mannitol For example, PARTECK (registered trademark) M200 (average particle size of about 50 μm to about 500 μm) mannitol), PARTECK® M100 (average particle size less than 212 μm) mannitol)], cellulose, polyvinylpyrrolidone, polyethylene glycol, poly Vinyl alcohol, polymethacrylate, dibasic calcium phosphate, stearic acid malate Magnesium, calcium stearate, sodium stearate, stearic acid, hydrogenated Vegetable oil, mineral oil, sodium lauryl sulfate, magnesium lauryl sulfate, palmitosteal Glyceryl Phosphate, Sodium Benzoate, Sodium Stearyl Fumarate, Colloidal Diglycerides of Fatty Acids Silicon dioxide (e.g., sodium benzoate, sodium oleate, sodium acetate, ant Alginic acid, alginate (e.g., sodium alginate), calcium silicate, ion exchange and combinations thereof. In embodiments, the cellulose is microcrystalline cellulose (e.g., AVICEL® PH-101 (microcrystalline cellulose with an average particle size of approximately 50 μm) or AVICEL (registered trademark Trademark) PH200 (microcrystalline cellulose with an average particle size of approximately 180 μm), methylcellulose cellulose, ethyl cellulose, croscarmellose sodium, hydroxypropyl cellulose , hydroxypropyl methylcellulose, or a combination thereof In some embodiments, the polyvinylpyrrolidone is KOLLIDON®. CL (crospovidone with an average particle size of 90 μm to 130 μm), or KOLLIDO Cross-linking agent such as N (registered trademark) CL-SF (crospovidone with an average particle size of 10 μm to 30 μm) In some embodiments, the filler is a binder, a disintegrant, Or a combination thereof.

[0249] In some embodiments, the filler comprises a disintegrant. In some embodiments, the disintegrant , present in an amount of about 0.5% to about 5% w / w of the total composition. For example, about 0.5% about 2.5% w / w, about 2.5% to about 5% w / w, or about 1% to about 4% w / w. In some embodiments, the disintegrant comprises from about 1% to about 2% w / w, from about 1.5% to about 2% w / w, of the total composition. about 2.5% w / w, about 2% to about 3% w / w, about 2.5% to about 3.5% w / w, or about 3 % to about 4% w / w of the total composition. w, about 2.5% w / w, about 3% w / w, or about 3.5% w / w.

[0250] In some embodiments, disintegrants include sodium starch glycolate, alginic acid, Selected from the group consisting of sodium alginate, anion exchange resins, and combinations thereof. It is selected.

[0251] In some embodiments, the disintegrant is sodium starch glycolate or croscarmellose. In some embodiments, sodium starch glycolate. The gel is present in an amount of about 0.5% to about 5% w / w of the total composition. For example, about 0. 5% to about 2.5% w / w, about 2.5% to about 5% w / w, or about 1% to about 4% w / w In some embodiments, sodium starch glycolate comprises about 1% of the total composition. ~approximately 2% w / w, approximately 1.5% to approximately 2.5% w / w, approximately 2% to approximately 3% w / w, approximately 2.5% It is present in an amount of about 3.5% w / w, or about 3% to about 4% w / w of the total composition. about 1.5% w / w, about 2% w / w, about 2.5% w / w, about 3% w / w, or about 3.5% It is w / w.

[0252] In some embodiments, the composition includes a glidant that is magnesium stearate. The glidant is present in an amount of from about 0.1% to about 1% wt / wt of the total composition weight. In embodiments, the glidant is preferably present in an amount of about 0.25% to 0.75% wt / wt of the total composition. More preferably, it is present in an amount of about 0.5% wt / wt.

[0253] In some embodiments, the first composition is present in an amount of about 90% to about 99% w / w of the total composition. In some embodiments, the pharmaceutical composition comprises a first composition, a disintegrant, and a lubricant. In some embodiments, the first composition comprises about 90% to about 99% of the total composition. The disintegrant is present in an amount of about 0.5% to about 5% w / w of the total composition, and the moisturizing agent is present in an amount of about 0.5% to about 5% w / w of the total composition. The lubricant is present in an amount of about 0.05% to about 2% w / w of the total composition. The first composition is present in an amount of about 97% w / w of the total composition, and the disintegrant is present in an amount of about 97% w / w of the total composition. 2.5% w / w and the lubricant is present in an amount of about 0.25% w / w of the total composition. .

[0254] In some embodiments, the disintegrant is sodium starch glycolate and the lubricant is Magnesium stearate. In some embodiments, sodium starch glycolate. Sodium is present in an amount of about 0.5% to about 5% w / w of the total composition, magnesium stearate The starch glycol is present in an amount of about 0.05% to about 2% w / w of the total composition. Sodium phosphate may be present in an amount of about 0.5% to about 2.5% w / w, about 2.5% to about 5% w / w of the total composition. Magnesium stearate is present in an amount of about 1% to about 4% w / w of the total composition. About 0.05% to about 1% w / w, about 1% to about 2% w / w, or about 0.5% to about 1.5% w / w of the substance In some embodiments, sodium starch glycolate is present in an amount of , about 1% to about 2% w / w, about 1.5% to about 2.5% w / w, about 2% to about 3% of the total composition w / w, about 2.5% to about 3.5% w / w, or about 3% to about 4% w / w. Magnesium phosphate is present in an amount of about 0.05% to about 0.5% w / w, about 0.1% to about 0.5% w / w of the total composition. It is present in an amount of about 0.8% w / w, or about 0.5% to about 1% w / w. For example, starch Sodium glycolate is about 1.5% w / w, about 2% w / w, about 2.5% of the total composition w / w, about 3% w / w, or about 3.5% w / w, magnesium stearate The amount of the hydroxybenzoates is about 0.1% w / w, about 0.2% w / w, about 0.3% w / w, about 0.4% w / w, or about 1% w / w of the total composition. % w / w, or about 0.5% w / w.

[0255] In other embodiments, the first composition is present in an amount of about 15% to about 60% w / w of the total composition. For example, about 15% to about 35% w / w, about 35% to about 60% w / w, or In some embodiments, the first composition comprises about 25% to about 45% w / w of the total composition. of the substance, about 20% to about 30% w / w, about 25% to about 35% w / w, about 30% to about 40% w / w / w, about 35% to about 45% w / w, or about 40% to about 50% w / w. For example, about 20% w / w, about 25% w / w, about 30% w / w, about 35% w / w, of the total composition. It is about 40% w / w, about 45% w / w, or about 50% w / w.

[0256] In some embodiments, the binder is present in an amount of about 40% to about 85% w / w of the total composition. For example, about 40% to about 60% w / w, about 60% to about 85% w / w, or In some embodiments, the binder is about 55% to about 75% w / w of the total composition. , about 40% to about 50% w / w, about 45% to about 55% w / w, about 50% to about 60% w / w, Approximately 55% to 65% w / w, approximately 60% to 70% w / w, approximately 65% ​​to 75% w / w, or In some embodiments, the binder is present in an amount of about 70% to about 80% w / w. of the composition, about 45% w / w, about 50% w / w, about 55% w / w, about 60% w / w, about 62% w / w %w / w, about 65%w / w, about 70%w / w, about 75%w / w, or about 80%w / w exist.

[0257] In some embodiments, the binder is selected from the group consisting of microcrystalline cellulose, cellulose ethers, hydrogels, and the like. Hydroxypropyl cellulose, Hydroxypropyl methylcellulose, Sodium carboxylate Dimethylcellulose starch, methylcellulose, ethylcellulose, hydroxypropyl cellulose, mannitol, xylitol, sorbitol, lactose, sucrose, Sorbitol, gelatin, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohols, polymethacrylates, and combinations thereof .

[0258] In some embodiments, the binder is microcrystalline cellulose, mannitol, or the like. In some embodiments, the microcrystalline cellulose comprises about 100% of the total composition. Present in an amount of 10% to about 85% w / w, e.g., about 10% to about 45% w / w of the total composition. , about 45% to about 85%, or about 20% to about 60% w / w. The microcrystalline cellulose may comprise about 10% to about 20%, about 15% to about 25%, or about 20%~30%, 25%~35%w / w, 30%~40%w / w, 35%~ It is present in an amount of about 45% w / w, or about 40% to about 50% w / w of the total composition. , about 20%w / w, about 25%w / w, about 30%w / w, about 31%w / w, about 35%w / w , about 40% w / w, or about 45% w / w.

[0259] In some embodiments, mannitol is present in an amount of about 10% to about 85% w / w of the total composition. For example, from about 10% to about 45% w / w, from about 45% to about 85%, or In some embodiments, mannitol is present in an amount of about 20% to about 60% w / w of the total composition. About 10% to about 20%, about 15% to about 25%, about 20% to about 30%, about 25% to about 3 5% w / w, about 30% to about 40% w / w, about 35% to about 45% w / w, or about 40% or more It is present in an amount of about 50% w / w, e.g., about 20% w / w, about 25% w / w of the total composition. , about 30% w / w, about 31% w / w, about 35% w / w, about 40% w / w, or about 45% It is w / w.

[0260] In some embodiments, the microcrystalline cellulose and mannitol comprise about 1% of the total composition. For example, microcrystalline cellulose may be present in an amount of about 10% to about 85% w / w of the total composition. Present in an amount of 0% to about 45% w / w, about 45% to about 85%, or about 20% to about 60% w / w. Mannitol is present in an amount of about 10% to about 45% w / w, about 45% to about 85%, or In some embodiments, the microcrystalline cellulose is present in an amount of about 20% to about 60% w / w. The amount of sucrose is about 10% to about 20%, about 15% to about 25%, or about 20% to about 30% of the total composition. , about 25% to about 35% w / w, about 30% to about 40% w / w, about 35% to about 45% w / w, or about 40% to about 50% w / w, and mannitol is present in an amount of about 10% of the total composition. ~ about 20%, about 15% to about 25%, about 20% to about 30%, about 25% to about 35% w / w, about In amounts of 30% to approximately 40% w / w, approximately 35% to approximately 45% w / w, and approximately 40% to approximately 50% w / w For example, microcrystalline cellulose may be present in an amount of about 20% w / w, about 25% w / w, or about 30% w / w of the total composition. w, about 30% w / w, about 31% w / w, about 35% w / w, about 40% w / w, or about 45 % w / w of the total composition, with mannitol being present in an amount of about 20% w / w, about 25% w / w , about 30% w / w, about 31% w / w, about 35% w / w, about 40% w / w, or about 45% Present in w / w amounts.

[0261] In some embodiments, the first composition is blended with one or more pharmaceutical excipients. In some embodiments, the pharmaceutical compositions are co-milled.

[0262] In some embodiments, the pharmaceutical compositions described herein are formulated as tablets. In some embodiments, the compound of formula I is present in a pharmaceutical composition formulated as a tablet. For example, about 10 mg to about 30 mg, about 30 mg to about In some embodiments, the compound of Formula I is administered in an amount of about 50 mg, or about 15 mg to about 35 mg. The compound is preferably present in a pharmaceutical composition formulated as a tablet at a concentration of about 10 mg to about 20 mg, about 15 mg to about 20 mg, or about 15 mg to about 20 mg. About 25 mg, about 30 mg to about 40 mg, about 35 mg to about 45 mg, or about 40 mg to about For example, about 10 mg, about 15 mg, about 20 mg, about 25 mg, The amount is about 30 mg, about 35 mg, about 40 mg, about 45 mg, or about 50 mg.

[0263] In some embodiments, the compound of formula I is present in a pharmaceutical composition formulated as a tablet. It is present in an amount of 25 mg to about 220 mg. For example, about 25 mg to about 120 mg, about 120 mg In some embodiments, the amount is from about 70 mg to about 170 mg. The compound of formula I is present in a pharmaceutical composition formulated as a tablet in an amount of about 25 mg to about 75 mg. Approximately 50mg to approximately 100mg, approximately 75mg to approximately 125mg, approximately 100mg to approximately 150mg, About 125 mg to about 175 mg, about 150 mg to about 200 mg, or about 175 mg to about 2 In some embodiments, the compound of formula I is present in an amount of about 50 mg to about 60 mg. 0 mg, about 60 mg to about 70 mg, about 70 mg to about 80 mg, about 80 mg to about 90 mg, Approximately 85mg to approximately 95mg, approximately 90mg to approximately 100mg, 80mg to approximately 120mg, approximately 95 mg ~ approx. 105 mg, approx. 100 mg ~ approx. 110 mg, approx. 105 mg ~ approx. 115 mg, approx. 1 20mg to about 130mg, about 130mg to about 140mg, about 140mg to about 150mg, About 150 mg to about 160 mg, about 160 mg to about 170 mg, or about 170 mg to about 1 For example, about 50 mg, about 55 mg, about 60 mg, about 65 mg, About 70mg, about 75mg, about 80mg, about 85mg, about 90mg, about 95mg, about 100 mg, about 105mg, about 110mg, about 115mg, about 120mg, about 125mg, about 1 30mg, about 135mg, about 140mg, about 145mg, about 150mg, about 155mg, About 160 mg, about 170 mg, about 175 mg, or about 180 mg.

[0264] In some embodiments, the tablets are coated.

[0265] As used herein, a compound of Formula I, an HPMCAS polymer, and one or more pharmaceutical excipients Pharmaceutical compositions comprising the excipient are also provided. In some embodiments, the HPMCAS polymer is HPMCAS-MG.

[0266] In some embodiments, the one or more pharmaceutical excipients include fillers, lubricants, and the like. The compound is selected from the group consisting of:

[0267] In some embodiments, the filler is glucose, sucrose, lactose, starch [Modified starch such as sodium starch glycolate (EXPLOTAB®)] Contains gluten, xylitol, dextrin, sucrose, sorbitol, mannitol [For example, PARTECK (registered trademark) M200 (average particle size: about 50 μm to about 500 μm) mannitol), PARTECK® M100 (average particle size of less than 212 μm) Mannitol)], cellulose, polyvinylpyrrolidone, polyethylene glycol, poly Vinyl alcohol, polymethacrylate, dibasic calcium phosphate, magnesium stearate Sodium stearate, calcium stearate, sodium stearate, stearic acid, hydrogenated plant Oil, mineral oil, sodium lauryl sulfate, magnesium lauryl sulfate, palmitostearin Glyceryl Stearate, Sodium Benzoate, Sodium Stearyl Fumarate, Colloidal Dioxide Silicon (e.g., sodium benzoate, sodium oleate, sodium acetate, aliquots of silicon dioxide) Phosphate, alginate (e.g., sodium alginate), calcium silicate, ion exchange resins, or combinations thereof. In embodiments, the cellulose is microcrystalline cellulose (e.g., AVICEL® P H-101 (microcrystalline cellulose with an average particle size of approximately 50 μm) or AVICEL (registered trademark) PH200 (microcrystalline cellulose with an average particle size of approximately 180 μm), methylcellulose , ethyl cellulose, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, or a combination thereof. In some embodiments, the polyvinylpyrrolidone is KOLLIDON® ) CL (crospovidone with an average particle size of 90 μm to 130 μm), or KOLLIDON (registered trademark) CL-SF (crospovidone with an average particle size of 10 μm to 30 μm) and other crosslinking agents It is polyvinylpyrrolidone.

[0268] In some embodiments, the filler is selected from the group consisting of a binder, a disintegrant, or a combination thereof. In some embodiments, the binder is selected from microcrystalline cellulose, cellulose acetate, and the like. ester, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium Carboxymethyl cellulose starch, methyl cellulose, ethyl cellulose, hydro Dihydroxypropyl cellulose, mannitol, xylitol, sorbitol, lactose, cellulose, sorbitol, gelatin, polyvinylpyrrolidone, polyethylene glycol, From the group consisting of polyvinyl alcohol, polymethacrylate, and combinations thereof In some embodiments, the disintegrant is sodium starch glycolate, alginic acid, sodium alginate, anion exchange resins, and combinations thereof The compound is selected from the group consisting of:

[0269] In some embodiments, the lubricant is magnesium stearate, calcium stearate, or Calcium, sodium stearate, stearic acid, hydrogenated vegetable oil, mineral oil, polyethylene glycol Cole, sodium lauryl sulfate, magnesium lauryl sulfate, glycerin palmitostearate Lyceryl, Sodium Benzoate, Sodium Stearyl Fumarate, Colloidal Silicon Dioxide sodium benzoate, sodium oleate, sodium acetate, and combinations thereof The compound is selected from the group consisting of:

[0270] In some embodiments, the pharmaceutical composition comprises a compound of Formula I, an HPMCAS polymer, a conjugate The composition includes a disintegrant, a disintegrant, and a lubricant.

[0271] In some embodiments, the pharmaceutical composition is present in an amount of about 5% to about 30% w / w of the total composition. a compound of formula I present in an amount of about 5% to about 30% w / w of the total composition; and HPMCAS present in an amount of about 5% to about 30% w / w of the total composition. a polymer, a binder present in an amount of about 10% to about 90% w / w of the total composition, Disintegrants present in an amount of about 0.5% to about 5% w / w and about 0.05% to about 2% w / w of the total composition. and a lubricant present in an amount of 1 / w. In some embodiments, the compound of formula I is present in an amount of 1 / w. The HPMCAS polymer is present in an amount of about 5% to about 15% w / w of the total composition. The binder is present in an amount of about 70% to about 85% w / w of the total composition. The disintegrant is present in an amount of about 2.5% to about 4.5% w / w of the total composition, and the lubricant is present in an amount of about 2.5% to about 4.5% w / w of the total composition. For example, the compound of formula I may be present in an amount of about 0.1% to about 1% w / w of the total composition. % w / w of the total composition, and the HPMCAS polymer is present in an amount of about 8% w / w of the total composition. The binder is present in an amount of about 80% w / w of the total composition, and the disintegrant is present in an amount of about 3.5% w / w of the total composition. The lubricant is present in an amount of about 0.3% w / w of the total composition. In an embodiment, the HPMCAS polymer is HPMCAS-MG.

[0272] In some embodiments, the binder is a combination of mannitol and microcrystalline cellulose. In some embodiments, the compound of formula I is present in an amount of about 5% to about 30% w / w of the total composition. wherein the HPMCAS polymer is present in an amount of about 5% to about 30% w / w of the total composition; Mannitol and microcrystalline cellulose are present in an amount of about 10% to about 90% w / w of the total composition. the disintegrant is present in an amount of about 0.5% to about 5% w / w of the total composition, and the lubricant is present in an amount of about 0.5% to about 5% w / w of the total composition. In some embodiments, the compound of formula I is present in an amount of about 0.05% to about 2% w / w. The HPMCAS polymer is present in an amount of about 5% to about 15% w / w of the total composition. Mannitol and microcrystalline cellulose are present in an amount of 5% to about 15% w / w of the total composition. and the disintegrant is present in an amount of about 2.5% to about 4.5% of the total composition. The lubricant is present in an amount of about 0.1% to about 1% w / w of the total composition. For example, the compound of Formula I is present in an amount of about 8% w / w of the total composition and the HPMCAS polymer is , present in an amount of about 8% w / w of the total composition, and mannitol and microcrystalline cellulose The disintegrant is present in an amount of about 3.5% w / w of the total composition. The lubricant is present in an amount of about 0.3% w / w of the total composition. ethanol and microcrystalline cellulose in a ratio of about 4:1, about 3:2, about 1:1, about 2:3, or In some embodiments, the HPMCAS polymer is present in a ratio of about 1:4. It is AS-MG.

[0273] In some embodiments, the disintegrant is sodium starch glycolate. In this embodiment, the compound of formula I is present in an amount of about 5% to about 30% w / w of the total composition, and HP The MCAS polymer is present in an amount of about 5% to about 30% w / w of the total composition, and the binder is and sodium starch glycolate is present in an amount of about 10% to about 90% w / w of the total composition. and the lubricant is present in an amount of about 0.05% to about 2% w / w of the total composition. In some embodiments, the compound of formula I is present in an amount of about 5% to about 1% by weight of the total composition. 5% w / w, and the HPMCAS polymer is present in an amount of about 5% to about 15% w / w of the total composition. The binder is present in an amount of about 70% to about 85% w / w of the total composition, and the starch The sodium cholate is present in an amount of about 2.5% to about 4.5% w / w of the total composition, and the lubricant is For example, the compound of Formula I may be present in an amount of about 0.1% to about 1% w / w of the total composition. The HPMCAS polymer is present in an amount of about 8% w / w of the total composition. the binder is present in an amount of about 80% w / w of the total composition, and sodium starch glycolate The thorium is present in an amount of about 3.5% w / w of the total composition, and the lubricant is present in an amount of about 0.3% w / w of the total composition. In some embodiments, the HPMCAS polymer is present in an amount of HPMCAS- It's MG.

[0274] In some embodiments, the lubricant is magnesium stearate. In the form, the compound of formula I is present in an amount of about 5% to about 30% w / w of the total composition, and HPMCA The S polymer is present in an amount of about 5% to about 30% w / w of the total composition, and the binder is present in an amount of about 1% to about 30% w / w of the total composition. The disintegrant is present in an amount of about 0.5% to about 5% w / w of the total composition. and magnesium stearate is present in an amount of about 0.05% to about 2% w / w of the total composition. In some embodiments, the compound of formula I is present in an amount of about 5% to about 15% w / w of the total composition. the HPMCAS polymer is present in an amount of about 5% to about 15% w / w of the total composition; The binder is present in an amount of about 70% to about 85% w / w of the total composition, and the disintegrant is present in an amount of about 2. Magnesium stearate is present in an amount of about 0.1% to about 4.5% w / w of the total composition. For example, the compound of formula I may be present in an amount of about 8% w / w to about 1% w / w of the total composition. the HPMCAS polymer is present in an amount of about 8% w / w of the total composition, and the binder is , present in an amount of about 80% w / w of the total composition, and the disintegrant in an amount of about 3.5% w / w of the total composition. and magnesium stearate is present in an amount of about 0.3% w / w of the total composition. In some embodiments, the HPMCAS polymer is HPMCAS-MG.

[0275] In some embodiments, the binder is a combination of microcrystalline cellulose and mannitol. The disintegrant is sodium starch glycolate and the lubricant is magnesium stearate. In some embodiments, the pharmaceutical composition comprises about 5% to about 30% w / v of the total composition. and a compound of formula I present in an amount of about 5% to about 30% w / w of the total composition. PMCAS polymer and microcrystalline cellulose present in an amount of about 30% to about 60% w / w of the total composition. and mannitol, present in an amount of about 30% to about 60% w / w of the total composition. sodium starch glycolate present in an amount of about 0.5% to about 5% w / w of the total composition; magnesium stearate present in an amount of about 0.05% to about 2% w / w of the composition; For example, the compound of Formula I is present in an amount of about 8% w / w of the total composition, and the HPMCAS polymer The cellulose is present in an amount of about 8% w / w of the total composition, and the microcrystalline cellulose is present in an amount of about 4% w / w of the total composition. 0% w / w, and mannitol is present in an amount of about 40% w / w of the total composition. Sodium starch glycolate is present in an amount of about 3.5% w / w of the total composition, and stearin In some embodiments, the magnesium salt is present in an amount of about 0.3% w / w of the total composition. , the HPMCAS polymer is HPMCAS-MG.

[0276] In other embodiments, the pharmaceutical composition is present in an amount of about 10% to about 30% w / w of the total composition. and a compound of formula I present in an amount of about 10% to about 30% w / w of the total composition. a polymer, a binder present in an amount of about 35% to about 70% w / w of the total composition, and Disintegrants present in an amount of 2% to about 8% w / w and disintegrants present in an amount of about 0.05% to about 2% w / w of the total composition. and a lubricant present in an amount of about 100% of the total composition. The HPMCAS polymer is present in an amount of about 15% to about 25% w / w of the total composition. The binder is present in an amount of about 40% to about 60% w / w of the total composition. The disintegrant is present in an amount of about 4% to about 6% w / w of the total composition, and the lubricant is present in an amount of about 0.1% w / w of the total composition. For example, the compound of formula I is present in an amount of about 22% w / w to about 1% w / w of the total composition. and the HPMCAS polymer is present in an amount of about 22% w / w of the total composition, The agent is present in an amount of about 50% w / w of the total composition, and the disintegrant is present in an amount of about 5% w / w of the total composition. In some embodiments, the lubricant is present in an amount of about 0.5% w / w of the total composition. , the HPMCAS polymer is HPMCAS-MG.

[0277] In some embodiments, the binder is a combination of mannitol and microcrystalline cellulose. In some embodiments, the compound of formula I is present in an amount of about 10% to about 30% w / w of the total composition. and the HPMCAS polymer is present in an amount of about 10% to about 30% w / w of the total composition. The amount of mannitol and microcrystalline cellulose is about 35% to about 70% w / w of the total composition. the disintegrant is present in an amount of about 2% to about 8% w / w of the total composition, and the lubricant is present in an amount of about 1% to about 8% w / w of the total composition. In some embodiments, the pharmaceutical composition is present in an amount of about 0.05% to about 2% w / w. A compound of formula I present in an amount of about 15% to about 25% w / w of the total composition, and HPMCAS polymer present in an amount of about 40% to about 6% w / w of the total composition. Mannitol and microcrystalline cellulose present in an amount of 0% w / w and approximately 4% of the total composition a disintegrant present in an amount of about 0.1% to about 1% w / w of the total composition; For example, the compound of formula I is present in an amount of about 22% w / w of the total composition. The HPMCAS polymer is present in an amount of about 22% w / w of the total composition, and the microcrystalline cellulose The cellulose and mannitol are present in an amount of about 50% w / w of the total composition, and the disintegrant is present in an amount of about 50% w / w of the total composition. The emulsion is present in an amount of about 5% w / w of the total composition, and the lubricant is present in an amount of about 0.5% w / w of the total composition. In some embodiments, the mannitol and microcrystalline cellulose are mixed in a ratio of about 4:1, about 3:2, In some embodiments, the HP is present in a ratio of about 1:1, about 2:3, or about 1:4. The MCAS polymer is HPMCAS-MG.

[0278] In some embodiments, the disintegrant is sodium starch glycolate. In this embodiment, the compound of formula I is present in an amount of about 10% to about 30% w / w of the total composition, The PMCAS polymer is present in an amount of about 10% to about 30% w / w of the total composition, and the binder is present in an amount of about 10% to about 30% w / w of the total composition. The sodium starch glycolate is present in an amount of about 35% to about 70% w / w of the total composition. The lubricant is present in an amount of about 0.05% to about 2% w / w of the total composition. In some embodiments, the compound of formula I is present in an amount of about 15% to about 15% by weight of the total composition. 25% w / w, and the HPMCAS polymer is present in an amount of about 15% to about 25% w / w of the total composition. the binder is present in an amount of about 40% to about 60% w / w of the total composition; and the starch The sodium glycolate is present in an amount of about 4% to about 6% w / w of the total composition, and the lubricant is present in an amount of about 4% to about 6% w / w of the total composition. For example, the compound of Formula I may be present in an amount of about 0.1% to about 1% w / w of the total composition. The HPMCAS polymer is present in an amount of about 22% w / w of the total composition. the binder is present in an amount of about 50% w / w of the total composition, and sodium starch glycolate The thorium is present in an amount of about 5% w / w of the total composition, and the lubricant is present in an amount of about 0.5% w / w of the total composition. In some embodiments, the HPMCAS polymer is present in an amount of HPMCAS-MG is.

[0279] In some embodiments, the lubricant is magnesium stearate. In the form, the compound of formula I is present in an amount of about 10% to about 30% w / w of the total composition, and HPMC The AS polymer is present in an amount of about 10% to about 30% w / w of the total composition, and the binder is present in an amount of about 10% to about 30% w / w of the total composition. The disintegrant is present in an amount of about 2% to about 8% w / w of the total composition. and magnesium stearate is present in an amount of about 0.05% to about 2% w / w of the total composition. In some embodiments, the compound of formula I is present in an amount of about 15% to about 25% w / w of the total composition. and the HPMCAS polymer is present in an amount of about 15% to about 25% w / w of the total composition. The binder is present in an amount of about 40% to about 60% w / w of the total composition, and the disintegrant is present in an amount of about 4% to about 6% w / w of the total composition, and magnesium stearate is present in an amount of about 0.1% to about 6% w / w of the total composition. For example, the compound of formula I is present in an amount of about 22% w / w of the total composition. wherein the HPMCAS polymer is present in an amount of about 22% w / w of the total composition, and the binder is , present in an amount of about 50% w / w of the total composition, and the disintegrant, present in an amount of about 5% w / w of the total composition. and magnesium stearate is present in an amount of about 0.5% w / w of the total composition. In an embodiment, the HPMCAS polymer is HPMCAS-MG.

[0280] In some embodiments, the pharmaceutical composition is present in an amount of about 10% to about 30% w / w of the total composition. a compound of formula I present and HPMC present in an amount of about 10% to about 30% w / w of the total composition AS polymer and microcrystalline cellulose present in an amount of about 20% to about 30% w / w of the total composition. and mannitol present in an amount of about 20% to about 30% w / w of the total composition. Sodium starch glycolate present in an amount of about 2% to about 8% w / w of the total composition and magnesium stearate present in an amount of 0.05% to about 2% w / w. In some embodiments, the HPMCAS polymer is HPMCAS-MG.

[0281] In some embodiments, the pharmaceutical composition comprises a compound of formula (I) present in an amount of about 22% w / w of the total composition. Compound I, HPMCAS polymer present in an amount of about 22% w / w of the total composition, and Microcrystalline cellulose present in an amount of about 25% w / w of the total composition and starch glycol present in an amount of about 5% w / w of the total composition. sodium phosphate and magnesium stearate present in an amount of about 0.5% w / w of the total composition. In some embodiments, the HPMCAS polymer comprises HPMCAS-MG is.

[0282] In some embodiments, the pharmaceutical compositions described herein are formulated as tablets. In some embodiments, the tablets are coated.

[0283] Also provided herein are methods for preparing the pharmaceutical compositions described herein, the methods comprising: , mixing a compound of formula I, an HPMCAS polymer, and a solvent to form a solution; spray drying the solution to form a spray-dried dispersion; and granulating the spray-dried dispersion to form a first composition.

[0284] In some embodiments, the HPMCAS polymer is HPMCAS-MG.

[0285] In some embodiments, the solvent is an organic solvent. The solvents used were methanol, acetone, dichloromethane, tetrahydrofuran, and combinations thereof. In some embodiments, the solvent is selected from the group consisting of a mixture of an organic solvent and water. In some embodiments, the solvent is a mixture of tetrahydrofuran and water. In some embodiments, the mixture is 95:5 tetrahydrofuran:water. In some embodiments, the organic solvent is a mixture of dichloromethane and methanol. In some embodiments, the organic solvent is 80:20 dichloromethane:methanol.

[0286] In some embodiments, the spray-dried dispersion may be granulated with one or more pharmaceutical agents. In some embodiments, the spray-dried dispersion is blended with excipients before being granulated. In some embodiments, the spray-dried dispersion is dried in an oven before being granulated. In some embodiments, the spray-dried composition is blended with one or more pharmaceutical excipients. The dispersion is granulated by roller compaction.

[0287] In some embodiments, the first composition is blended with one or more pharmaceutical excipients. In some embodiments, the first composition is co-milled. The first composition is compressed into a tablet. In some embodiments, the tablet is coated. In some embodiments, the coating comprises a polymer, a plasticizer, a pigment, or Including combinations thereof.

[0288] In some embodiments, the compound of Formula I and the HPMCAS polymer in the spray-dried dispersion In some embodiments, the ratio of the compound of Formula I to HP is about 1:4 to about 4:1. The ratio of MCAS polymer is about 4:1, about 3:1, about 7:3, about 13:7, about 3:2, about 11:9, approximately 1:1, approximately 9:11, approximately 2:3, approximately 7:13, approximately 3:7, approximately 1:3, or In some embodiments, the ratio of the compound of Formula I to HP in the spray-dried dispersion is about 1:4. The ratio of MCAS polymer to MCAS polymer is about 1:1. In some embodiments, the spray-dried dispersion The ratio of the compound of Formula I to the HPMCAS polymer in the In an embodiment, the HPMCAS polymer is HPMCAS-MG.

[0289] Compounds of formula I, or pharmaceutically acceptable salts thereof, amorphous or polymorphic forms thereof, The daily dosage of the spray-dried dispersion of the present invention or a pharmaceutical composition thereof is about 100 mg / kg / day for an adult. A broad range of 1.0 to 10,000 mg or more, or any range therein. When administered orally, the composition may be administered in an amount appropriate for the symptoms of the subject being treated. The active ingredient for conditioning is available in 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 75.0, 80.0, 90.0, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, It is preferably provided in the form of tablets containing 475 and 500 milligrams. The usual dose is about 0.1 mg / kg to about 1000 mg / kg of body weight per day, or The range is from about 0.5 to about 500 ml per day. g / kg body weight, or any range therein. The range may be from about 1.0 to about 1.5 g / kg body weight per day. 250 mg / kg body weight, or any range therein. The range is from about 0 to 250 mg / kg body weight per day. It can be from 0.1 to about 100 mg / kg body weight, or any range therein. For example, the range is about 0.1 to about 50.0 mg / kg body weight per day, or any amount or range therein. As another example, the range may be from about 0.1 to about 15.0 mg / kg of body weight per day. As yet another example, the range may be about 0 to 100 mg / day, or any range therein. The dosage may be from 0.5 to about 7.5 mg / kg body weight, or any amount or range therein. The pharmaceutical compositions provided herein may be administered on a regimen of 1 to 4 times daily or as a single daily dose. It can be done.

[0290] Optimal dosages to be administered can be readily determined by those skilled in the art and will vary depending on the mode of administration, preparation, This will vary with the strength of the agent, the mode of administration, and the progression of the disease state. The dosage may vary depending on factors related to the particular subject being treated, including the subject's age, weight, diet, and time of administration. Dosage adjustments may be necessary.

[0291] Those skilled in the art will readily appreciate that suitable known and generally accepted cell and / or animal models are readily available. Both the in vivo and in vitro tests used are tests to treat or prevent a given disorder. It will be appreciated that the present invention predicts the potency of compounds.

[0292] Those skilled in the art will further appreciate that the human Human clinical trials, including first-in-human trials, dose-ranging and efficacy studies, are being conducted in clinical and medical settings. It will be appreciated that this can be accomplished by methods well known in the art. Determining the appropriate dosage for a patient depends on the body weight, age, and the patient's age, the compound of Formula I, the drug Biocompatible salts, or combinations thereof, and body surface area (BSA) clearance It is possible to establish a pharmacokinetic approach for administration that takes into account the occurrence of different pathways of administration. Simcyp® Pediatric Simulation modeling Use known methods, including models such as those from CERTARA, Princeton, NJ can be determined.

[0293] 2. Polymorphs The present disclosure also provides (S)-5-amino-3-(4-((5-fluoro-2- Methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane -2-yl)-1H-pyrazole-4-carboxamide [ka] and crystalline forms of pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising crystalline forms of the compound of formula I , a process for making crystalline forms of the compound of Formula I, and methods for treating BTK-associated diseases and disorders and the use of compounds of formula I in the treatment and prevention of diseases treatable by BTK kinase inhibitors, including steroids, steroid agonists, and steroid agonists. The present invention relates to the use of crystalline forms of the compound of formula (I).

[0294] Provided herein are polymorphic forms of the compound of Formula I. Forms include, for example, polymorphic forms of the compound of Formula I. The term "compounds" includes free bases, solvates, hydrates, salts, and unsolvated forms of the compounds, e.g., polymorphic forms. In some embodiments, the polymorphic forms of the compound of Formula I include pharmaceutically acceptable salts. is.

[0295] Form A One such polymorph is the polymorph of the compound of Formula I known as Form A. In embodiments, Form A has a β-glucan content of 11.9±0.2, 15.8±0.2, and 16.2±0. XRPD patterns obtained with CuKα1 radiation with at least a peak at a 2θ value of 0.2 In some embodiments, Form A has a β-glucan content of 11.9±0.2, 15.8±0. at °2θ values ​​of 2, 16.2±0.2, 18.3±0.2, and 19.0±0.2. In some embodiments, Form A has an XRPD pattern with peaks at 1 1.9±0.2, 15.8±0.2, 16.2±0.2, 18.3±0.2, 19.0± The sample had at least peaks at °2θ values ​​of 0.2, 20.5 ± 0.2, and 23.8 ± 0.2. In some embodiments, Form A has an XRPD pattern of 9.5±0.2, 11.9±0.2, 15.8±0.2, 16.2±0.2, 18.3±0.2, 19.0 ±0.2, 20.1±0.2, 20.5±0.2, 23.8±0.2, and 25.7± have an XRPD pattern with at least a peak at a °2θ value of 0.2. In some embodiments, Form A has a pH of 9.5±0.2, 11.1±0.2, 11.9±0.2 , 15.8±0.2, 16.2±0.2, 18.3±0.2, 19.0±0.2, 20. 1±0.2, 20.5±0.2, 23.8±0.2, 25.0±0.2, and 25.7 It has an XRPD pattern with at least peaks at °2θ values ​​of ±0.2.

[0296] In some embodiments, provided herein are compositions comprising polymorph Form A. In some embodiments, the composition may be substantially pure. For example, the composition may be at least about 90% pure. % purity. In some embodiments, the composition has a purity of at least about 95%. In some embodiments, the composition has a purity of at least about 98%. The composition is at least 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 9 9%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 9 It may have a purity of 9.7%, 99.8%, or 99.9%. In some embodiments, The composition is substantially free of other forms of the compound of formula I. In some embodiments, the composition The composition contains less than about 15% by weight of other forms of the compound of formula I. For example, the composition may contain less than about 14% by weight of other forms of the compound of formula I. %, 13% by weight, 12% by weight, 11% by weight, 10% by weight, 9% by weight, 8% by weight, 7% by weight , 6% by weight, 5% by weight, 4% by weight, 3% by weight, 2% by weight, or less than 1% by weight For example, the composition may contain less than about 15% amorphous form. It may include.

[0297] In some embodiments, the sorbed water has a molecular weight of about 185 to 1950 kJ / cm2, as measured by DSC. Polymorphic Form A is provided herein, which exhibits an endotherm observed at 195°C, e.g., about 189.9°C. It is served.

[0298] In some embodiments, provided herein are compounds having a solubility in water, as measured by TGA. , a polymorphic form of the compound of formula I that exhibits a weight loss of about 0.14% from the start of heating to about 150°C. It is state A.

[0299] Also provided herein are methods for preparing polymorph Form A. In some embodiments, the polymorph has the formula Polymorphic Form A of the compound of formula I can be obtained by dissolving the compound of formula I in a polar protic solvent to obtain the compound of formula I. In some embodiments, the polar protic solvent is prepared by forming a solution of In some embodiments, the method comprises dissolving a solution of a compound of Formula I in about In some embodiments, the water is added at a rate of about 5 mL / min. is added to the solution of the compound of Formula I over a period of about 2 hours. The compound of formula I may precipitate from solution to form a suspension comprising the solid of the compound of formula I suspended in a solvent. In some embodiments, the method comprises heating the suspension at a rate of about 10° C. / hour for about 1 hour. In some embodiments, the method further comprises cooling the cooled suspension to 5°C. The method further comprises stirring the suspension at room temperature for about 10 to 20 hours, for example, about 15 hours. In an embodiment, the method further comprises isolating the solid compound of Formula I from the suspension by filtration. In some embodiments, the solid of the compound of Formula I is dried. In embodiments, the solid of the compound of Formula I is dried under vacuum. The solid is dried at about 55°C.

[0300] In some embodiments, polymorph Form A of the compound of Formula I is a compound of Formula I that is substituted with a polar proton. In some embodiments, the compound is prepared by adding the compound to a solvent to form a mixture. The mixture is heated until a solution is formed. The solvent is isopropanol, ethanol, water, or a combination thereof. In some embodiments, the polar protic solvent is isopropanol. In some embodiments, the solution is cooled slowly to room temperature. In some embodiments, the solution is added to a reactor containing water. In some embodiments, the solution is polish filtered before being added to the reactor. In some embodiments, the compound of Formula I precipitates from the solution, forming a compound of Formula I suspended in the solvent. In some embodiments, the method provides a suspension containing the solids of a compound of formula I. and isolating the solid from the suspension by filtration. In some embodiments, the solid is of Formula I The solid compound is dried. In some embodiments, the solid compound of Formula I is dried under vacuum. In some embodiments, the solid is dried at about 55°C.

[0301] In some embodiments, the compound of formula I can be prepared in polar protic and non-polar solvents, e.g., It is crystallized using ethanol or ethyl acetate and heptane. Polymorph Form A of the compound of formula I can be obtained by adding the compound of formula I to a polar protic solvent to form a mixture. In some embodiments, the mixture is prepared by forming a solution. In some embodiments, the mixture is heated to about 70°C. In some embodiments, the polar protic solvent is ethanol. The solution is cooled and charged with seeds of Form A of the compound of Formula I to form a charged solution. In some embodiments, the solution is cooled to about 59°C. The solution is polish filtered before being cooled. In some embodiments, the loaded solution is about 55 The mixture is cooled to 0°C and heptane is added to the charged solution. In some embodiments, the heptane is added dropwise over a period of about 4 hours. In some embodiments, the compound of Formula I precipitates from the loading solution and is suspended in the solvent. In some embodiments, the suspension comprises about 1% by weight of the compound of Formula I. In some embodiments, the suspension is cooled to about 15° C. over about 1 hour. In some embodiments, the method further comprises filtering the solid compound of Formula I. In some embodiments, the solid form of the compound of formula I is isolated from the suspension. In some embodiments, the solid of the compound of Formula I is dried under vacuum. In some embodiments, the solid is dried at about 55°C.

[0302] In some embodiments, the compound of formula I can be prepared in polar protic and non-polar solvents, e.g., It is crystallized using ethanol or ethyl acetate and heptane. Polymorph Form A of the compound of formula I can be obtained by adding the compound of formula I to a polar protic solvent to form a mixture. In some embodiments, the mixture is prepared by forming a solution. In some embodiments, the mixture is heated to about 75°C. In some embodiments, the polar protic solvent is ethyl acetate. The solution is cooled and charged with seeds of Form A of the compound of Formula I to form a charged solution. In some embodiments, the solution is cooled to about 45° C. before being filled. In embodiments, the solution is polish filtered before being cooled. In some embodiments, the compound of formula I is The compound of formula I precipitates from the solution to give a suspension containing the solids suspended in the solvent. In some embodiments, the suspension is incubated with ink to form a suspension. In some embodiments, the suspension is incubated at about 45°C. In some embodiments, the suspension is incubated overnight. The incubated suspension is then cooled. The resulting suspension is cooled to about 24° C. In some embodiments, the method comprises: The method further comprises isolating the compound solids from the incubated suspension by filtration. In some embodiments, the solid of the compound of Formula I is dried. The solid of the compound of Formula I is dried under vacuum. In some embodiments, the solid is dried at about 55° C. It is dried in.

[0303] Forms B and C In addition to Form A, other forms of the compound of Formula I have been observed. Form B occurs in mixtures with Form A. The DSC of a mixture of Form A and Form B shows an onset of approximately 120°C and possibly a A small exotherm with an onset of melting at about 145°C is observed, which is the melting of B. Following the melting, there is an exothermic event due to the transformation of the melt into Form A. Onset temperature 180°C The endothermic event at is due to the melting of Form A. To determine the DSC curve of Form B, A pure sample of B is required.

[0304] In some embodiments, Form B of the compound of Formula I can be prepared by: 1) dissolving the compound of Formula I in methanol; 1) dissolving the compound of Formula I in a solution of Form A to form a solution of the compound of Formula I; and 2) mixing the solution with Form A by stirring. In some embodiments, the solution is prepared by stirring at a temperature of about 20°C to about 30°C. In some embodiments, the solution is stirred at about 25° C. In the method, the compound of formula I precipitates from the solution to form a solid of the compound of formula I suspended in the solvent. In some embodiments, the method provides a suspension containing the compound of Formula I by filtration. In some embodiments, the solid of the compound of Formula I is dried. In some embodiments, the solid of the compound of Formula I is dried under vacuum. In an embodiment, the solids are dried at about 55°C.

[0305] Form C is a hemi-1,4-dioxane formed from crystallization of the compound of formula I in 1,4-dioxane. Form C is a 1,4-dioxane solvate. The DSC curve for Form C shows a loss of 1,4-dioxane. The endothermic event is followed by a small exothermic event. , followed by a melting endotherm due to the melting of Form A. Desolvation converts to polymorphic Form A. This may occur before the reaction to provide isomorphous desolvates or different physical forms.

[0306] In some embodiments, Form C of the compound of Formula I can be prepared by: 1) converting the compound of Formula I to a 1,4-dihydro-2,4-dihydro-2,4-dihydro-1 ... 2) by dissolving the compound of Formula I in hexane to form a solution of the compound of Formula I; and 3) by stirring the solution. In some embodiments, the solution is stirred at a temperature of about 20° C. to about 30° C. In some embodiments, the solution is stirred at about 25° C. In some embodiments, the compound of formula The compound of formula I precipitates from the solution to form a suspension comprising the solid compound of formula I suspended in the solvent. In some embodiments, the method further comprises isolating the solid compound of Formula I by filtration. In some embodiments, the solid compound of Formula I is dried. In some embodiments, the solid of the compound of Formula I is dried under vacuum. The solids are dried at about 55°C.

[0307] XRPD patterns for crystalline forms of the compound of formula I and its pharmaceutically acceptable salts The 2-theta values ​​may vary slightly from instrument to instrument and may be affected by variations in sample preparation and Batch-to-batch variations may also occur, so quoted values ​​should not be considered absolute. It will be understood that the peak positions in the XRPD patterns should not be interpreted as It is understood that the allowable variation is reported in angular position (2 theta) of ±0.2° 2θ The ±0.2° 2θ variation is significant when comparing two powder XRPD patterns. In practice, the diffraction pattern peaks from one pattern are used for measurement. A range of angular positions (2 theta) that is ±0.2° from the peak position is assigned, and those peaks are If the ranges of peak positions overlap, the two peaks are considered to have the same angular position. For example, if the peak position of a pattern is determined to be 11.0° 2θ, The peak was positioned in the range of 10.8° to 11.2° 2θ due to the allowable variation. The relative intensities of the peaks may vary depending on orientation effects. and therefore the intensities shown in the XRPD traces contained herein are exemplary; It is not intended to be used for absolute comparison. Furthermore, for comparison purposes, XRPD tradeoffs may be made. Some variation in peak intensity from that shown on the source is acceptable. Therefore, it should be understood that "an XRPD pattern substantially identical to that shown in Figure 1" The phrase "presence" means that, for purposes of comparison, at least 90% of the peaks shown in Figure 1 are present. Please understand that.

[0308] The compounds provided herein also include any one or more of the atoms that make up such compounds. The compounds of formula I may contain unnatural proportions of atomic isotopes. When referred to in relation to an atom, the atom is referred to in relation to its natural abundance, such as an isotope as it occurs naturally. For example, when hydrogen is mentioned, it includes all isotopes and isotopic mixtures of the atoms. teeth, 1 H, 2 H, 3 H, or mixtures thereof, and carbon is referred to When it is, 12 C. 13 C. 14 C, or mixtures thereof, When nitrogen is mentioned, it is 14 N, 15 N, or a mixture thereof. It is understood that when oxygen is mentioned, it is 16 O. 17 O. 18 O, or a mixture of these It is understood that the present invention refers to all isotopic variations of the compounds provided herein. are intended to be included within the scope of the present invention.

[0309] For illustrative purposes, Scheme 1 illustrates the synthesis of compounds and key intermediates provided herein. A general method for the preparation is given. For a more detailed description of the individual reaction steps, see See, for example, International Patent Publication No. WO2017 / 1 See US Pat. No. 03611. Those skilled in the art will recognize that other synthetic routes can be used to synthesize the compounds. It will be understood that certain starting materials and reagents are shown in the schemes and described below. Other starting materials and reagents can be easily substituted to provide a variety of derivatives and / or reaction conditions. It can be provided. [ka]

[0310] Scheme 1 shows a general scheme for the synthesis of compounds of formula I.

[0311] 3.Treatment method Compounds of Formula I, including polymorphic forms and pharmaceutically acceptable salts thereof, are useful as BTK inhibitors. The ability to use the method is described in International Patent Application Publication WO2017 / 103611 and Example 1. This can be demonstrated by assays that have been used.

[0312] In some embodiments, compounds of Formula I provided herein exhibit potent and selective B For example, compounds of Formula I inhibit wild-type BTK and, e.g., C481S. BTK kinases encoded by BTK genes containing BTK kinase inhibitor-resistant mutations, including In some embodiments, the inhibitors of C481S exhibit nanomolar potency against ATPases. is similar to that observed for wild-type BTK.

[0313] In some embodiments, the compound of formula I, or a pharmaceutically acceptable salt thereof, is amorphous, Alternatively, the polymorphic form selectively targets the BTK kinase. For example, the compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof, may be used in combination with another kinase or non-kinase. The BTK kinase can be selectively targeted relative to the target of some enzymes. In embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorph thereof The morphology is BRK, CSK, ERBB4, FYN, MEK1, MEK2, TEC, TXK, YES1, BMX, BLK, EGFR, ITK, SRC, JAK1, JAK2, and J Selectively target the BTK kinase over one or more of the AK3 kinases. In embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorph thereof The form selectively targets BTK kinase over TEC kinase.

[0314] In some embodiments, the compound of formula I, or a pharmaceutically acceptable salt thereof, is amorphous, Alternatively, the polymorphic form may have at least 30-fold higher selectivity for BTK kinase over another kinase. For example, a compound of Formula I, or a pharmaceutically acceptable salt thereof, amorphous or The polymorphic form is at least 40-fold more selective for BTK kinase than for other kinases. Selectivity, at least 50-fold selectivity, at least 60-fold selectivity, at least 70-fold selectivity , at least 80-fold selective, at least 90-fold selective, at least 100-fold selective , at least 200-fold selective, at least 300-fold selective, at least 400-fold selective Selectivity, at least 500-fold selectivity, at least 600-fold selectivity, at least 700-fold selectivity selectivity, at least 800-fold selectivity, at least 900-fold selectivity, or at least In some embodiments, the compound of Formula I, or a combination thereof, exhibits 1000-fold selectivity. A physiologically acceptable salt, amorphous, or polymorphic form of BTK kinase may be used in combination with other kinases. In some embodiments, the selectivity is at least 100-fold over another kinase. In comparison, selectivity for the BTK kinase can be demonstrated in cellular assays (e.g., as provided herein). In some embodiments, the compound of Formula I, or a compound thereof, A physiologically acceptable salt, amorphous, or polymorphic form of BTK kinase may be used in combination with other kinases. Due to its selectivity for β-actin, it exhibits lower off-target toxicity.

[0315] Compounds of formula I, or pharmaceutically acceptable salts thereof, amorphous or polymorphic forms thereof, or pharmaceutical compositions thereof, for the treatment of BTK-related diseases and disorders, e.g. proliferative disorders such as cancer, including hematologic and solid tumors, and rheumatoid arthritis or Inflammatory and autoimmune disorders such as rheumatoid arthritis can be treated with BTK kinase inhibitors. It is useful in treating diseases and injuries.

[0316] Provided herein is a method for treating cancer (e.g., BTK-associated cancer) in a patient in need of treatment. A method of treating rheumatoid arthritis is provided, which comprises administering to a patient a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form of, or a spray-dried dispersion thereof; or For example, the present invention relates to the treatment of BTK-associated cancers. A method of treating a BTK-associated cancer in a subject in need thereof is provided, the method comprising: ) detecting a BTK gene, a BTK kinase, or any of them in a sample from a subject. b) detecting dysregulation of the expression or activity or level of Formula I; and or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof, and administering the dried dispersion, or a pharmaceutical composition thereof.

[0317] In some embodiments, the BTK gene, the BTK kinase, or any of them Dysregulation of expression or activity or levels can include increased expression of BTK kinase, BTK gene expression, These include increased gene transcription or increased activation or phosphorylation of the BTK kinase. In some embodiments, the BTK gene, the BTK protein, or expression of either thereof is also The dysregulation of activity or levels can be due to genetic mutations (e.g., dysregulation of expression of fusion proteins). BTK gene translocation resulting in at least one amino acid sequence change compared to the wild-type BTK protein Deletions in the BTK gene that result in expression of the BTK protein, including deletions of the 1 in the BTK gene, resulting in the expression of a BTK protein with one or more point mutations Mutation, or at least one agonist, of the BTK protein compared to the wild-type BTK protein Alternative splicing of BTK mRNA leads to amino acid-deleted BTK protein version), or the activity of the kinase domain of the BTK protein in cells. resulting in a selective increase in the amount of a constitutively active kinase domain of the BTK protein (e.g., a constitutively active kinase domain of the BTK protein), Overexpression or overexpression of BTK protein due to overexpression of the BTK gene in cells In some embodiments, the B The TK gene, the BTK protein, or the expression or activity or level of either thereof Dysregulation of bell by BTK genes that are constitutively active or do not contain mutations Encodes a BTK protein with increased activity compared to the encoded protein The mutations can be in the BTK gene. Non-limiting examples of BTK mutations (and fusions) are listed in Table 1. 1. The BTK gene, the BTK protein, or expression of either thereof Another example of dysregulated activity or levels is a BTK inhibitor-resistant mutation. Non-limiting examples of BTK resistance mutations are listed in Tables 2 and 3.

[0318] In some embodiments, the BTK gene, the BTK kinase, or any of them Dysregulation of expression or activity or levels of the BCR complex or downstream signaling components Activating mutations within the molecule result in interaction with microbial or autoantigens present in the tissue microenvironment. This may result in persistent BCR stimulation or a pathogenic increase in BTK protein expression or activation. This is a ligand-independent sustained BCR signaling pathway. For example, the BTK gene, BT Dysregulation of the expression or activity or levels of K proteins, or any of them , genetic mutations in BCR signaling pathway proteins (e.g., expression of fusion proteins) BCR signaling pathway gene translocations that result in the expression of wild-type BCR signaling pathway proteins BCR signaling pathway proteins containing at least one amino acid deletion compared to the BCR protein Deletion of one or more BCR signaling pathway genes that result in expression of a gene BCR signaling pathway leading to expression of mutated BCR signaling pathway proteins Mutations in genes, BCR signaling pathway proteins compared to wild-type proteins BCR signaling leading to deletion of at least one amino acid in a transduction pathway protein Alternative splicing of BCR signaling pathway protein mRNAs leads to pathway proteins Non-limiting examples of BCR signaling pathway mutations include: are listed in Table 4.

[0319] In some embodiments, the compound of formula I is in a polymorphic form. The compound of formula I is polymorphic form A.

[0320] In some embodiments, the spray-dried dispersion comprises a compound of formula I and an HPMCAS polymer. In some embodiments, the pharmaceutical composition comprises a spray-dried dispersion of a compound of formula I and In some embodiments, the HPMCAS polymer comprises HPM It is CAS-MG.

[0321] Compounds of formula I, or pharmaceutically acceptable salts thereof, amorphous or polymorphic forms thereof, Spray-dried dispersions of, or pharmaceutical compositions thereof, may also be used to treat BTK-associated cancers. It is useful.

[0322] In some embodiments of any of the methods or uses described herein, the method comprises administering to a subject a cancer (e.g., , BTK-associated cancer) is a blood cancer. In some embodiments, the cancer (e.g., a BTK-associated cancer) is a solid tumor. In some embodiments of any of the methods or uses described herein, the present invention provides a method for treating cancer (e.g., BTK The B-cell related cancers are B-cell malignancies. In some embodiments, the cancer (e.g., BTK-associated cancer) is Hodgkin's lymphoma, diffuse large bowel disease, or diffuse large bowel disease. Diarrheal large B-cell lymphoma (DLBCL) (e.g., activated B-cell-like DLBCL (ABC) -DLBCL), follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., Extranodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma), Burkitt's lymphoma, Waldenstrom's lymphoma Lymphoplasmacytic lymphoma (LPL), primary central nervous system Nervous system lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia (CLL), acute lymphocytic Leukemia (ALL), B-cell prolymphocytic leukemia, precursor B-lymphoblastic leukemia, hairy cell leukemia Blood diseases, acute myeloid leukemia (AML), chronic myeloid leukemia, multiple myeloma, plasma cell myeloma , plasmacytoma, bone cancer, bone metastasis, breast cancer, gastroesophageal cancer, pancreatic cancer, ovarian cancer, prostate cancer , lung cancer, colon cancer, uterine cancer, hepatocellular carcinoma, head and neck cancer, or glioma.

[0323] In some embodiments, a hematological cancer (e.g., a hematological cancer that is a BTK-associated cancer) Leukemia, lymphoma (non-Hodgkin's lymphoma), Hodgkin's disease (also called Hodgkin's lymphoma) ), and myelomas, e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), ML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia blood disease (CML), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL) , acute undifferentiated leukemia (AUL), anaplastic large cell lymphoma (ALCL), prolymphocytic leukemia Hematopoietic disease (PML), juvenile myelomonocytic leukemia (JMML), adult T-cell ALL, trilineage bone marrow AML with dysplasia (AML / TMDS), mixed lineage leukemia (MLL), myelodysplasia Myeloproliferative Disorders (MDS), Myeloproliferative Disorders (MPD), Diffuse Large B-Cell Lymphoma (DLB) CL) (e.g., activated B-cell-like DLBCL (ABC-DLBCL)), follicular lymphoma lymphoma, mantle cell lymphoma, marginal zone lymphoma (e.g., extranodal marginal zone B-cell lymphoma, splenic lymphoma) Visceral marginal zone lymphoma), Burkitt lymphoma, Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma (LPL)), primary central nervous system lymphoma, small lymphocytic lymphoma Lymphoma, precursor B lymphoblastic leukemia, hairy cell leukemia, chronic myeloid leukemia, anaplastic large cell leukemia Lymphoma, MALT lymphoma, plasma cell myeloma, plasmacytoma, and multiple myeloma (MM) Further examples of hematological cancers include polycythemia vera (PV), Essential thrombocytopenia (ET) and idiopathic primary myelofibrosis (IMF / IPF / PMF) In one embodiment, the present invention includes myeloproliferative disorders (MPDs), such as hematological cancers (e.g., B TK-related cancers (blood cancers) include mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphoma. lymphocytic lymphoma, Waldenström macroglobulinemia, or marginal zone lymphoma be.

[0324] In some embodiments, the BTK-associated cancer is not transformed. Non-limiting examples of transformations in cancer include Richter's transformation, prolymphocytic transformation (e.g., For example, prolymphocytic transformation of CLL, transformed non-Hodgkin's lymphoma, and blastoid lymphoma. Included are cytoid lymphomas (e.g., blastoid variant mantle cell lymphoma).

[0325] In some embodiments, the BTK-associated cancer is a cancer known to involve the central nervous system by lymphoma. It is not a cancer that is being treated.

[0326] In some embodiments, the cancer (e.g., a BTK-associated cancer) is a solid tumor. Examples of tumors (e.g., solid tumors that are BTK-associated cancers) include, for example, bone cancer, bone metastasis, breast cancer, Cancer, gastroesophageal cancer, pancreatic cancer, ovarian cancer, prostate cancer, lung cancer, colon cancer, uterine cancer, liver cancer Cancers of the present invention include, for example, gliomas, head and neck cancers, and gliomas. Incorporated herein, Campbell, et al., Journal of Cli nical Medicine,2018,7(4):62 and Zucha et al. al., Oncotarget.6(15):13255-68, 2015 sea ​​bream.

[0327] In some embodiments, the B-cell malignancy is a B-cell non-Hodgkin's lymphoma, In some embodiments, the B-cell malignancy is a hodgkin's lymphoma, a leukemia, or a B-cell leukemia. lymphoma, diffuse large B-cell lymphoma (DLBCL) (e.g., activated B-cell ABC-like DLBCL (ABC-DLBCL), follicular lymphoma, mantle cell lymphoma, marginal lymphoma Zone lymphoma (e.g., extranodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma), Burkitt's Lymphoma, Waldenström's macroglobulinemia (lymphoplasmacytic lymphoma (L PL), primary central nervous system lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia Myocardial Lymphoblastic Leukemia (ALL), B-cell Prolymphocytic Leukemia, Precursor B-lymphoblastic Leukemia disease, or hairy cell leukemia.

[0328] In some embodiments, the subject has active uncontrolled autoimmune cytopenia. In some embodiments, the subject has not been diagnosed with an autoimmune cytopenia. In some embodiments, the subject receives a steroid drug within 6 months of starting a treatment described herein. have a history of clinically significant, uncontrolled cardiac disease, cardiovascular disease, or myocardial infarction In some embodiments, the subject has not been diagnosed with heart disease or cardiovascular disease. In some embodiments, the subject does not have a myocardial infarction. In some embodiments, the subject does not have a clinically significant active malabsorption syndrome. The subject has not been diagnosed with a malabsorption syndrome. In some embodiments, the subject is During any of the treatments described in In some embodiments, the subject has not been treated with a toxic or inducing agent as described herein. Patients receiving proton pump inhibitor therapy within 7 days of starting any of the above treatments In some embodiments, the subject does not have an active second malignancy. In some embodiments, the subject has an active second malignancy that is in remission, and the subject's average Life expectancy is more than two years.

[0329] In some embodiments, the subject is a human. In some embodiments, the subject is BTK inhibitor naive. In other embodiments of any of the methods or uses, the subject is not BTK inhibitor naive. stomach.

[0330] Therefore, BTK-associated cancers, such as those described herein, are also encompassed by the present invention. Also provided are methods for treating a subject diagnosed or identified as having any of the BTK-associated cancers. and administering to the subject a therapeutically effective amount of a compound of Formula I, or a compound thereof, as defined herein. Pharmaceutically acceptable salts, amorphous or polymorphic forms thereof, spray-dried dispersions thereof, or The method includes administering these pharmaceutical compositions.

[0331] Expression of BTK kinase, BTK gene, or either(one or more) thereof Dysregulation of the activity or levels of BTK kinase can contribute to tumorigenesis. , BTK gene, or kinase, or the expression or activity of any of them Dysregulation of levels of BTK kinase, the BTK gene, or the BTK kinase domain It may be overexpressed, activated, amplified, mutated, or translocated. Dysregulation of K kinases leads to aberrant cell signaling (e.g., compared to control non-cancer cells). Mammalian signaling due to transmission and / or dysregulated autocrine / paracrine signaling increased expression (e.g., increased levels) of wild-type BTK kinase in human cells, and can be increased activation (e.g., increased phosphorylation). Increased expression of BTK kinase may be due to increased transcription of the BTK gene. In embodiments, dysregulation of BTK kinase is associated with a decrease in the expression of BTK kinase in cancer cells (e.g., when compared to control non-cancer cells). ) e.g., aberrant cell signaling and / or autocrine / paracrine signaling increased expression of wild-type BTK kinase in mammalian cells due to In some embodiments, the dysregulation of BTK kinase can be (e.g., at elevated levels). In some embodiments, the expression of the IL-1 receptor may be hyperactivated (e.g., compared to control non-cancer cells). Hyperactivation can result from increased phosphorylation of BTK. Mutations in the gene affect the BTK ligand binding site, extracellular domain, kinase domain, and mutations in regions involved in protein:protein interactions and downstream signaling. In some embodiments, a mutation (e.g., an activating mutation) in the BTK gene is one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid substitutions (e.g., BT with one or more amino acid substitutions In some embodiments, the mutation may result in the expression of the BTK kinase. In some embodiments, the mutation in the BTK gene (e.g., an activation A mutated BTK protein is a mutation that alters at least one amino acid (e.g., At least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, at least 14, At least 16, at least 18, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 amino acids ), resulting in expression of a BTK kinase or BTK receptor lacking the BTK kinase or BTK receptor. In this study, mutations in the BTK gene (e.g., activating mutations) were found to increase the activity of wild-type BTK protein. In comparison, at least one amino acid (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least At least 10, at least 12, at least 14, at least 16, at least 18, At least 20, at least 25, at least 30, at least 35, at least 40, The expression of BTK kinases containing inserted amino acids (45 or at least 50 amino acids) was achieved. Translocation can result in the expression of a fusion protein containing the BTK kinase domain and a fusion partner. For example, the fusion protein may contain a gene translocation that results in the expression of a wild-type BTK protein. Other dysregulations include increased kinase activity relative to the mRNA sequence of BTK. In some embodiments, the wild-type BTK protein includes price variants. 1 is an exemplary wild-type BTK protein described herein.

[0332] In some embodiments, the BTK gene, the BTK kinase, or any of them Dysregulation of expression or activity or levels includes overexpression of wild-type BTK kinase. In some embodiments, the BTK gene, the BTK kinase protein, or their The dysregulation of any expression or activity or level may be, for example, a kinase domain portion. a portion of the BTK gene or a portion thereof, including a portion capable of exhibiting kinase activity The present invention includes overexpression, activation, amplification, or mutation in a chromosomal segment comprising:

[0333] In some embodiments, the BTK gene, the BTK kinase, or any of them The dysregulation of expression or activity or level of BTK kinase is due to one or more deletions (e.g., deletion of amino acid position 4), insertions, or point mutation(s). In some embodiments, the BTK gene, the BTK kinase, or the expression or non-expression of either thereof is Dysregulation of the activity or levels of the BTK kinase domain results in constitutive activity. , which contains a deletion of one or more residues from the BTK kinase.

[0334] In some embodiments, the BTK gene, the BTK kinase, or any of them Dysregulation of expression, activity, or levels of one or more BTK kinases compared to wild-type BTK kinase or multiple amino acid substitutions, insertions, or deletions, resulting in the production of BTK kinases. Contains at least one point mutation in the BTK gene (e.g., a point mutation listed in Table 1). See the reference. [Table 1]

[0335] In some embodiments, the BTK gene, the BTK kinase, or any of them Dysregulation of expression or activity or levels leads to one or more BTK gene fusions In some embodiments, the BTK gene, BTK kinase, Dysregulation of the expression or activity or levels of any of the enzymes, The total number of expressed proteins is 100. ... It is the result of a gene translocation that contains a minimal functional BTK kinase domain.

[0336] Non-limiting examples of BTK gene fusion proteins are shown in Table 1a. [Table 2]

[0337] In some embodiments, the BTK gene, the BTK kinase, or any of them Dysregulation of expression, activity, or levels of BTK is due to alternative splicing of BTK mRNA. In some embodiments, alternatively spliced ​​variants of BTK are included. The RNA was a BTK kinase with at least one deleted residue (compared to wild-type BTK kinase). K kinase, resulting in constitutive activity of the BTK kinase domain. Wild-type BTK An example of an alternative splicing variant of the BTK kinase is wild-type BTK. p65BTK contains a first exon that is different from that of other kinases. It can start at the putative start codon in exon 4, not exon 2 as in the wild-type BTK kinase. (Grassilli et al., incorporated herein by reference in its entirety). , Oncogene. 35(33):4368-78, 2016). In this study, p65BTK is expressed in colon cancer.

[0338] In some embodiments, the BTK gene, the BTK kinase, or any of them Dysregulation of expression or activity or levels of BTK kinase compared to wild-type BTK kinase At the N-terminus of the kinase, at least one amino acid (e.g., at least 2, at least 3 , at least 4, at least 5, at least 6, at least 7, at least 8, at least At least 14, at least 9, at least 10, at least 12) kinases 16, at least 18, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50 amino acids, or at least This results in a BTK with an additional amino acid sequence (approximately 100 amino acids) compared to the wild-type BTK kinase. Translated from an alternative promoter. Examples of BTK kinases that have been studied include BTK-C, which is a mutant of wild-type BTK kinase. It has a different first exon due to alternative splicing compared to wild-type BTK kinase. A different initiation codon results in a BTK kinase with an N-terminal extension of 34 amino acids compared to (Eifert, each of which is incorporated herein by reference in its entirety). et al.,Genes Chromosomes Cancer.52(10):9 61-75, 2013 and Kokabee et al. Cancer Biol. T her. 16(11):1604-15, 2015). In some embodiments, BTK -C is expressed in prostate or breast cancer.

[0339] In some embodiments, the BTK gene, the BTK kinase, or any of them Dysregulation of expression or activity or levels of BTK kinase compared to wild-type BTK kinase or resulting in the production of BTK kinases with multiple amino acid insertions or deletions. BTK kinases with one or more amino acid substitutions, insertions, or deletions in the gene The present invention also includes at least one point mutation in the BTK gene that results in the production of a β-glucanase. The resulting BTK kinase may be a wild-type BTK kinase or a BTK kinase that does not contain the mutation. and inhibiting its hormonal activity by one or more first BTK kinase inhibitor(s) compared to the BTK kinase. Such mutations are optionally selectively (e.g., compared with cancer cells or tumors that do not contain a specific BTK inhibitor resistance mutation) 2.) Treatment with a compound of formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof does not reduce the sensitivity of cancer cells or tumors that contain the BTK kinase to treatment. In such embodiments, the BTK inhibitor-resistant mutation is present in the presence of a first BTK kinase inhibitor. and (b) inhibiting the activity of wild-type BTK kinase or a mutant thereof in the presence of the same first BTK kinase inhibitor. When compared to the unaffected BTK kinase, V max Increase in ATP K m Decrease in and the K of the first BTK kinase inhibitor D BTK kinase with one or more of the following increases: In other embodiments, the BTK gene, BTK kinase, or its Dysregulation of the expression or activity or levels of any of these kinases is associated with a difference from wild-type BTK kinase. resulting in the production of a BTK kinase having one or more amino acid substitutions compared to wild-type. A compound of Formula I, or or a pharmaceutically acceptable salt thereof, amorphous or polymorphic form, or a spray-dried dispersion thereof; or at least one mutation in the BTK gene that increases resistance to those pharmaceutical compositions. In such embodiments, the BTK inhibitor-resistant mutation comprises a single point mutation. or in the presence of a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof, of the formula I wild-type in the presence of the compound, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof. When compared with the V type BTK kinase or a BTK kinase without the mutation, max of Increased, K m The decrease in K D BTK kinase having one or more of the following reductions: This can result in:

[0340] Examples of BTK inhibitor-resistant mutations include, for example, mutations in gatekeeper residues (e.g., wild-type BTK kinase amino acid position 474), P-loop residues at or near the DFG motif These include, but are not limited to, residues that bind to the ATP cleft and the solvent front amino acid residues. point mutations, insertions, or mutations in and near the ATP binding site of the BTK kinase tertiary structure Further examples of these types of mutations include mutations of activation loop residues, Residues near or interacting with the activation loop, active or inactive enzyme including, but not limited to, residues that contribute to the conformation, enzymatic activity, and / or drug binding Changes in residues that may affect the C-helix progression, including the loop and C-helix In some embodiments, the alterations include mutations, deletions, and insertions in the gene. The wild-type BTK protein is an exemplary wild-type BTK kinase described herein. Specific residues or residue regions that can be altered (e.g., BTK inhibitor-resistant mutations) are identified in human genomes. The following are listed in Table 2, numbered based on the native BTK protein sequence (e.g., SEQ ID NO: 1): As will be appreciated by those skilled in the art, the specific The amino acid positions in the reference protein sequence corresponding to the amino acid positions in the reference protein sequence can be determined by aligning the sequence to SEQ ID NO: 1 (e.g., ClustalW2 (Use software programs such as ). Modifications to these residues can be single or multiple. Amino acid changes of several amino acids, insertions within or adjacent to the sequence, and The present invention may include deletions that result in the formation of a nucleotide sequence similar to that of the nucleotide sequence of the present invention. tra,GKKanev,OPJVan Linden,R.Leurs,I .JPDe Esch,and C.De Graaf,“KLIFS:A str uctural kinase-ligand interaction databa se,” Nucleic Acids Res.,vol.44,no.D1,pp. See also D365-D371,2016.

[0341] Exemplary sequence of mature human BTK protein (SEQ ID NO: 1) [Sequence Table 1] TIFF0007596441000009.tif61163

[0342] In some embodiments, the compound of formula I, or a pharmaceutically acceptable salt thereof, is amorphous, or polymorphic forms, spray-dried dispersions thereof, or pharmaceutical compositions thereof, and / or other BTK kinase inhibitors, e.g., primary and / or secondary BTK inhibitors. kinase inhibitors) in combination with, or as a follow-on or add-on therapy (e.g., BTK inhibitor resistance mutations (e.g., first BTK inhibitor) due to either those that result in increased resistance to, for example, a substitution at amino acid position 481, e.g. , C481S, C481T, C481R, C481G, and / or Tables 2 and 3 For the treatment of subjects with cancer containing one or more BTK inhibitor resistance mutations listed Exemplary first and second BTK kinase inhibitors are described herein. In some embodiments, the first or second BTK kinase inhibitor is ibrutinib. , PRN1008, PRN473, ABBV-105, AC0058, acalabrutinib , zanubrutinib, spebrutinib, posertinib, evobrutinib, M7583, Chira Brutinib, CG'806, ARQ531, BIIB068, becabrutinib, AS87 1, CB1763, CB988, GDC-0853, RN486, dasatinib, GNE- 504, GNE-309, BCB-311, BTK Max, CT-1530, CGI- 1746, CGI-560, LFM A13, TP-0158, dtrmwxhs-12 , CNX-774, and LOU064. In some embodiments, the first or second BTK kinase inhibitor is a covalent inhibitor. Exemplary covalent inhibitors of α-glucose include ibrutinib, PRN1008, PRN473, A BBV-105, AC0058, acalabrutinib, zanubrutinib, spebrutinib, These include posertinib, evobrutinib, M7583, and tirabrutinib. In some embodiments, the first or second BTK kinase inhibitor is , a non-covalent inhibitor. Exemplary non-covalent inhibitors of BTK kinase include CG'8 06, ARQ531, BIIB068, becabrutinib, AS871, CB1763, C These include, but are not limited to, B988, GDC-0853, RN486, and dasatinib. Not determined.

[0343] In some embodiments, the compound of formula I, or a pharmaceutically acceptable salt thereof, is amorphous, or polymorphic forms, spray-dried dispersions thereof, or pharmaceutical compositions thereof, Multiple BTK inhibitor resistance mutations (leading to increased resistance to the first or second BTK inhibitor) substitutions at amino acid position 481, e.g., C481S, C481T, C48 1R, and C481R, or a substitution at, for example, amino acid position 474, e.g., T474 These compounds are useful for treating cancers identified as having the T474I, T474M, and T474S mutations. Non-limiting examples of BTK inhibitor resistance mutations are listed in Table 2. [Table 3]

[0344] In other embodiments, the compound of Formula I, or a pharmaceutically acceptable salt thereof, amorphous or The polymorphic forms, spray-dried dispersions thereof, or pharmaceutical compositions thereof may contain one or more BTK inhibitor resistance mutations (those that result in increased resistance to the first or second BTK inhibitor) a substitution at amino acid position 707 in PLCγ2, e.g., S707Y, S70 7P, and S707F, or a substitution at amino acid position 251 in, for example, CARD11 These compounds are useful for treating cancers identified as having BTK inhibitors (e.g., L251P). Non-limiting examples of toxicant resistance mutations are listed in Table 3. [Table 4]

[0345] In some embodiments, the BTK gene, the BTK kinase, or any of them Dysregulation of expression or activity or levels of the BCR complex or downstream signaling components Activating mutations within the molecule result in interaction with microbial or autoantigens present in the tissue microenvironment. This may result in persistent BCR stimulation or a pathogenic increase in BTK protein expression or activation. In some embodiments, BCR signaling is ligand-independent and sustained. TK gene, BTK kinase, or the expression, activity, or level of either thereof Dysregulation of the BCR signaling pathway genes, BCR signaling pathway proteins, or dysregulation of the expression or activity or level of any of them. In embodiments, BCR signaling pathway genes, BCR signaling pathway proteins, or dysregulation of the expression or activity or levels of any of them, the BCR complex or one or more activating mutations in downstream signaling components, present in the tissue microenvironment Continuous BCR stimulation by microbial or autoantigens or expression of the BTK protein Ligand-independent sustained BCR signaling leading to increased expression or activation pathogenicity For example, the BTK gene, the BTK protein, or the expression or non-expression of either of them Dysregulation of activity or levels of BCR signaling pathway proteins is due to genetic mutations. Concomitant mutations (e.g., BCR signaling pathway gene translocations leading to expression of fusion proteins, Contains at least one amino acid deletion compared to the wild-type BCR signaling pathway protein BCR signaling pathway genes that result in the expression of BCR signaling pathway proteins, including Expression of BCR signaling pathway proteins with deletion or one or more point mutations Mutations in BCR signaling pathway genes that result in the expression of wild-type BCR signaling pathway genes At least one amino acid of a BCR signaling pathway protein compared to a tract protein BCR signaling pathway leading to deletion of BCR signaling pathway proteins It may be the result of alternatively spliced ​​versions of the protein mRNA.

[0346] In some embodiments, the BTK gene, the BTK kinase, or any of them Dysregulation of expression, activity, or levels of wild-type BCR signaling pathway proteins BCR signaling pathway with one or more amino acid insertions or deletions compared to the original One or more genes in the BCR signaling pathway that result in the production of pathway proteins Production of BCR signaling pathway proteins with amino acid substitutions, insertions, or deletions Several gene mutations in the BCR signaling pathway result in In embodiments, the mutation (e.g., activating mutation) in a BCR signaling pathway gene is One or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid substitutions (e.g., BCR sequences with one or more amino acid substitutions) In some embodiments, the mutation may result in the expression of a signal transduction pathway protein. In some embodiments, the gene amplification may be a gene in the BCR signaling pathway. Mutations in signaling pathway genes (e.g., activating mutations) disrupt wild-type BCR signaling. At least one amino acid (e.g., at least two, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, At least 9, at least 10, at least 12, at least 14, at least 16, a few At least 18, at least 20, at least 25, at least 30, at least 35, BCR signal lacking at least 40, at least 45, or at least 50 amino acids This can result in the expression of a BCR signaling pathway protein or a BCR signaling pathway receptor. In some embodiments, a mutation (e.g., an activating mutation) in a BCR signaling pathway gene is (different) has at least one amino acid change compared to the wild-type BCR signaling pathway protein (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, At least 7, at least 8, at least 9, at least 10, at least 12, at least At least 14, at least 16, at least 18, at least 20, at least 25, At least 30, at least 35, at least 40, at least 45, or at least 50 This can result in the expression of BCR signaling pathway proteins containing inserted amino acids. Dysregulation involves mRNA splice variants of the BCR signaling pathway. Non-limiting examples of CR signaling pathway mutations are listed in Table 4. [Table 5]

[0347] In other embodiments, the BTK gene, the BTK kinase, or the expression of either thereof is also or dysregulated activity or levels compared to wild-type BCR signaling pathway proteins. Production of BCR signaling pathway proteins having one or more amino acid substitutions relative to the and BCR signaling pathway proteins or mutations thereof that result in BCR signaling. a compound of formula I, or a pharmaceutically acceptable salt thereof, or polymorphic forms thereof, spray-dried dispersions thereof, or pharmaceutical compositions thereof. Contains at least one point mutation in a BCR signaling pathway gene that increases sexual maturity .

[0348] Thus, as used herein, a subject diagnosed with (or identified as having) cancer is treated with A method of treating a subject comprising administering to the subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. salts, amorphous or polymorphic forms thereof, spray-dried dispersions thereof, or pharmaceutical compositions thereof As used herein, a method is provided for treating a patient suffering from a BTK-associated cancer, comprising administering A method of treating an identified or diagnosed subject, comprising administering to the subject a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, an amorphous or polymorphic form, or a spray-dried dispersion thereof Also provided are methods comprising administering the compound of formula (I) or a pharmaceutical composition thereof. In this embodiment, the subject is provided with a BTK gene, a BTK kinase, or a mutated BTK kinase gene in the subject or in a biopsy sample from the subject. To identify dysregulation of the expression or activity or levels of any of the enzymes by the use of a regulatory approved, e.g., FDA-approved, test or assay, or or by performing any of the non-limiting examples of assays described herein. In some embodiments, the patient has been identified or diagnosed as having a TK-associated cancer. Alternatively, the assay is provided as a kit. In some embodiments, the cancer is a BTK-associated cancer. For example, BTK-associated cancers contain one or more BTK inhibitor resistance mutations. It could be mugan.

[0349] Also provided is a method of treating cancer in a subject in need thereof, comprising: (a) detecting a BTK-associated cancer in a subject; and (b) administering to the subject a therapeutically effective amount of a compound of Formula I. or a pharmaceutically acceptable salt thereof, an amorphous or polymorphic form thereof, a spray-dried and administering a dry dispersion, or a pharmaceutical composition thereof. Some embodiments of the method further comprise administering to the patient a second anti-cancer agent (e.g., a second BTK inhibitor or immunotherapy). In some embodiments, the subject has previously administered a first are being treated with a BTK inhibitor or another anti-cancer treatment, e.g., to treat at least part of the tumor In some embodiments, the subject has been previously treated with fractional resection or radiation therapy. or a gene encoding the BTK gene, BTK kinase, or a gene encoding the same in a subject or a biopsy sample from the subject. To identify dysregulation of the expression or activity or levels of any of these by use of an approved, e.g., FDA-approved, test or assay, or by other methods described herein. BTK-associated cancers can be diagnosed by performing any of the non-limiting examples of assays described in In some embodiments, the test or assay is provided as a kit. In some embodiments, the cancer is a BTK-associated cancer. For example, a BTK-associated The cancer may be a cancer containing one or more BTK inhibitor resistance mutations. In some embodiments, the BTK gene, the BTK kinase, or the expression or activity of either thereof Alternatively, the dysregulated levels of one or more BCR signaling pathway proteins In some embodiments, the BCR signaling pathway is the result of one or more mutations in the BCR signaling pathway. Pathway proteins include cyclin-D1, CARD11, CD79B, CD79A, and MYD 88, and combinations thereof.

[0350] Also provided are methods of treating a subject, comprising administering to a subject a tumor obtained from the subject. and performing an assay to determine whether the subject is a BTK gene, a BTK kinase, or either of these. determining whether the subject has a dysregulated expression or activity or level of The BTK gene, the BTK kinase, or the expression or activity or level of either thereof a subject determined to have dysregulation of the thyroid gland, the subject being administered a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form of, or a spray-dried dispersion thereof; or and administering (specifically or selectively administering) these pharmaceutical compositions. Some embodiments of these methods involve administering another anti-cancer agent (e.g., a second BTK inhibitor). or immunotherapy) to the subject. In this state, the subject may have previously been treated with a first BTK inhibitor or may have received another anti-cancer therapy. have been previously treated, for example, with at least partial resection of the tumor or radiation therapy. In some embodiments, the subject is a subject suspected of having a BTK-associated cancer, a subject suspected of having a BTK-associated cancer, Subjects who exhibit one or more symptoms of, or are at high risk for developing, a BTK-associated cancer In some embodiments, the assay is performed using next generation sequencing, pyrosequencing, Utilizing immunostaining, immunohistochemistry, immunoblotting, or break-apart FISH analysis In some embodiments, the assay is a regulatory approved assay, e.g., FDA approved. In some embodiments, the assay is a liquid biopsy. Additional non-limiting assays that can be used in the method are described herein. Assays for the BTK gene, BTK Dysregulation of the expression or activity or levels of any of the kinases, Contains one or more BTK inhibitor resistance mutations.

[0351] Also provided are methods for treating a subject's BTK gene, BTK kinase, or any of the foregoing. To determine whether the expression or activity or level of For samples obtained from elephants, the BTK gene, the BTK kinase, or either of them The presence of dysregulated expression or activity or levels of BTK indicates that a patient has a BTK-associated cancer. performing an assay (e.g., an in vitro assay) to identify the presence of and the treatment of BTK-associated cancer in subjects identified or diagnosed with BTK-associated cancer. A compound of formula I, or a pharmaceutically acceptable salt thereof, amorphous or is a polymorphic form, a spray-dried dispersion thereof, or a pharmaceutical composition thereof. The subject is considered to have a mutation in the BTK gene, the BTK kinase, or the expression or function of either of them. is obtained from the subject to determine whether the subject has dysregulated activity or levels The sample is identified as having a BTK-associated cancer through a step of performing an assay. 1. A method for the treatment of a BTK-associated cancer in a subject diagnosed or having a BTK-associated cancer, comprising administering to a subject a compound of formula I or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof, and the use of a spray-dried dispersion of any of the methods or uses described herein. In some embodiments, the subject is able to identify the BTK gene, BTK kinase, or is determined to have dysregulation of the expression, activity or level of any of them. and a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof. and that the patient is to be administered a pharmaceutical composition thereof, a spray-dried dispersion thereof, or a pharmaceutical composition thereof. and further comprising recording the result in the subject's clinical record (e.g., in a computer-readable medium). In some embodiments, the assay is performed using next generation sequencing, pyrosequencing, immunoassay, or other methods. Utilize immunohistochemistry, immunoblot, or break-apart FISH analysis. In this embodiment, the assay is a regulatory approved assay, e.g., an FDA approved kit. In some embodiments, the assay is a liquid biopsy. , the BTK gene, the BTK kinase, or the expression or activity of any of them The dysregulated levels include one or more BTK inhibitor resistance mutations. In this state, the BTK gene, the BTK kinase, or the expression or activity of either of them or dysregulated levels of one or more BCR signaling pathway proteins. In some embodiments, the mutation is the result of one or more mutations in the BCR signaling pathway. Tract proteins include cyclin-D1, CARD11, CD79B, CD79A, and MYD8 8, and combinations thereof.

[0352] Also provided is a method for treating cancer, or a BTK-associated cancer, in a subject in need of treatment. 1. A method for treating cancer in a subject identified or diagnosed as having a compound of formula Compounds of formula I, or pharmaceutically acceptable salts thereof, amorphous or polymorphic forms thereof, Also provided are spray-dried dispersions of BTK-related compounds, or pharmaceutical compositions thereof. Manufacture of a medicament for treating cancer in a subject identified or diagnosed as having cancer a compound of formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof, for , a spray-dried dispersion thereof, or a pharmaceutical composition thereof. In some cases, the cancer may be a BTK-associated cancer, e.g., a cancer that has one or more BTK inhibitor resistance mutations. In some embodiments, the subject has a BTK-associated cancer. In the test sample, the expression or activity of the BTK gene, the BTK kinase, or either of them is detected. to identify dysregulated activity or levels of a regulatory approved, e.g., FDA-approved, By using the kit, a patient can be identified or diagnosed as having a BTK-associated cancer. As provided herein, BTK-associated cancers include those described herein, and These include those known in the art.

[0353] In some embodiments of any of the methods or uses described herein, the subject has BT K gene, BTK kinase, or the expression or activity or level of any of them The subject has been identified or diagnosed as having a cancer involving dysregulation of In some embodiments of any of the or the uses, the subject has a gene encoding the BTK gene, a BTK kinase Positive for dysregulation of expression or activity or levels of any of these Some embodiments of any of the methods or uses described herein In the present invention, the subject is a patient with a BTK gene, a BTK kinase, or any of the expression or The subject may have a tumor(s) that is positive for dysregulation of activity or level. In some embodiments of any of the methods or uses described herein, the subject The tumor expresses the BTK gene, the BTK kinase, or neither of these expression or activity. The subject may be a tumor with dysregulated levels of the protein. In some embodiments of any of the uses, the subject has a BTK-associated cancer (e.g., one or more or cancer with multiple BTK inhibitor resistance mutations). In some embodiments of any of the methods or uses, the subject is BTK inhibitor naive. In other embodiments of any of the methods or uses described herein, the subject has In some embodiments, the BTK-associated cancers described herein are not inhibitor-naive. A method of treating a BTK-associated cancer in a patient in need of treatment is provided, the method comprising: a) detecting in a sample from a patient the BTK gene, the BTK kinase, or any of them; b) detecting dysregulation of the expression or activity or level of Compounds of formula I, or pharmaceutically acceptable salts thereof, amorphous or polymorphic forms thereof and administering the spray-dried dispersion, or a pharmaceutical composition thereof. In some embodiments, the BTK gene, the BTK kinase, or the expression or activity of either thereof Alternatively, the dysregulated levels include one or more fusion proteins. Non-limiting examples of conjugated proteins are listed in Table 1a. In some embodiments, B TK gene, BTK kinase, or the expression, activity, or level of either thereof Dysregulation of the kinase involves point mutations / insertions / deletions in one or more BTK kinase proteins. Non-limiting examples of point mutations / insertions / deletions in the BTK kinase protein are listed in Table 1. In some embodiments, the point mutation / insertion / deletion in the BTK kinase protein is T117P, T316A, T474I, T474M, T474S, C481S, C481 S, C481T, C481G, C481R, L528W, P560L, R562W, R5 In some embodiments, the BTK is selected from the group consisting of: F601L, F601G, and F601L. gene, BTK kinase, or the expression or activity or level of any of them The dysregulation includes one or more BTK inhibitor resistance mutations. Non-limiting examples are listed in Tables 2 and 3. In some embodiments, BTK-resistant mutants The mutation is at amino acid 481 of BTK. In some embodiments, the BTK inhibitor In some embodiments, the BTK inhibitor resistance mutation is C481S. 481F. In some embodiments, the BTK inhibitor resistance mutation is T474I. In some embodiments, the BTK inhibitor resistance mutation is a mutation in PLCγ2 (e.g., For example, amino acid positions 244, 257, 334, 495, 664, 665, 707, and 708 , 742, 845, 848, 993, 1140, or 1141). In this study, the BTK gene, the BTK kinase, or the expression or activity of either of them was investigated. Dysregulation of the levels of one or more BCR signaling pathway proteins In some embodiments, the BCR signaling pathway is the result of one or more mutations. Proteins include cyclin-D1, CARD11, CD79B, CD79A, and MYD88 In some embodiments, the BT K gene, BTK kinase, or the expression or activity or level of any of them Cancers involving dysregulation of In some embodiments, the BTK gene, BTK kinase, or Tumors positive for dysregulation of the expression or activity or levels of any of them are tumors that are positive for one or more BTK inhibitor resistance mutations. In embodiments, the BTK gene, the BTK kinase, or the expression or Tumors with dysregulated activity or levels may be treated with regulatory approved, e.g., FDA approved, It is determined using an assay or kit.

[0354] In some embodiments of any of the methods or uses described herein, the subject has BT K gene, BTK kinase, or the expression or activity or level of any of them Tumors with dysregulation of BTK (e.g., tumors with one or more BTK inhibitor resistance mutations) In some embodiments, the clinical record indicates that the subject has: The subject is administered a compound of Formula I, as provided herein, or a pharmaceutically acceptable salt thereof, Treating with amorphous or polymorphic forms, spray-dried dispersions thereof, or pharmaceutical compositions thereof In some embodiments, the BTK gene, BTK kinase or a cancer involving dysregulation of the expression or activity or levels of any of them, In some embodiments, the cancer has one or more BTK inhibitor resistance mutations. The BTK gene, the BTK kinase, or the expression or activity or level of either thereof Cancers associated with dysregulated signaling can be detected by regulatory-approved, e.g., FDA-approved, assays or assays. In some embodiments, the BTK gene, BTK kinase, or or positive for dysregulation of the expression, activity, or levels of any of them The tumor is one that is positive for one or more BTK inhibitor resistance mutations. In some embodiments, the BTK gene, the BTK kinase, or the expression or non-expression of either thereof is Tumors with dysregulated activity or levels are treated with regulatory approved, e.g., FDA-approved, The activity is determined using an assay or kit.

[0355] Also provided are methods of treating a subject, comprising administering a therapeutically effective amount of a compound of Formula I, or or a pharmaceutically acceptable salt thereof, amorphous or polymorphic form, or a spray-dried dispersion thereof; or the pharmaceutical composition thereof, have clinical documentation showing dysregulation of the expression, activity, or level of any Also provided are methods for administering to a subject a gene encoding the BTK gene, BTK kinases, or dysregulation of the expression or activity or levels of any of them A medical device for treating BTK-associated cancer in a subject with clinical documentation showing that the A compound of formula I, or a pharmaceutically acceptable salt thereof, amorphous, or The use of these polymorphic forms, their spray-dried dispersions, or pharmaceutical compositions thereof. Some embodiments of the methods and uses involve assaying (e.g., In one embodiment, a subject may be tested for the BTK gene, BTK kinase, or its related functions by performing an in vitro assay (e.g., an in vitro assay) to determine whether the subject has a BTK gene, BTK kinase, or its related functions. and determining whether the expression, activity, or level of any of these is dysregulated. and wherein the subject is also expressing the BTK gene, the BTK kinase, or any of them. or dysregulated activity or level of the subject. and recording the result in a file (e.g., a computer-readable medium). In some embodiments, the assay is an in vitro assay. For example, the assay , next generation sequencing, immunohistochemistry, immunoblot, or break-apart FIS In some embodiments, the assay utilizes regulatory approved, e.g., F The kit is DA approved. In some embodiments, the assay is a liquid biopsy. In some embodiments, the BTK gene, the BTK kinase, or expression of either thereof is also or dysregulated activity or levels include one or more BTK inhibitor resistance mutations. In some embodiments, the BTK gene, the BTK kinase, or either thereof Dysregulation of expression or activity or levels may occur via one or more BCR signaling pathways. In some embodiments, the B CR signaling pathway proteins include cyclin-D1, CARD11, CD79B, and C D79A, MYD88, and combinations thereof. Also provided herein are methods of treating a subject. In some embodiments, the methods include administering to a subject a therapeutically effective amount of a compound obtained from the subject. Assays are performed on the collected samples to determine whether the subject has a BTK gene, BTK protein, or The method determines whether the expression, activity, or level of any of these is dysregulated. In some such embodiments, the method also includes determining the BTK gene, B TK proteins, or dysregulation of the expression or activity or levels of any of them a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, to a subject determined to have salts, amorphous or polymorphic forms thereof, spray-dried dispersions thereof, or pharmaceutical compositions thereof In some embodiments, the method comprises administering to a subject a gene encoding the BTK gene, BTK having dysregulation of the expression or levels of any of the proteins, This includes determining the level of a specific antibody by an assay performed on a sample obtained from the subject. In such embodiments, the method comprises administering to the subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutical or a spray-dried dispersion thereof, or a salt thereof, amorphous or polymorphic form thereof, which is acceptable for In some embodiments, the BTK gene, BTK kinase, Dysregulation of the expression or activity of any of the enzymes in the BTL gene is a risk factor for BTL gene mutations. Expression of a BTK fusion protein (e.g., any of the BTK fusion proteins described herein) In some embodiments, the BTK gene, BTK kinase protein, or the expression or activity or level of any of them Dysregulation in the BTK gene can be mediated by one or more point mutations in the BTK gene (e.g., as described herein). BTK point mutations in the BTK gene (either one or more of the following): Multiple point mutations include, for example, T117P, T316A, T474I, T474M, T474 S, C481S, C481F, C481T, C481G, C481R, L528W, P5 one of the amino acid substitutions R60L, R562W, R562G, and F601L; or In some embodiments, the BTK protein may be translated into a BTK protein having more than one BTK. gene, BTK kinase protein, or the expression or activity of any of them. Dysregulation in BTK levels can be due to one or more BTK inhibitor resistance mutations (e.g., mutations in the genes described herein). (any combination of one or more BTK inhibitor resistance mutations described in the document). In some embodiments, the BTK gene, the BTK kinase, or expression of either thereof Alternatively, the dysregulation of activity or levels of one or more BCR signaling pathways In some embodiments, the mutation is the result of one or more mutations in the BCR protein. Signaling pathway proteins include cyclin-D1, CARD11, CD79B, and CD7 9A, MYD88, and combinations thereof. Some embodiments of the present invention further comprise administering to a subject a therapeutically effective amount of a compound selected from the group consisting of a medicament for the treatment of cancer, ... and administering to the subject.

[0356] Also provided are methods for treating a subject identified or diagnosed with a BTK-associated cancer. In some embodiments, the method of selecting a treatment is an in vitro method. and administering the treatment to a subject identified or diagnosed as having a BTK-associated cancer. For example, the selected treatment may include a therapeutically effective amount of a compound of Formula I, or a pharmaceutical formulation thereof. a commercially available commercially acceptable salt, amorphous, or polymorphic form thereof, a spray-dried dispersion thereof, or a Some embodiments may include administering a pharmaceutical composition comprising: Assays are performed to determine whether the subject has a BTK gene, a BTK kinase, or either thereof. B. determining whether the expression or activity or level of the antibody is dysregulated; TK gene, BTK kinase, or the expression, activity, or level of either thereof Subjects determined to have dysregulation of the BTK gene are identified and diagnosed as having BTK-associated cancer. In some embodiments, the BTK gene, BTK Dysregulation of the expression or activity or levels of any of the kinases, The result of one or more mutations in one or more BCR signaling pathway proteins In some embodiments, the BCR signaling pathway protein is cyclin- D1, CARD11, CD79B, CD79A, MYD88, and their combinations In some embodiments, the cancer is characterized by one or more BTK inhibitors. In some embodiments, the subject has a BTK-associated cancer with a drug resistance mutation. The present invention provides a method for detecting a BTK gene, a BTK kinase, or any of them in a biopsy sample from a subject. Regulatory approved, e.g., for identifying dysregulation of expression or activity or levels of For example, patients may be identified or diagnosed as having a BTK-associated cancer by use of an FDA-approved kit. In some embodiments, the BTK-associated cancer is a cancer described herein or is a cancer known in the art. In some embodiments, the assay comprises an in vitro For example, assays include next-generation sequencing, immunohistochemistry, immunoblotting, In some embodiments, break-apart FISH analysis is utilized. The kit is regulatory approved, e.g., FDA approved. , the assay is a liquid biopsy.

[0357] Also provided herein are methods of selecting a treatment for a subject, the methods comprising: Assays are performed on the sample to determine whether the subject has a BTK gene, BTK kinase, or Dysregulation of the expression or activity or level of any of them (e.g., one or more determining whether the patient has a BTK inhibitor-resistant mutation (number of BTK inhibitor-resistant mutations); TK kinase, or dysregulation of the expression or activity or levels of any of them identifying and diagnosing the subject as having a BTK-associated cancer; Some embodiments include the selected treatment as a treatment for a patient with a BTK-associated cancer. For example, the selected treatment may be a therapeutic agent. a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof , a spray-dried dispersion thereof, or a pharmaceutical composition thereof for use in treating a patient suffering from a BTK-associated cancer. In some embodiments, the assay may include administering the antibody to a subject identified or diagnosed with the antibody. is an in vitro assay. For example, the assay can be used in next generation sequencing, immunohistochemistry, Utilizing chemical, immunoblot, or break-apart FISH analysis. In some embodiments, the assay is a regulatory approved, e.g., FDA approved, kit. In an embodiment, the assay is a liquid biopsy.

[0358] Also provided is a method of selecting a subject for treatment, the method comprising: and administering to a subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form of, or a spray-dried dispersion thereof; or and selecting the subject for treatment comprising administering the pharmaceutical composition. Some embodiments identify or diagnose a subject as having a BTK-associated cancer. means performing an assay on a sample obtained from a subject to determine whether the subject has a BTK gene, BTK kinase, or dysregulation of the expression or activity or levels of any of them determining whether the BTK gene, the BTK kinase, or any of them is present; A subject determined to have dysregulated expression, activity, or level of BTK is and identifying or diagnosing the patient as having an associated cancer. In some embodiments, the method of selecting a subject for treatment includes administering a variety of treatments for BTK-associated cancers. In some embodiments, the BTK-associated cancer can be In some embodiments, the cancer has one or more BTK inhibitor resistance mutations. The assay is an in vitro assay. For example, the assay is performed using next generation sequencing, Immunohistochemistry or break-apart FISH analysis is utilized. The assay is regulatory approved, e.g., an FDA-approved kit. In some embodiments, the assay is a liquid biopsy. K kinase, or dysregulation of the expression or activity or levels of any of them, In some embodiments, the BTK gene comprises one or more BTK inhibitor-resistant mutations. , BTK kinase, or dysregulation of the expression or activity or level of any of them. The total number of mutations in one or more BCR signaling pathway proteins In some embodiments, the BCR signaling pathway protein is Cullin-D1, CARD11, CD79B, CD79A, MYD88, and their combinations combinations thereof.

[0359] Similarly, the present invention provides a method for treating cancer (e.g., a BTK-associated cancer) in a subject in need of treatment. A method of treating cancer using BC in a sample from a subject is provided, the method comprising: a) detecting BC in a sample from a subject; R signaling pathway genes, BCR signaling pathway proteins, or both detecting dysregulation of the expression or activity or level of one of the or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof, and administering a spray-dried dispersion of the compound of formula (I), or a pharmaceutical composition thereof. Some embodiments of the present invention further comprise performing an assay (e.g., in vitro) on a sample obtained from a subject. Assay) to determine whether the subject has BCR signaling pathway genes, BCR signaling pathway protein, or dysregulation of the expression or activity or levels of any one of them determining whether the subject has a BCR signaling pathway gene, BCR signal transduction pathway proteins, or the expression or activity of any one of them The information that the subject was identified as having dysregulated levels was included in the subject's clinical file (e.g., and recording the information on a computer-readable medium. In the present specification, the assay is an in vitro assay. For example, the assay is performed using next-generation sequencing. Utilize immunofluorescence, immunohistochemistry, immunoblotting, or break-apart FISH analysis. In some embodiments, the assay is performed in a regulatory approved, e.g., FDA approved, kit. In some embodiments, the BCR signaling pathway protein is cyclin-D 1, CARD11, CD79B, CD79A, MYD88, and their combinations is selected from the group consisting of:

[0360] Also provided are methods of treating a subject, comprising administering a therapeutically effective amount of a compound of Formula I, or or a pharmaceutically acceptable salt thereof, amorphous or polymorphic form, or a spray-dried dispersion thereof; or the pharmaceutical composition thereof, when the subject is or the expression or activity or level of any one of the pathway proteins. The method comprises administering to a subject having clinical documentation indicating that the subject has nodal failure. Some embodiments of these methods involve performing an assay (e.g., an immunoassay) on a sample obtained from a subject. In vitro assays are performed to determine whether the subject has BCR signaling pathway genes, BCR signaling pathway genes, or transduction pathway proteins, or the expression or activity or level of any one of them determining whether the subject has dysregulation of a BCR signaling pathway gene; , BCR signaling pathway proteins, or the expression or activity of any one thereof or dysregulation of the level of For example, the method may further include recording the information on a computer-readable medium. In embodiments, the assay is an in vitro assay. For example, the assay is a next-generation system Use sequencing, immunohistochemistry, immunoblot, or break-apart FISH analysis. In some embodiments, the assay is a regulatory approved, e.g., FDA approved, In some embodiments, the BCR signaling pathway protein is a cyclin- Lin-D1, CARD11, CD79B, CD79A, MYD88, and their combinations The compound is selected from the group consisting of:

[0361] In some embodiments of any of the methods or uses described herein, a sample from a subject is The subject is then tested for the expression of the BTK gene, or the BTK kinase, or either of them. used to determine whether a patient has a dysregulation of expression, activity, or level of Assays include, for example, next-generation sequencing, pyrosequencing, immunohistochemistry, Fluorescence microscopy, break-apart FISH analysis, Southern blotting, Western blotting ting, FACS (fluorescence activated cell sorting) analysis, Northern blotting, and PCR Based amplification (e.g., RT-PCR (reverse transcription-polymerase chain reaction) and quantitative PCR) As is well known in the art, assays can be performed using, for example, For example, at least one labeled nucleic acid probe or at least one labeled antibody. or an antigen-binding fragment thereof. BTK kinase, or dysregulation of the expression or activity or levels of any of them Other detection methods known in the art for detecting See, e.g., the references cited herein. In some embodiments, B TK gene, BTK kinase, or the expression, activity, or level of either thereof In some embodiments, the dysregulation of the BTK inhibitor comprises one or more BTK inhibitor resistance mutations. The sample may be a biological sample or biopsy sample (e.g., a paraffin-embedded biopsy sample) from a subject. In some embodiments, the subject is a subject suspected of having a BTK-associated cancer, Subjects with one or more symptoms of a BTK-associated cancer and / or who develop a BTK-associated cancer These are subjects at high risk of

[0362] In some embodiments, the BTK gene, the BTK kinase, or any of them Dysregulation of expression or activity or levels can be determined by liquid biopsy (fluid biopsy or fluid phase biopsy, etc. For example, Karachialio u et al., “Real-time liquid biopsies beco me a reality in cancer treatment”,Ann.Tr See ansl. Med., 3(3):36, 2016. Using liquid biopsy , total tumor burden and / or expression of the BTK gene, BTK kinase, or any of them. The liquid biopsy method can detect dysregulation of expression, activity, or level of a target gene. It can be performed on biological samples that can be obtained relatively easily (e.g., by a simple blood draw) from In some embodiments, the liquid biopsy method can detect BT at an earlier stage than conventional methods. K gene, BTK kinase, or the expression or activity or level of any of them In some embodiments, the liquid can be used to detect the presence of dysregulation of Biological samples used in biopsies include blood, plasma, urine, cerebrospinal fluid, saliva, sputum, and bronchoalveolar lavage. These may include stool, bile, lymph, cyst fluid, feces, ascites, and combinations thereof. In some embodiments, liquid biopsies can be used to detect circulating tumor cells (CTCs). In some embodiments, a liquid biopsy can be used to detect cell-free DNA. In some embodiments, the cell-free DNA detected using a liquid biopsy can be Circulating tumor DNA (ctDNA) derived from tumor cells. Analysis of ctDNA (e.g., Techniques include, but are not limited to, next-generation sequencing (NGS), conventional PCR, digital PCR, and Using highly sensitive detection techniques such as microarray analysis, the BTK gene, BTK kinase and identifying dysregulation of the expression, activity, or levels of any of the enzymes. It is possible.

[0363] In some embodiments, ctDNA derived from a single gene is isolated using a liquid biopsy. In some embodiments, multiple genes (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more, or any of these numbers In some embodiments, the markers of the markers (and any number between) can be detected using a liquid biopsy. ctDNA derived from multiple genes can be used in a variety of commercially available test panels (e.g., BTK gene). Modulation of the expression or activity or levels of a protein, a BTK kinase, or any of them (commercially available test panels designed to detect deficiency) Liquid biopsies can be used to identify point mutations or single nucleotide variants (SNVs), Copy number variants (CNVs), gene fusions (e.g., translocations or rearrangements), insertions, and deletions BTK gene, ... and detecting dysregulation of the expression, activity, or levels of any of the K kinases. In some embodiments, to detect germline mutations, a liquid A biopsy can be used. In some embodiments, to detect somatic mutations, Liquid biopsy can be used. In some embodiments, liquid biopsy is used to determine the primary Genetic variations (e.g., primary mutations or fusions associated with the early development of diseases such as cancer) In some embodiments, a liquid biopsy can be used to detect primary genetic mutations. Genetic mutations that occur after the occurrence of a disease (e.g., resistance mutations that arise in response to a treatment administered to a subject) In some embodiments, B, identified using liquid biopsy, can be detected. TK gene, BTK kinase, or the expression, activity, or level of either thereof Dysregulation of the receptor is also present in cancer cells (e.g., tumors) present in a subject. In embodiments, any type of BTK gene, BTK kinase, or their derivatives described herein is used. Dysregulation of the expression or activity or levels of any of the In some embodiments, genetic mutations identified via liquid biopsy can be used to can be used to identify a subject as a candidate for a particular treatment. The BTK gene, the BTK kinase, or the expression or activity of either of them Detection of dysregulation of the level of IL-1 or IL-2 can be achieved by administering to a subject a compound of Formula I, or a pharmaceutically acceptable salt thereof. salts, amorphous or polymorphic forms thereof, spray-dried dispersions thereof, or pharmaceutical compositions thereof The subject may be shown to be responsive to treatment including administration of the compound.

[0364] At multiple time points during the diagnostic, monitoring, and / or treatment process, A body biopsy may be performed to assess disease progression, efficacy of treatment, or resistance mutations after the subject has been treated. one or more clinically relevant parameters, including but not limited to the occurrence of For example, diagnostic procedures, monitoring procedures, and / or During the course of treatment, a first liquid biopsy is performed at a first time point and a second liquid biopsy is performed at a second time point. In some embodiments, the first time point is a time point at which a subject is diagnosed with a disease. The first time point can be before the subject has diagnosed the disease (e.g., when the subject is healthy), and the second time point can be after the subject has developed the disease. a time point after the subject has developed a disease (e.g., the second time point can be used to diagnose the subject with the disease) In some embodiments, the first time point may be prior to diagnosing the subject with the disease. The subject may then be monitored and a second The time point can be a time point after the subject has been monitored. The time point can be a time point after diagnosing the subject with the disease, after which treatment is administered to the subject. The second time point may be a time point after the treatment is administered, in which case the second time point may be used and the efficacy of the treatment (e.g., a significant reduction in the number of gene mutations detected at the first time point). or as a result of treatment. The presence of any resulting resistance mutations can be determined. The treatment to be administered comprises administering to a subject a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorph thereof. The present invention may include a pharmaceutical composition thereof, a spray-dried dispersion thereof, or a pharmaceutical composition thereof.

[0365] In some embodiments, the compound of formula I, or a pharmaceutically acceptable salt thereof, is amorphous, The potency of the polymorphic forms, spray-dried dispersions thereof, or pharmaceutical compositions thereof may vary. cfDNA obtained from a subject at a different time point, e.g., cfDNA obtained from a subject at a first time point. Dysregulated alleles of the BTK gene in cfDNA obtained from subjects at time points A and B. The gene expression level can be determined by assessing the gene frequency and the effect of a compound of Formula I or a pharmaceutical or a spray-dried dispersion thereof, or a salt thereof, amorphous or polymorphic form thereof, which is acceptable for At least one dose of the pharmaceutical composition is administered to the subject between the first and second time points. Some embodiments of these methods include administering at least one dose of a compound of Formula I, or its pharmaceutically acceptable salts, amorphous or polymorphic forms, spray-dried dispersions thereof, and The method further includes administering the pharmaceutical composition to a subject between the first and second time points. For example, dysregulation of the BTK gene in cfDNA obtained from a subject at a first time point may be detected. BTK in cfDNA obtained from subjects at a second time point compared to allele frequency (AF) A reduction in the allele frequency (AF) of a gene that is dysregulated (e.g., a 1% to approximately 99% reduction, 1 % to approximately 95% reduction, 1% to approximately 90% reduction, 1% to approximately 85% reduction, 1% to approximately 80% reduction Decrease, 1% to approximately 75% decrease, 1% to approximately 70% decrease, 1% to approximately 65% ​​decrease Small, 1% decrease to approximately 60% decrease, 1% decrease to approximately 55% decrease, 1% decrease to approximately 50% decrease Decrease of 1% to about 45% Decrease of 1% to about 40% Decrease of 1% to about 3 5% decrease, 1% decrease to approximately 30% decrease, 1% decrease to approximately 25% decrease, 1% decrease or more Approximately 20% decrease, 1% decrease to approximately 15% decrease, 1% decrease to approximately 10% decrease, 1% to approximately 5% reduction, approximately 5% to approximately 99% reduction, approximately 10% to approximately 99% reduction, approximately 15% to approximately 99% reduction, reduction of about 20% to about 99%, reduction of about 25% to about 99%, reduction of about 30% to about 99% Reduction, reduction of about 35% to about 99%, reduction of about 40% to about 99%, reduction of about 45% to about 99% Small, approximately 50% to 99% reduction, approximately 55% to 99% reduction, approximately 60% to 99% reduction , reduction of about 65% to about 99%, reduction of about 70% to about 99%, reduction of about 75% to about 95%, Approximately 80% to 99% reduction, approximately 90% to 99% reduction, approximately 95% to 99% reduction, approximately 5% to 10% reduction, 5% to 25% reduction, 10% to 30% reduction, 20% reduction ~40% reduction, ~25%~50% reduction, ~35%~55% reduction, ~40%~ Approximately 60% reduction, approximately 50% reduction to approximately 75% reduction, approximately 60% reduction to approximately 80% reduction, or about a 65% to about a 85% reduction) is a compound of Formula I, or a pharmaceutically acceptable salt thereof , amorphous, or polymorphic forms thereof, spray-dried dispersions thereof, or pharmaceutical compositions thereof Alternatively, cfDNA obtained from the subject at a first time point is used to demonstrate efficacy in the treatment of a subject. BTK gene dysregulation allele frequency (AF) from subjects at a second time point compared to The increase in the allele frequency (AF) of dysregulated BTK gene in the obtained cfDNA was determined by Equation I or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof, The dried dispersion, or a pharmaceutical composition thereof, is not effective in the subject (e.g., the subject Compounds of formula I, or pharmaceutically acceptable salts thereof, amorphous or polymorphic forms thereof or a pharmaceutical composition thereof) Some embodiments of these methods involve administering to a subject a compound of Formula I, or a pharmaceutically acceptable salt thereof. salts, amorphous or polymorphic forms thereof, spray-dried dispersions thereof, or pharmaceutical compositions thereof an additional dose of a compound of formula I, or a pharmaceutically acceptable salt, amorphous, or polymorph thereof; The formulation, spray-dried dispersion thereof, or pharmaceutical composition thereof is determined to be effective. Some embodiments of these methods may further comprise administering to an elephant a different treatment. (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof) a compound of formula I or a pharmaceutically acceptable salt thereof) administered as a single agent. salts, amorphous or polymorphic forms thereof, spray-dried dispersions thereof, or pharmaceutical compositions thereof It may further comprise administering the product to a subject for whom it is determined to be ineffective.

[0366] In some examples of these methods, the time difference between the first time point and the second time point is about 1 Days to about 1 year, about 1 day to about 11 months, about 1 day to about 10 months, about 1 day to about 9 months, about 1 day to about 8 months, about 1 day to about 7 months, about 1 day to about 6 months, about 1 day to about 5 months, about 1 day to about 4 months, About 1 day to about 3 months, about 1 day to about 10 weeks, about 1 day to about 2 months, about 1 day to about 6 weeks, about 1 day ~1 month, ~25 days, ~20 days, ~15 days, ~10 days Days, about 1 day to about 5 days, about 2 days to about 1 year, about 5 days to about 1 year, about 10 days to about 1 year, about 15 days or more About 1 year, about 20 days to about 1 year, about 25 days to about 1 year, about 1 month to about 1 year, about 6 weeks to about 1 year, Approximately 2 months to 1 year, approximately 3 months to 1 year, approximately 4 months to 1 year, approximately 5 months to 1 year, approximately 6 months ~1 year, 7 months to 1 year, 8 months to 1 year, 9 months to 1 year, 10 months to 1 year ~11 months to 1 year, 1 day to 7 days, 1 day to 14 days, 5 days to 10 days, 5 days ~ about 20 days, about 10 to about 20 days, about 15 days to about 1 month, about 15 days to about 2 months, about 1 week to 1 month, 2 weeks to 1 month, 1 month to 3 months, 3 months to 6 months, approx. The period may be from 4 months to about 6 months, from about 5 months to about 8 months, or from about 7 months to about 9 months. In some embodiments of the method, the subject has a dysregulated BTK gene (e.g., a gene encoding a BTK gene as described herein). previously identified as having a cancer having a dysregulated BTK gene (any of the examples of dysregulated BTK genes described in In some embodiments of these methods, the subject may be Some of these methods may be used to treat cancer. In this embodiment, the subject has one or more metastases (e.g., one or more bone metastases). It may be possible.

[0367] In some of the above-described embodiments, the cfDNA is ctDNA, such as BTK-associated ctDNA. For example, cfDNA is ctDNA, such as BTK-associated ctDNA. In some embodiments, at least a portion of the cfDNA is determined to be BTK-associated ctDNA. For example, sequencing and / or quantification of total cfDNA may identify BTK fusion and and / or BTK resistance mutations.

[0368] In the field of medical oncology, a combination of different forms of treatment is used to treat each subject with cancer. In medical oncology, the compositions provided herein are typically used in combination. In addition to the above, other component(s) of such combination treatment or therapy may include surgery, radiation, Therapies, and chemotherapeutic agents, such as kinase inhibitors, signal transduction inhibitors, and / or can be a monoclonal antibody. For example, the surgery is an open surgery or a minimally invasive surgery. Thus, a compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof, The compounds may also be useful as adjuvants in cancer treatment, i.e., they may be administered in combination with one or more Multiple additional therapies or therapeutic agents, e.g., chemicals that act by the same or different mechanisms of action. In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt, amorphous, or polymorphic form thereof, or a spray-dried dispersion thereof or pharmaceutical compositions thereof used in combination with an additional therapeutic agent or therapy. For example, a subject in need of treatment may be administered one or more doses of a compound of Formula I, or its pharmaceutically acceptable salts, amorphous or polymorphic forms, spray-dried dispersions thereof, and The patient may be administered these pharmaceutical compositions for a period of time, followed by at least partial resection of the tumor. In some embodiments, a compound of formula I, or a pharmaceutically acceptable salt thereof, Amorphous or polymorphic forms, spray-dried dispersions thereof, or pharmaceutical compositions thereof or multiple doses of treatment to reduce tumor size before at least partial resection of the tumor (e.g., tumor burden)

[0369] In some embodiments of any of the methods described herein, a compound of Formula I, or a drug thereof a physiologically acceptable salt, amorphous, or polymorphic form thereof, a spray-dried dispersion thereof, or These pharmaceutical compositions may contain a therapeutically effective amount of one or more additional therapies or therapeutic agents (e.g., chemicals). and (iii) a therapeutic agent selected from the group consisting of a chemotherapeutic agent, ... .

[0370] Non-limiting examples of additional therapeutic agents include other BTK-targeted therapeutic agents (i.e., first or second BTK kinase inhibitors), other kinase-targeted therapeutics (e.g., JAK, Src, or IRAK family kinase targeted therapeutics, such as JAK1, JAK2, JAK3, and TYK 2, IRAK1, IRAK4, Src, Yes, Fyn, Fgr, Lck, Hck, Bl k, Lyn, or Frk inhibitors), signaling pathway inhibitors, checkpoint inhibitors , apoptosis pathway modulators (e.g., obataclax); other protein inhibitors ( For example, anti-apoptotic protein inhibitors, heat shock protein inhibitors, nuclear export proteins protein inhibitors, histone deacetylase inhibitors, E3 ubiquitin ligase inhibitors, or Histone-lysine N-methyltransferase inhibitors); cytotoxic chemotherapy, angiogenesis These include targeted therapies, immune-targeted drugs including immunotherapy, and radiation therapy.

[0371] In some embodiments, the other BTK-targeted therapeutic is a multikinase inhibitor that exhibits BTK inhibitory activity. In some embodiments, the other BTK targeted therapeutic inhibitor is a BTK enzyme inhibitor. Exemplary BTK kinase inhibitors are those described herein that are selective for the kinase. When measured by an assay, the concentration is less than about 1000 nM, less than about 500 nM, less than about 200 nM, or less than about less than 100 nM, less than about 50 nM, less than about 25 nM, less than about 10 nM, or less than about 1 nM Inhibitory activity against BTK kinase (IC 50 ) may be shown. is a BTK kinase inhibitor that exhibits a potency of about 25n when measured in the assays provided herein. less than about 10 nM, less than about 5 nM, or less than about 1 nM against BTK kinase Inhibitory activity (IC 50 ) can be shown.

[0372] Non-limiting examples of BTK-targeted therapeutic agents (e.g., first BTK inhibitors or second BTK inhibitors) include: Typical examples include ibrutinib (PCI-32675, Imbruvica®) 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4 -d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one); AC0058(AC0058TA);N-(3-((2-((3-fluoro-4-(4- Methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin (4-( ...(4-((4-((((((((((((((((((((((((((((((((((((((((((((((((((((( 6. Calquence® (rINN) (4-[8-amino-3-[(2S) -1-but-2-ynoylpyridin-2-yl]imidazo[1,5-a]pyrazine-1- yl]-N-pyridin-2-ylbenzamide); zanu...

Claims

1. A crystalline form of a compound which is (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide, characterized in that the crystalline form has an X-ray powder diffraction pattern including peaks at °2θ values ​​of 15.8±0.2, 16.2±0.2, 11.9±0.2, 19.0±0.2, and 18.3±0.

2.

2. The crystal of claim 1, wherein the crystalline form has an X-ray powder diffraction pattern including peaks at °2θ values ​​of 15.8±0.2, 16.2±0.2, 11.9±0.2, 19.0±0.2, 18.3±0.2, 23.8±0.2, 20.5±0.2, 25.7±0.2, 20.1±0.2, and 9.5±0.

2.

3. 3. The crystal of claim 1 or 2 having a purity of more than 90%.

4. 3. The crystal of claim 1 or 2 having a purity of more than 95%.

5. A solid oral pharmaceutical composition comprising a pharmaceutical excipient and a crystal according to any one of claims 1 to 4.

6. 6. The pharmaceutical composition of claim 5 for use in the treatment of a BTK-associated cancer.

7. 7. The pharmaceutical composition of claim 6, wherein the BTK-associated cancer is selected from the group consisting of mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom's macroglobulinemia, and marginal zone lymphoma.

8. 7. The pharmaceutical composition of claim 6 comprising 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 75.0, 80.0, 90.0, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or 500 milligrams of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide.

9. 9. The pharmaceutical composition of claim 8, administered on a regimen of 1 to 4 times per day or in a single daily dose.

10. 8. The pharmaceutical composition of claim 7 comprising 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 75.0, 80.0, 90.0, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or 500 milligrams of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide.

11. 11. The pharmaceutical composition of claim 10, administered on a regimen of 1 to 4 times per day or in a single daily dose.

12. 7. The pharmaceutical composition of claim 6, wherein (i) the subject's cancer has relapsed during treatment with the first BTK inhibitor, and / or (ii) the subject's cancer has not responded to treatment with the first BTK inhibitor, and / or (iii) the subject is intolerant to the first BTK inhibitor.

13. The pharmaceutical composition of claim 6 for use in combination with one or more therapeutic agents.

14. The pharmaceutical composition of claim 7 for use in combination with one or more therapeutic agents.

15. 6. The pharmaceutical composition of claim 5 for use in the treatment of an autoimmune or inflammatory disease.

16. 16. The pharmaceutical composition of claim 15, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, osteoporosis, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, chronic urticaria, myasthenia gravis, and systemic lupus erythematosus.

17. The crystal according to any one of claims 1 to 4, which exhibits an endotherm observed at 185 to 195°C when measured by differential scanning calorimetry (DSC).

18. The crystal according to any one of claims 1 to 4, which exhibits a weight loss of 0.14% from the start of heating to 150°C as measured by thermogravimetric analysis (TGA).

Citation Information

Patent Citations

  • Compounds useful as kinase inhibitors

    WO2017103611A1